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Introduction  
 
Diabetes mellitus is a chronic disease characterized by high blood sugar levels with 
serious complications, particularly if it is not adequately treated. It is increasingly 
prevalent and burdensome from both a health and economic standpoint globally, 
amounting to hundreds of billions of dollars in expenditure each year [1,2]. Also 
increasing are the numbers and types of pharmaceutical interventions being introduced to 
treat this disease. Over the next decade, numerous diabetes compounds currently in 
development are expected to be commercialized, making it essential for the most robust 
and accurate evidence to be available to healthcare decision-makers [3]. 
 
Approximately 90% of people with diabetes are diagnosed as Type 2 (T2D), most often 
in adulthood [4]. In contrast, Type 1 diabetes (T1D) patients are commonly diagnosed as 
juveniles, but live well into adulthood with effective treatment [4]. Consequently, adult 
patients with diabetes, namely T2D, are responsible for most of the health and economic 
burden of this disease. Therefore, much of the effort to improve outcomes and reduce 
costs in diabetes concentrates on this population.  
 
The goal of diabetes treatment has remained to control glycated hemoglobin (HbA1c) 
while reducing the risk of adverse events (e.g., hypoglycemia). However, recent 
international guidelines emphasize an individualized, patient-centered approach to setting 
treatment targets given the many unique clinical, social, and environmental risk profiles, 
rather than establishing a single target for all patients (e.g., HbA1c < 7.0%) [5]. For T1D, 
an unpreventable autoimmune disorder causing destruction of pancreatic beta cell activity, 
the treatment requirement is exogenous insulin over a lifetime [5]. 
 
The underlying causes and treatment options are more complex for T2D, which is a 
metabolic disorder associated with a combined effect of reduced ability to properly 
absorb sugar (insulin resistance) and loss of normal beta cell function (relative insulin 
deficiency) [5-7]. Its onset may be influenced by a multitude of factors – lack of exercise, 
a diet high in saturated fats (obesity), medical conditions such as hypertension and 
hypercholesterolemia, and inheritable genetics [6,7]. Initial treatment commonly begins 
with diet and exercise, followed by one or multiple oral anti-diabetic drugs (OADs), and 
later may include insulin or other injectable medication as disease progresses [5]. As the 
prevalence of T2D and its associated economic impact are much higher than with T1D, 
this thesis focuses predominantly on adult T2D patients, although a modeling application 
of insulin treatments among adult T1D patients is found in Chapter 3.  
 
However, irrespective of diabetes type, an important part of tailoring treatment involves 
the consideration of not only the biological factors of care, but also the non-biological. It 
is important to account not only for how a patient’s body will respond to a specific 
compound, but how likely the patient will comply with and remain on therapy [5]. As 
such, unique product features potentially impacting a patient’s satisfaction with and 
preference for treatment are relevant [5].  
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As treatments for diabetes continuously evolve, it’s become ever more difficult to 
consistently demonstrate improved clinical efficacy at historical rates – earlier 
compounds have more readily been able to demonstrate significant HbA1c reductions, as 
they’ve competed with older, less potent therapies at time of their launch [3,8]. The 
challenge of distinguishing modern products on biological grounds has led to intense 
efforts by manufacturers to differentiate therapies by highlighting non-biological product 
features, while only meeting minimum efficacy requirements. Indeed, as it pertains to 
clinical efficacy and safety, critics have defined the current era of diabetes drug 
development as me too, citing the manufacturers’ increased replacement of head-to-head 
superiority trials with non-inferiority designs [3,8].  
  
Non-biological product innovations in diabetes have predominantly been patient-centered 
and aim at making products less intrusive and easier to use (e.g., alleviating problems 
with needle phobia). These innovations may influence patients’ perceptions of treatment, 
and can thereby improve their ability and willingness to properly self-manage and 
maintain therapy [9]. Improved handling and device ergonomics for injecting insulin, 
reduced dosages, and less frequent, simpler routes of drug administration are all non-
biological product characteristics that have been progressively refined specifically to 
increase the preference for and satisfaction with treatment. [3,5]. Patient preferences in 
diabetes are economically important for a wide range of reasons pertaining to both 
biological and non-biological factors, and their importance is only rising for decision-
makers [10,11]. 
 
A substantial amount of originality and diversity surrounding non-biological product 
features is being introduced into the diabetes market, and healthcare payers and decision-
makers have struggled with assigning value to these product features. This is because the 
methods they currently have for doing so are largely focused on clinical changes (HbA1c) 
only [12]. In this expanding, complex market environment, the question remains, “do 
current methods of economic evaluation used to make decisions on patient access and 
reimbursement reflect the rapidly evolving nature of diabetes products in the real world? 
Have methodologies adequately kept pace with innovations in non-biological product 
development?” Current studies suggest that historical approaches at economic evaluation 
in diabetes, in particular for cost-effectiveness analyses (CEAs), are not able to fully 
capture the value of non-biological, yet economically important, features of modern 
products [12]. This may lead to a misinformed and incomplete foundation for decision-
making in coming years.   
 
In context of the need to ensure that payers and decision-makers are well-equipped when 
considering future products, this thesis addresses two overarching themes: (1) the 
increased diversity of non-biological diabetes product features; and (2) the patient-
centered, economically relevant outcomes they impact. To this end, the specific 
objectives herein are to examine the broad, multifaceted relationships between patient-
centered, clinical, and cost outcomes associated with diabetes treatment, and to propose 
new methods which better incorporate these relationships in CEAs used for 
reimbursement and policy decision-making in the real world. The emphasis of this 
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introductory section is to provide a working definition of terms, describe the general 
framework for the thesis, and outline the individual contribution of each chapter. 
 
Defining economically relevant patient-centered outcomes 
 
Several terms are used throughout this thesis to describe patient-centered outcomes which 
become important when proposing novel frameworks of economic evaluation. These 
include self-reported outcomes depicting experiences with treatment, as well as 
calculated metrics acting as surrogate measures to illustrate patient behaviors.  
  
The manner and context in which these outcomes were analyzed vary by chapter, 
spanning retrospective, observational to prospective, controlled research designs. 
Although there is some overlap, these outcomes generally fall within three categories: 
those that are (1) patient-reported; (2) measures of medication self-management; and (3) 
intrinsically relevant to economic analyses.  
 
The patient-reported outcomes (PROs), or perceptions of care, examined in this thesis are 
Patient Preference and Treatment Satisfaction, measured with validated instruments and 
specific to diabetes (e.g., ITSQ – Insulin Treatment Satisfaction Questionnaire). For the 
purposes of this thesis, patient preference is considered to be a measurement of the 
comparative desirability of treatments, or the extent to which a patient chooses or 
otherwise endorses the use of one treatment over another based on actual as well as 
perceived attributes [13]. Treatment Satisfaction is regarded as the measurement of a 
patient’s approval, or contentment, with the treatment process and its associated 
outcomes based on predefined criteria [14]. Conceptually, the objective for both is to 
quantify a patient’s subjective, personal sentiment toward treatment in order to better 
understand the impact that it can have on observed behavior, such as medication 
adherence and persistence [13,14].  
 
To that end, several chapters focus on generating and applying proxy indicators for 
adherence and persistence by utilizing healthcare claims databases to calculate 
Medication Possession Ratios (MPRs) and number-of-days covered. The MPR is a 
common metric intended to describe the proportion of time that a patient is covered by, or 
in possession of, the correct supply of their medication. It is often calculated as the sum 
of the days’ supply of a drug divided by the number of days between the first fill and the 
last refill, plus the days’ supply of the last refill [15]. Number of days covered is simply 
the time from drug initiation (index date) to discontinuation (defined by a period of 
absence of refill activity). 
 
Using those standards to calculate MPR and days covered, it becomes apparent how they 
relate to adherence and persistence. Medication adherence, which is a synonym for 
compliance, refers to a patient’s conformity to healthcare providers’ recommended or 
prescribed timing, dosage, and frequency of medication taking [16]. Similarly, yet 
distinct, persistence is defined as the duration of time from treatment initiation to 
discontinuation [16]. More simply, adherence may be viewed as the extent to which a 
patient follows the prescribed interval and dosage of their medication, and persistence 
 
15 
only relates to the length of time a patient continues to take any amount of their 
medication [16]. Operationally, both adherence and persistence are measured with units 
of time. However, adherence is reported as a percentage of time while persistence is 
described in units of total time [16]. 
 
The culminating effort for this thesis is aimed at improving upon methods used in the 
economic evaluation of treatments for diabetes, and T2D in particular. Although Chapter 
3 examines the cost-effectiveness of insulin treatments in adult T1D patients, the primary 
aim for purposes of this thesis was to build on Chapter 2 by demonstrating that modeling 
is sensitive to treatment-specific differences in HbA1c and hypoglycemia. The ultimate 
aim for each patient-centered outcome was to examine its relationship to costs. The 
outcomes previously mentioned – preference, satisfaction, adherence and persistence – 
have a downstream effect on pharmacy and medical costs. Others, such as Health-related 
Quality of Life (HRQoL), are more inherently linked to economic evaluations through 
their association with actual health benefit and not just costs, and therefore deserve 
careful consideration.  
 
Measures of HRQoL may be broadly defined as a patient’s appraisal of their level of 
functioning and health while on treatment in comparison to what they perceive to be ideal 
or more desirable without it [17]. They begin as preference-based PROs, but may be 
expressed mathematically in the form of utility scores calculated from patient responses 
to HRQoL instruments. Utilities are valuable for CEAs since they make it possible to 
compare the ability of treatments to impact not only survival, but also quality of life. 
Quality-adjusted life-years (QALYs), the combination of life-years lived with the quality 
of that life, represent an important health outcome used in many cost-effectiveness 
analyses. For chronic diseases like diabetes, the inclusion of utilities in CEAs is 
particularly important since patients tend to remain in various health states with a reduced 
quality of life for a prolonged period of time.  
 
The historical paradigm and new dynamic of economic evaluation in diabetes 
 
The majority of CEAs comparing diabetes treatments have taken an inside-out approach. 
Incremental Cost-effectiveness Ratios (ICERs) that are intended to facilitate decision-
making in the real world have instead been calculated extensions of clinical efficacy and 
safety observed within rigidly defined clinical trial populations of limited sample size 
[Figure 1]. The primary driver of modeled health events, resource use, and costs in these 
CEAs are intermediate levels of HbA1c based first and foremost on RCT results. 
Although supplemental information from large epidemiological studies, healthcare claims 
and registry databases, and general population surveys are routinely incorporated, this is 
done on a secondary basis after the impact of treatment on HbA1c been applied. This 
often produces only isolated, or indirect, effects on health state transition probabilities, 
cost estimates, and utilities. 
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Figure 1. Historical inside-out paradigm of economic evaluation in the context of real-
world application for decision-making in diabetes 
 
 
 
The core of this historical approach at economic evaluation is flawed for making 
decisions in the real world due in part to the structural makeup of RCTs. This flaw 
largely excludes the impact of non-biological product features [12,18]. The main purpose 
of a RCT is to test the efficacy and safety of a chemical entity on a disease in a controlled 
setting among restricted types of patients, not to serve as the foundation for health 
economic analyses.  
 
Additionally, non-structural biases inherent to RCTs further limit their applicability for 
economic evaluations used in real world reimbursement decision-making. For example, 
this includes the tendency of study investigators, intentionally or unintentionally, to 
selectively enroll patients with greater likelihood of attending routine follow-up visits and 
taking medication according to study protocol. Furthermore, the requirement of informed 
consent may predispose enrolled patients to achieve much higher levels of adherence than 
they might otherwise if they were not actively watched, or did not feel they were being 
relied upon as part of a scientific study [12,19]. Both forms of bias may mean that the 
RCT results provide no indication of the impact of non-biological product features on 
patient behavior, and may therefore overestimate what may be expected for non-selected 
patients in uncontrolled, real world settings. 
 
Still, RCTs will always remain an essential component for economic evaluation, as they 
are a rich source of the requisite comparative clinical information. The key for 
developing novel approaches at CEA is not to change this fact, but rather to enhance their 
usefulness by: (1) identifying all non-biological factors that have a direct or indirect 
economic impact and may be captured outside the RCT setting; (2) measuring how much 
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they affect economic outcomes; and (3) testing the application of additional knowledge in 
new analytic frameworks. Without these augmentations, the absence of real-world 
influences on patient perceptions of care and self-management would prevent CEAs from 
revealing the true value of many forthcoming diabetes products. 
 
CEA as a primary means for economic evaluation in diabetes 
 
The purpose of CEA, and more broadly, health technology assessment (HTA), is to aid 
healthcare decision-making, rather than be a statement of fact; in other words, it’s a 
means and not an end in itself [ [18,19]. As such, the more accurate and relevant a CEA, 
the better its results serve decision-makers [18,19]. Although specific methodologies for 
CEA may differ, the basic intent remains to generate an ICER that describes the potential 
value for money of using one healthcare intervention versus another. In order to 
understand how CEAs are meaningful in diabetes (and to establish it as a method of 
economic evaluation that would be most appropriate to target for revision), we first had 
to (1) identify a suitable clinical marker to serve as the main driver of modeled results, 
and (2) test its ability to differentiate health outcomes and costs in relevant patient 
populations. 
 
The primary methodological construct for CEAs within this thesis is the Markov / Monte-
Carlo simulation (M/MC). The Markov component is used to illustrate the structural 
approach for a given CEA, where the general flow of health states in which modeled 
patients may transition over time is portrayed [12,18,19]. Each potential health state is 
coupled to a transition probability (derived from literature), resulting in adjustment of 
HR-QoL and costs for patients with applicable risk factors [12,18,19]. The Monte-Carlo 
component may be thought of as the mathematical engine allowing transition 
probabilities to be applied, at either the individual patient or cohort level [12,18,19]. It 
also facilitates sensitivity analyses, where the uncertainty in transition rates and other 
parameters may be applied to reveal the possible range of ICERs given changing 
assumptions. The M/MC approach has historically been considered optimal for 
simulating diabetes and other chronic diseases, as it can accommodate the numerous 
health states which are impacted and also allow for complex sensitivity analyses 
[12,18,19]. 
  
The second chapter of this thesis aims to establish the applicability of M/MC simulations 
for CEA in diabetes, starting with a demonstration of how HbA1c may be used as the 
clinical marker of modeled disease progression. If modeled changes in HbA1c, regardless 
of treatment, were not able to successfully differentiate outcomes and costs over time, 
then it would not make sense to move forward in applying specific treatment effects and 
costs directly or indirectly related to HbA1c control, including non-biological and real-
world factors. The rationale for choosing HbA1c stemmed from (1) its widespread 
availability as a primary measure of efficacy or effectiveness in diabetes clinical studies, 
(2) its rising importance in not only monitoring disease progression, but in screening for 
and diagnosing diabetes, and (3) the high likelihood that it will remain a core marker of 
disease progression for the foreseeable future [20]. 
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Within a validated M/MC model, we hypothesized that pre-defined, incremental 
improvements in HbA1c could be used to differentiate disease progression and costs over 
the long-term, natural course of diabetes. Three separate HbA1c thresholds were 
specified, realistic to what could be achieved in the real world – reductions from (1) 9.5% 
to 8.0%; (2) 7.9% to 7.0%; and (3) 6.9% to 6.5% – and all were compared to no 
reductions (e.g., remain at 9.5%, 7.9%, and 6.9%, respectively). This difference in 
differences approach allowed us to isolate the impact of step-wise improvements in 
HbA1c, and evaluate whether reasonable changes in HbA1c are sensitive enough within 
M/MC simulations to detect gains in health and economic benefit. 
 
Treatment-specific Markov / Monte-Carlo modeling  
 
Building on this, the next stage entailed demonstrating the ability to include treatment-
specific effects on HbA1c as well as direct pharmacy costs. In doing so, we would ensure 
that diabetes treatments with varying degrees of HbA1c control and safety could be 
differentiated in terms of ICER results. Applying two separate RCTs comparing a total of 
three types of insulin within the same validated M/MC model, we hypothesized that 
because of improved HbA1c and reduced side effects (e.g., lower hypoglycemia), insulin 
detemir (IDet) would be cost-effective compared to both insulin glargine (IGlarg) and 
neutral protamine Hagedorn insulin (NPH). Specifically, this would occur because of 
reductions in modeled adverse events (i.e., poor health states) resulting in improved 
HRQoL, and less resource use and costs.  
 
Chapters 2 and 3 first explore concepts and assumptions in existing modeling approaches. 
In order to propose new methods of CEA which may accommodate non-biological and 
real-world characteristics of diabetes treatment, it is important to demonstrate that disease 
and treatment effects, independently, have the potential to result in meaningful CEA 
results. Next, this initial groundwork is then revised to include non-biological and real-
world factors, as generated from observational research evidence. 
 
The role of PROs in relation to clinical and non-biological treatment attributes 
 
A primary methodological concentration of this thesis is in PROs, with T2D as the main 
area of application. Having demonstrated that CEAs in diabetes can accommodate 
clinical changes (HbA1c) imparted by natural disease progression as well as individual 
treatments, attention could be placed on creating a foundation for describing the impact 
of non-biological aspects of therapy. Specifically, PROs such as patient preferences and 
treatment satisfaction have been noted as being sensitive to both clinical and non-
biological treatment attributes, and therefore are potentially important when predicting 
future health outcomes and costs in real-world populations [11]. 
 
To maintain consistency between chapters, variation in patient preferences and treatment 
satisfaction was investigated among patients specifically taking insulin. Insulin became a 
central therapy in this thesis because each of the non-biological innovations in modern 
products are relevant – device ergonomics (handling), medication timing and dosage, and 
route of administration (injectable, inhaled, etc.) [9,10]. Any important changes in 
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preference and satisfaction associated with treatment were more likely to be captured 
with insulin than with oral medication. For this reason, the effect of preference and 
satisfaction were first assessed among insulin patients. 
 
We used a prospective, open-label RCT design to investigate potential differences in 
preference and treatment satisfaction among patients injecting insulin with a vial/syringe 
compared to a pre-filled handheld device. The type of insulin did not differ between 
cohorts (cross-over design), only the method of injection, thus making it possible to 
isolate the influence of non-biological product attributes on PROs. These attributes may 
cause the pen device to be less burdensome due to improved handling (device flexibility), 
a less painful gauge and shorter needle, less complicated administration process (no need 
to manually fill syringe), and more accurate dosing. As such, it was expected that both 
preference and satisfaction would be significantly improved when using the device.  
 
Still, in order to weave a common thread warranting inclusion of non-biological 
treatment characteristics back into CEA, it was necessary to extend the hypothesis that a 
pen device could improve PROs by addressing possible correlations between PROs and 
actual clinical efficacy and safety. In other words, the next step was to evaluate whether 
or not PROs (treatment satisfaction in our case), which are sensitive to non-biological 
product features, could also be linked to changes in clinical outcomes that serve as the 
primary driver of modeled results in CEAs. It could therefore be seen that non-biological 
product features influence patient perceptions of care, which then may play a part in 
determining the likelihood of achieving HbA1c control, and therefore should be included 
as a primary consideration in CEA. We used a retrospective analysis of a multi-center 
RCT in which both clinical and PRO measures were captured to investigate the extent to 
which these correlations may exist. Specific domains of, and overall, treatment 
satisfaction were expected to improve as insulin patients’ HbA1c improved, and as 
certain side effects were reduced, namely those relevant to non-biological product 
features (e.g., neuropathy (injection site pain), retinopathy (visual acuity needed to 
properly fill syringe and accurately inject)). 
 
Insight from these complimentary analyses can be used as evidence that PROs may be the 
facilitating outcome measure between non-biological and clinical factors of treatment 
(with insulin as our example). Through its impact on PROs, which then may influence 
clinical markers applied in CEA, the relevancy of non-biological treatment factors in 
CEA can be established.  
 
The first half of this thesis intended to establish the relevancy of CEA and M/MC 
modeling in diabetes, and to evaluate interrelations between PROs, non-biological 
product features, and clinical changes. The remaining chapters aim to (1) assess real-
world factors such as treatment-specific levels of patient self-management, (2) inquire the 
extent to which medication adherence and persistence impact resource use and costs, and 
(3) develop and test new ways of incorporating this information back into CEA (Figure 2). 
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Figure 2. Development of conceptual framework and innovative approach at CEA in 
diabetes, by chapter and topic  
 
 
 
 
Associations of patient self-management with health economic outcomes 
 
The immediate effects of sub-optimal medication adherence seem obvious – pharmacy 
costs go down due to lowered utilization, yet the disease is undertreated and risk 
increases for poor health outcomes and a subsequent rise in resource use and medical 
costs. This was a core assumption underpinning our hypotheses for Chapters 6 and 7. 
However, several questions remained to actually quantify these relationships in a manner 
appropriate for inclusion in CEA, such as: (1) what ranges exist for levels of adherence 
among different diabetes treatment types? (e.g., oral vs. injectable); (2) to what extent 
does sub-optimal adherence impact resource use and costs, and for which types of health 
events?; and (3) are non-biological treatment factors involved in determining medication 
adherence? 
 
The answers to these questions were essential in developing and testing new frameworks 
for CEA in diabetes, as it was expected that they would provide information to create 
reasonable effect sizes (on resource use and costs) and ranges for sensitivity analysis 
when incorporating, for example, the real-world influence of medication adherence. 
Additionally, if non-biological product features inherent to various treatments were found 
to be significantly associated with adherence, further rationale would exist for including 
adherence in modeling. In order to begin obtaining these estimates, a systematic literature 
review was performed to assess current evidence on the overall prevalence and cost 
consequences of medication adherence for various diabetes treatments.  
 
Once it was confirmed that medication adherence in diabetes varies widely between 
treatments and may heavily influence healthcare costs in general, a follow-up analysis 
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was conducted at a more granular level to assess whether specific treatments with 
important differences in non-biological features would differ in adherence, and if these 
differences correlated to differences in health outcomes and costs in the real world. 
Utilizing a large database of administrative healthcare claims, several cohorts of insulin 
patients were analyzed retrospectively, hypothesizing that patients converting to injection 
of insulin with a pre-filled handheld injection device (from vial/syringe) would exhibit 
greater adherence, and that there would be observed correlations to improved health 
outcomes, lower resource use, and costs. In doing so, non-biological product features 
associated with handheld injection devices could be correlated to measures of self-
management and costs, and in turn, become relevant for inclusion in CEA.  
 
Novel framework and methods for application of CEA to modern treatments 
 
Having established broad and individual treatment-specific correlations between 
medication adherence and health economic outcomes, and assessing the relationship that 
non-biological treatment factors may have on self-management, it became important to 
critically evaluate current methods and published examples of economic models in 
diabetes, specifically T2D. The primary goal of Chapter 8 was to investigate whether 
current modeling approaches adequately address issues of self-management that are 
important for determining the true economic impact seen in real-world patient 
populations. Secondly, if current methods did not adequately incorporate these 
relationships, our goal was to propose a novel framework of interactions for PROs, 
measures of self-management, clinical changes (HbA1c), resource use, and costs. 
 
Chapter 9 builds on the novel framework of these interrelations by developing a unique 
M/MC model with structural and mathematical components incorporating the real-world 
impact of self-management on clinical changes, resource use, and costs. Two separate 
CEAs were conducted, one which served as a base case analysis ignoring medication 
adherence, and a second which incorporated adherence to adjust results. Simulated 
treatments were those with very distinct differences in non-biological product features 
(oral vs. injectable), and commonly used by T2D patients. The corresponding ICERs 
could then be compared, and an estimate of the impact of real-world adherence on 
calculated cost-effectiveness obtained. 
 
The overarching aim of this thesis is to propose new, enhanced means for CEA in 
diabetes in order to ensure that modeled results used in decision-making are more 
relevant for real-world populations. As modern treatments increasingly focus on non-
biological product innovations directly aimed at improving patient perceptions of care 
and, subsequently, self-management, the importance of continuously adapting and 
improving CEA per these parameters will remain.  
 
Non-biological treatment attributes may impact patient perceptions of care (PROs), 
which can then influence whether or not a patient is willing or able to properly self-
manage. They have become an important part of the patient-centered approach to 
tailoring therapy and achieving individualized HbA1c targets, and are central to 
successfully implementing prescribed therapy in the real world. Medication adherence is 
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able to impact HbA1c, which will influence whether or not a patient experiences poor 
health outcomes, and increased resource use and costs. Moving forward, decision-makers 
will be able to better understand these relationships and be equipped with the tools to 
generate more accurate estimates of the cost-effectiveness of modern therapies. This 
should help to ensure that patients receive more appropriate access to care in the most 
efficient way possible. 
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Modeling incremental HbA1c targets in Type 2 
diabetes 
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Summary 
 
The purpose of this chapter was to project the long-term clinical and cost outcomes that 
accompany pre-defined improvements in glycaemic control in patients with Type 2 
diabetes (T2D). A peer-reviewed, validated, non-product-specific Markov model of T2D 
was used to project the long-term clinical and cost outcomes associated with three HbA1c 
reduction scenarios (vs. no reduction): (i) decreasing mean HbA1c from 9.5% to 8.0%; (ii) 
from 8.0% to 7.0%; and (iii) from 7.0% to 6.5%. A typical baseline U.S. T2D cohort 
derived from National Health and Nutrition Examination Survey (NHANES) data was 
simulated over a lifetime horizon (35 years). Incidence of diabetes-related complications 
and costs (2005 USD) were accounted based on published data. Discount rates (3% per 
annum) were applied to clinical benefits and costs. Sensitivity analyses were performed.  
 
Stepwise reductions in HbA1c as an independent variable correlated with delayed time to 
diabetes-related complications and a reduced cumulative incidence of complications, 
including cardiovascular, renal and neurologic comorbidities. Related costs also 
decreased. Reductions in both poorly- (9.5–8.0%) and better-controlled (7.0–6.5%) 
patients produced incremental gains in undiscounted life expectancy (LE) [1.06 (0.31) 
and 0.32 (0.34) years [mean (SD)], respectively]. Similar improvement patterns were 
observed in quality-adjusted life expectancy (QALE). Benefits from sequential reduction 
scenarios, when aggregated, exhibited the most dramatic effect. Improved glycaemic 
control was associated with reductions in complication rates and costs, as well as 
increased LE and QALE among T2D patients. These data illustrate the long-term 
importance of reaching normoglycaemia and support intensified HbA1c control as a 
cornerstone of effective long-term T2D management. 
 
Introduction 
 
Glycaemic control is of fundamental importance in the management of diabetes [1]. 
Landmark clinical and epidemiological studies have provided evidence that improved 
glycaemic control is associated with decreased incidence of diabetes-related 
complications, including nephropathy, retinopathy, neuropathy and cardiovascular 
disease (CVD) [2–7]. The United Kingdom Prospective Diabetes Study 33 (UKPDS) 
reported that intensive treatment [mean glycosylated haemoglobin (HbA1c) 7.0%] 
resulted in a 12% lower risk of experiencing any diabetes-related complication and a 10% 
lower risk of diabetes-related death compared with conventional treatment (mean HbA1c 
7.9%) [3]. The importance of effective glycaemic control has been recognised in several 
publications of guidelines for the treatment of diabetes. The International Diabetes 
Federation (IDF) and American Association of Clinical Endocrinologists (AACE) 
guidelines recommend a target HbA1c level of 6.5% for adults [8,9]. More recently, the 
American Diabetes Association (ADA) published Clinical Practice Recommendations in 
which a target level for HbA1c of 7.0% was recommended for non-pregnant adults [1].  
 
Other risk factors included blood pressure (target 130/80 mmHg) and lipid levels (target 
low-density lipoprotein cholesterol 100 mg/dl, high-density lipoprotein cholesterol (HDL) 
140 mg/dl and triglycerides 150 mg/dl). A recent modeling study investigated the relative 
 
27 
impact of these risk factors by simulating independent variations in each among a cohort 
of patients with newly-diagnosed T2D [10]. A 10% improvement from baseline in 
HbA1c, systolic blood pressure (SBP), HDL or total cholesterol was simulated over 
patients’ lifetimes. The study concluded that of these four risk factors, glycaemic control 
defined by HbA1c level has the greatest impact on long-term health outcomes.  
 
Although the evidence supporting tight glycaemic control in T2D is very strong, the 
mean HbA1c of T2D patients is increasing in the U.S. According to the NHANES 1999–
2000 report, average HbA1c in 2000 was 7.9%, an increase of 0.3% compared with the 
period 1988–1994, and this despite an increase in use of prescription medication [11]. 
With the treatment emphasis being placed upon reaching recommended goals of HbA1c 
7.0%, patients often become de-motivated despite achieving a significant reduction when 
they fail to reach these targets. However, as noted by Gaede and Pederson [12], a target is 
not an all-or-nothing phenomenon; evidence from the UKPDS suggested that any 
reduction in glycaemia will be beneficial in clinical terms. 
 
The purpose of this study was to simulate the long-term effects on costs and clinical 
outcomes of improving glycaemic control in T2D patients. This was performed by 
applying three pre-defined HbA1c thresholds to T2D patients presenting baseline 
characteristics derived from NHANES data and simulating the costs and effects of 
reaching each target in a stepwise manner. A computer modeling approach was used to 
examine the impact of changing HbA1c levels independently of changes in other risk 
factors [lipid profiles, blood pressure, body mass index (BMI)] over patient lifetimes. 
 
Methods 
 
Overview 
 
A previously published and validated computer simulation model of diabetes was used to 
project the long-term clinical and cost outcomes of improving HbA1c levels in three 
separate glycaemic scenarios among a typical T2D cohort (base case analysis). Patients 
were assumed to progress from the preceding scenario to the next, with the resulting 
benefits of the improved glycaemic control then modeled over time. Patients in the 
simulation received hypothetical interventions to perform the following comparisons:  
 
 Scenario 1: reduction in mean HbA1c from 9.5% to 8.0% vs. no reduction 
(patients remained at an HbA1c level of 9.5%). The starting value of 9.5% was 
based on several recent prospective, cross-sectional analyses in poorly controlled 
T2D patients that focused on the extent to which intensification of glycaemic 
control improved outcomes [13–15]. These studies were designed to include 
patients with mean baseline HbA1c levels between 9.0% and 9.5%, corresponding 
to the definition of poor glycaemic control in adults by the National Quality 
Measures Clearinghouse of the Agency for Healthcare Research and Quality. 
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 Scenario 2: reduction in mean HbA1c from 8.0% to 7.0% (ADA recommended 
target HbA1c level) vs. no reduction (patients remained at an HbA1c level of 
8.0%). 
 
 Scenario 3: reduction in mean HbA1c from 7.0% to 6.5% (IDF and AACE 
recommended target HbA1c level) vs. no reduction (patients remained at an 
HbA1c level of 7.0%).  
 
Reductions in mean HbA1c level associated with the hypothetical interventions in this 
study were applied at the start of the simulation. HbA1c levels in all simulated patients, 
including those in the ‘no reduction’ treatment groups, then followed a pre-defined 
progression based on published long-term data from the UKPDS [3,4,16]. To assess the 
impact of lowering HbA1c in isolation, no treatment effects were applied to other risk 
factors such as SBP, BMI and lipid levels in the simulated cohorts. These parameters 
followed a natural progression over time as previously described by Palmer et al. [16]. 
Improvements in complication rates, life expectancy (LE) and quality-adjusted life 
expectancy (QALE) associated with decreasing HbA1c levels were reported for each of 
the three scenarios to provide a measure of the anticipated clinical benefits associated 
with tight glycaemic control. The cost of diabetes-related complications over patients’ 
lifetimes was also assessed. 
 
Model 
 
The analysis was performed using a published, peer-reviewed, validated, non-product-
specific model of T2D [17,18]. It is an interactive computer simulation model designed to 
project the long-term health outcomes and economic consequences of different clinical 
policies or treatment interventions. The model performs real-time simulations to evaluate 
the incidence of complications, LE, QALE and total costs within defined populations and 
has been extensively validated against ‘real life’ data from published prospective clinical 
and epidemiological studies of diabetes [18]. 
 
Simulation Cohort 
 
A hypothetical patient cohort was created for the analysis with the aim of mimicking a 
typical U.S. T2D population. Baseline demographic data was based on information from 
the NHANES database collected between 1999 and 2000 [19] (Table 1). Much of the 
necessary information on baseline complication rates was not available from NHANES 
(only data on previous myocardial infarction and heart failure were found), making it 
necessary to supplement this cohort with recently published characteristics from Initiation 
of Insulin to reach A1c Target (INITIATE), a randomised, controlled clinical trial in 233 
patients with T2D in the U.S. (20) (Table 1). Current patient management data specific to 
the U.S. setting were derived from several published sources [21–24] (Table 1). 
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Table 1. Baseline demographics, complications, relevant concomitant medications and 
management of patients in the simulated cohort 
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Costs 
 
U.S.-specific cost data were collected from numerous sources [25–30] and have been 
described previously [16]. All costs were inflated to 2005 values and are expressed in U.S. 
dollars ($). The present analysis takes into account the cost of complications associated 
with T2D in the simulated cohort. Treatment costs were not included in the study as the 
interventions commonly used to yield such HbA1c reductions are subject to significant 
variation and are often adjusted. 
 
Discounting, Time Horizon and Perspective 
 
In the base case analysis, undiscounted LE, QALE discounted at 3% per annum and 
direct costs discounted at 3% per annum were presented. The process of discounting 
clinical and economic outcomes is designed to weight gains that are obtained sooner 
more favourably than those achieved later. It is a common established practice in 
economic analyses. The discount rates applied are country specific (U.S.). Undiscounted 
cumulative incidence rates for diabetes-related complications were presented. A patient 
lifetime horizon was used (35 years). Complication costs were accounted from a third 
party, U.S.-payer perspective. 
 
Sensitivity Analyses 
 
Sensitivity analyses were performed to investigate the impact of varying discount rates 
and time horizon on simulation outcomes. Discount rates on clinical outcomes (LE and 
QALE) were varied between 0% and 6% and discount rates on costs were varied between 
3% and 6% per annum. Time horizon was varied between 0 and 35 years to evaluate the 
impact of improvements in HbA1c over shorter time periods. Cost and clinical outcomes 
at 2-, 5- and 10-year time horizons, as well as the 35-year base case values were reported 
in this study. 
 
Statistical Approach 
 
For each simulation performed in the present study (base case and sensitivity analyses), 
1000 patients were run 1000 times through the model and mean results and standard 
deviations (SD) were generated using a non-parametric bootstrapping approach [31]. 
Mean and SD values were presented for LE, QALE, cumulative incidence of 
complications and the costs of complications in the base case analysis. For the sensitivity 
analyses, only the differences between mean (and SD) values in the ‘reduced HbA1c’ and 
‘no reduction’ groups were presented for LE, QALE and total complications costs. 
 
Results 
 
Long-term Clinical Benefits of Improved Glycaemic Control: LE and QALE 
 
The base case analysis demonstrated that reductions in HbA1c were associated with 
improvements in undiscounted LE in all three base case scenarios (Table 2). The greatest 
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improvement in LE was observed in scenario 1, where baseline HbA1c was reduced from 
9.5% to 8% and undiscounted LE was extended by 1.11 years compared with no HbA1c 
change. When baseline HbA1c was lowered from 8.0% to 7.0% in scenario 2, the 
improvement in undiscounted LE was 0.72 years vs. no change. The smallest 
improvement in undiscounted LE was observed in scenario 3, where baseline HbA1c was 
reduced from 7.0% to 6.5% and there was an increase of 0.33 years. A similar pattern 
was observed in the QALE endpoint, which was discounted at 3% per annum in line with 
current recommendations for analyses in the U.S. settings (Table 2).  
 
 
Table 2 Summary of base case results 
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In scenario 1 (9.5–8.0%), mean QALE was increased by just over half a quality-adjusted 
life year (QALY) compared with no HbA1c reduction (0.58). In scenario 2 (8.0–7.0%), 
the improvement associated with reduced HbA1 was 0.38 QALYs, and in scenario 3 
(7.0–6.5%) it was 0.18 QALYs.  
 
Complication Rates and Costs of Complications 
 
The cumulative incidence of diabetes-related complications was projected to decrease 
over patient lifetimes with improved glycaemic control (Figure 1). For example, the 
cumulative incidence of end-stage renal disease (ESRD) was reduced from 13.2% (1.1%) 
to 7.9% (0.9%) with improved glycaemic control in scenario 1 (9.5–8.0%). In scenario 2 
(8.0–7.0%), the corresponding decrease was from 7.9% (0.9%) to 5.3% (0.7%) and in 
scenario 3 (7.0–6.5%) a reduction from 5.3% (0.7%) to 4.2% (0.6%) was exhibited. 
A similar pattern was observed with the cumulative incidence of retinopathy, neuropathy, 
other nephropathy and most CVD complications (Figure 1).  
 
Interestingly, an exception to this pattern was observed with stroke, where the cumulative 
incidence increased from 12.1% (1.1%) in patients with HbA1c remaining at 9.5% 
(scenario 1) to 15.1% (1.1%) in patients treated to target HbA1c of 6.5% (scenario 3). 
This effect was mirrored by the cumulative incidence of non-specific mortality. Both may 
be due to the survival paradox, where patients receiving a more efficacious intervention 
generally experience fewer complications and therefore live longer. As the population 
grows older, the likelihood of experiencing stroke or death because of other causes (non-
specific mortality) increases relative to other complications/diabetes-related mortality.  
 
The improvements in the cumulative incidence rates of diabetes-related complications 
were reflected in the total lifetime costs of complications (Table 2). The most substantial 
cost savings were projected in scenario 1 (9.5–8.0%) where mean total lifetime costs of 
$72,629 (2497) per patient were reduced to $67,420 (2583) with the hypothetical 
intervention, a savings of $5209 per patient. In scenario 2, the hypothetical intervention 
further reduced the total cost of complications to $64,322 (2498), corresponding to a 
savings of $3099. In scenario 3, reducing HbA1c to 6.5% decreased total lifetime 
complication costs to $62,684 (2333), saving $1637 per patient compared with no HbA1c 
change. 
 
Time to Onset of Complications 
 
In the base case analysis, reductions in HbA1c were associated with increased periods 
free of diabetes-related complications. For example, in scenario 1 (9.5–8.0%), the mean 
time alive and free of any complications was increased from 1.4 years in the no reduction 
group to 2.1 years with HbA1c reduction. In scenario 3 (7.0–6.5%), this value improved 
from 2.6 to 3.0 years with HbA1c reduction. A similar pattern of delayed time to onset 
was observed across the range of diabetes-related complications including retinopathy, 
nephropathy, neuropathy, lower extremity amputation and CVD. For example, mean time 
to onset of ESRD was delayed from 12.0 years to 13.2 years in scenario 1 (9.5–8.0%) and 
from 14.0 to 14.3 years in scenario 3 (7.0–6.5%). Similarly, the mean time to onset of 
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first myocardial infarction was delayed by just over 1 year in scenario 1 (from 10.1 to 
11.3 years) and by approximately 0.4 years in scenario 3 (from 12.1 to 12.5 years). 
 
 
Figure 1 Cumulative incidence of complications over patient lifetimes at target HbA1c 
levels 
 
 
 
 
Sensitivity Analyses 
 
Sensitivity analyses were performed to investigate the impact of discount rates and time 
horizon. In the base case analysis, LE was presented with no discounting applied. QALE 
and costs of complications were discounted at 3% per annum. In the first sensitivity 
analysis, a discount rate of 0% was applied to all clinical benefits. This decreased the 
projected QALE values from the base case and led to smaller improvements associated 
with the hypothetical interventions. Improvements in QALE ranged between 0.90 QALY 
in scenario 1 (9.5–8.0%) and 0.29 QALY in scenario 3 (7.0–6.5%) for hypothetical 
intervention vs. no HbA1c reduction.  
 
When a discount rate of 3% per annum was applied to all clinical benefits, in line with 
current recommendations for the U.S. setting, projected LE was lower than in the base 
case. Improvements in LE associated with treatment to target HbA1c levels were between 
0.58 years (scenario 1, 9.5–8.0%) and 0.18 years (scenario 3, 7.0–6.5%). Increasing the 
discount rates on costs and clinical benefits to 6% per annum decreased LE and QALE 
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projections and the improvements associated with decreasing HbA1c. Similarly, 
projections of mean total lifetime costs of complications were lower, with decreased cost 
savings associated with improved glycaemic control. Sensitivity analysis on the time 
horizon showed that clinical benefits associated with reduced HbA1c levels were evident 
after only 2 years. For example, QALE was increased by 0.01 QALY with HbA1c 
reduction in scenario 1 (9.5–8.0%) compared with no reduction. In scenario 3 (7.0–6.5%), 
an improvement of 0.004 QALY was projected. 
 
After 10 years, QALE was improved by 0.19 QALYs with HbA1c reduction in scenario 1 
(9.5–9.0%) and in scenario 3 (7.0–6.5%), this value was 0.05 years. Notable savings in 
the costs of complications were projected at the 10-year time horizon. A savings of $4041 
per patient was associated with improved glycaemic control in scenario 1 (9.5–8.0%), 
representing approximately 78% of the total per patient savings reported in the base case 
analysis. However, cost benefits took longer to accumulate with the other HbA1c 
reductions investigated. For instance, in scenario 3 (7.0–6.5%), cost savings of $723 were 
reported at the 10-year time horizon, accounting for only 44% of the base case savings 
associated with improved HbA1c. 
 
Discussion 
 
This modeling study is the first to report the long-term clinical benefits associated with a 
range of pre-defined, stepwise improvements in HbA1c independently of other risk 
factors in patients with T2D. Whilst the UKPDS study results demonstrated a direct 
relationship between glycaemia and the risk of microvascular complications over the 6 
year study period, we have quantified the clinical and economic impact of incremental 
improvements when viewed over a patient’s lifetime. Our simulations indicated that 
improved glycaemic control was associated with substantial improvements in 
undiscounted LE and QALE, reduced cumulative incidence and costs of diabetes-related 
complications, and increased time to onset of complications in a typical cohort of patients 
with T2D. 
 
In the simulated patient group, the increase in LE over the lifetime period was 
considerable [32–34]. The gain associated with decreasing HbA1c values from 9.5% to 
8.0% was 1.11 years and decreasing from 7% to 6.5% was associated with a gain of 0.3 
years of life. These improvements compare favourably with other medical interventions 
such as quitting smoking (for a 35-year-old man, mean improvement in LE is 0.83 years); 
routine beta-blocker therapy (for 55-year-old men who have survived a myocardial 
infarction, improvement of 0.1–0.47 years); chemotherapy for patients with advanced 
non-small cell lung cancer (improvement of 0.15–0.24 years); reduction of diastolic 
blood pressure (from 95 mmHg to 88 mmHg in 35-year-old men results in an 
improvement of 1.08 years); and reduction in cholesterol (from 239 to 200 mg/dl results 
in an improvement of 0.5 years) or thrombolytic therapy with recombinant tissue 
plasminogen activator during suspected myocardial infarction (improvement of 1.25 
years) [33].  
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The most substantial improvements in clinical outcomes were observed in the 
hypothetical treatment groups where the greatest improvements in HbA1c were simulated 
(i.e. scenario 1 > scenario 2 > scenario 3). Perhaps the main strength of the present 
analysis is that it provides an illustration of the anticipated benefits associated with 
treating patients to a range of HbA1c targets that are realistic for the majority of T2D 
patients. As there are individual differences in the risks of hypoglycaemia, weight gain 
and other adverse effects which are vital considerations when intensifying the treatment 
of type 2 patients, it is important to estimate the incremental difference between HbA1c 
goals. A limitation of currently recommended glycaemic goals is that they often do not 
provide detailed, comparative, differential data, but rather set a generic target which may 
be inappropriate for certain patients with specific baseline risk factors. In addition to this, 
many interventions such as patient education [35,36] and self-monitoring of blood 
glucose [37] amongst type 2 diabetics achieve moderate improvements in glycaemic 
control and patient quality of life. Therefore patients beginning with higher HbA1c levels, 
although achieving improvement in glycaemic control, are unlikely to reach 
recommended targets based solely on these interventions. Evaluation of such 
interventions requires an appreciation for the long-term clinical and economic benefits 
that incremental improvements in HbA1c can yield.  
 
The results presented here provide a reference against which to consider the costs of such 
interventions when provided to patients with differing baseline levels of glycaemic 
control. Although the present study indicates that improved glycaemic control with 
conservative HbA1c targets (9.5% and 8.0%) can lead to substantial clinical benefits, it 
indicates that more aggressive HbA1c targets (7.0% and 6.5%) provide the greatest 
benefits in patient health, cost containment, quality of life and LE, allowing clinicians to 
compare these outcomes and assess the appropriateness of instituting a more rigorous 
treatment approach.  
 
Improvements in HbA1c have been studied in isolation. Some may argue that this is not a 
completely accurate reflection of a patient’s clinical progression. However, this was an 
exploratory analysis specifically designed to assess only the impact of HbA1c 
improvements with other clinical considerations pre-defined. If there were data pertaining 
to simulated improvements in a range of risk factors in the present study, it would have 
become very difficult to conclusively identify drivers of long-term clinical benefits. As a 
result, the present study may underestimate the clinical benefits of a multifactorial 
approach to the management of patients with T2D including proactive treatment of other 
risk factors such as SBP and lipid levels. Indeed, as new clinical knowledge and best 
practices are continuously evolving, the importance of SBP, lipids, and inflammatory 
processes on diabetes outcomes are becoming more apparent. However, it should be 
noted that the present modeling simulation did not ignore the treatment of hypertension 
or hyperlipidaemia, but applied published data on patient management in the U.S. to 
accurately simulate the treatment of a typical U.S. cohort [21,23,24,38]. 
 
A potential shortcoming of the present study was that, because the interventions used to 
reduce HbA1c levels were hypothetical, the simulation did not take into account any 
negative effects associated with currently available treatments (i.e., weight gain and/or 
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elevated risk of hypoglycaemia). This may have led to an overestimation of the clinical 
benefits associated with these treatments in relation to real-life interventions used to treat 
patients to target HbA1c. However, the simulation did take into account hypoglycaemia, 
with an annual probability of severe hypoglycaemic events of 3% applied to all of the 
hypothetical treatments, in line with published observations in T2D patients from the 
UKPDS [3]. 
 
Conclusions 
 
This modeling study provides evidence that improvements in glycaemic control over a 
range of HbA1c values between 9.0% and 6.5% are associated with substantial 
improvements in long-term clinical outcomes in patients with T2D. Improved glycaemic 
control, independent of improvements in other risk factors such as blood pressure or lipid 
levels, was associated with extended LE and time to complications, improvements in 
QALE, and a reduced cumulative incidence of complications over patient lifetimes. 
These findings reinforce the idea that intensified therapy aimed at optimising glycaemic 
control should be the foundation of effective long-term management of type 2 patients.  
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Summary 
 
The purpose of this study was to compare in clinical and economic terms the long-acting 
insulin analogue detemir with intermediate-acting Neutral Protamine Hagedorn (NPH) 
insulin and with long-acting insulin glargine. We used the validated Center for Outcomes 
Research (CORE) Diabetes Model to project clinical and cost outcomes over a 35-year 
base case time horizon; outcome data were extracted directly from randomized, 
controlled trials designed to compare detemir with NPH and with insulin glargine. 
Modeled patient characteristics were derived from corresponding trials, and simulations 
incorporated published quality-of-life utilities with cost data obtained from a Medicare 
perspective.  
 
Detemir, when compared with NPH, increased quality-adjusted life expectancy by 0.698 
quality-adjusted life-years (QALYs). Lifetime direct medical costs were increased by 
$10,451 per patient, although indirect costs were reduced by $4688. On the basis of direct 
costs, the cost per QALY gained with detemir was $14,974. In comparison with glargine, 
detemir increased quality-adjusted life expectancy by 0.063 QALYs, reduced direct 
medical costs by $2072 per patient, and decreased indirect costs by $3103 (dominant). 
Reductions in diabetes-related comorbidities were also associated with detemir in both 
instances, most notably in the complications of retinopathy and nephropathy. Relative 
reductions in rates of complications were greatest in the comparison of detemir with NPH. 
Results were most sensitive to variation in hemoglobin A1c (HbA1c) levels. However, 
variation among any of the key assumptions, including HbA1c, did not alter the relative 
results. Detemir represents an attractive clinical and economic intervention in the U.S. 
health care setting compared with both NPH insulin and insulin glargine.  
 
Introduction 
 
The landmark Diabetes Control and Complications Trial (DCCT) of insulin treatment in 
type 1 diabetes (T1D) clearly demonstrated that intensive insulin therapy administered 
over a 6.5 year period significantly reduces the incidence and progression of diabetic 
complications [1]. On the basis of the DCCT findings, current diabetes guidelines issued 
by the American Association of Clinical Endocrinologists recommend intensive insulin 
therapy for all patients with T1D [2]. However, the DCCT also showed that intensive 
insulin therapy was associated with an increased incidence of hypoglycemia and weight 
gain [3,4]. The occurrence of hypoglycemia is largely due to the pharmacodynamics of 
commonly used human insulin preparations. Intermediate acting insulins, such as Neutral 
Protamine Hagedorn (NPH) insulin, are characterized by a 12-hour duration of action that 
peaks approximately 5 hours after injection; patient absorption rates are highly variable 
[5]. Consequently, NPH must be injected twice daily by most patients, and it often fails to 
mimic physiologic insulin activity in that it begins more slowly, peaks later, and lasts 
longer than the endogenous insulin response.  
 
In an attempt to overcome these drawbacks, long-acting insulin analogues have recently 
been developed that exhibit a more rapid onset of action with a 24 hour duration and 
peak-less activity, resulting in a near-physiologic basal level of insulin between meals [6]. 
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In numerous randomized clinical trials of long-acting insulin analogues, insulin detemir 
(IDet) and insulin glargine (IGlarg) have demonstrated at least equivalent or moderately 
improved glycemic control compared with NPH [7-13]. It is important to note, however, 
that treatment with IDet was associated with less weight gain, reduced within-patient 
variability, and decreased rates of nocturnal and major hypoglycemia when compared 
with NPH insulin [7,9,10,14]. The clinical efficacy and cost-effectiveness of IDet were 
recently highlighted in a combined clinical trial meta-analysis and economic cost-
effectiveness evaluation of IDet versus NPH conducted in the United Kingdom [15]. On 
the basis of a meta-analysis of 4 relevant randomized studies, it was concluded that 
treatment with IDet (similar to IGlarg) results in modest improvements in glycemic 
control, reduced hypoglycemia, and less patient weight gain compared with NPH. In the 
long-term economic analysis, this translated into reduced complications and improved 
quality of life; these outcomes represent excellent value for money spent [15].  
 
However, because of differences in health care and treatment costs between countries, 
investigators must evaluate the cost-effectiveness of treatments in a country-specific 
manner. For this reason, and on the basis of findings of a randomized, controlled trial 
reported by Hermansen et al. [7], this report presents a discussion of the cost-
effectiveness of IDet compared with that of NPH within the United States. In a second 
and separate analysis that is presented in the following report, IDet is directly compared 
with IGlarg. This comparison has been made possible by the recent completion of a 26 
week, multicenter, randomized trial of IDet and IGlarg administered in conjunction with 
the rapid-acting insulin aspart [16]. In this head-to-head comparison, it was found that 
although improvements in glycemic control were comparable, adverse events such as risk 
for major and nocturnal hypoglycemia were significantly less frequent with IDet 
treatment. The more predictable glucose-lowering effect of IDet compared with both 
NPH and IGlarg has been previously suggested on the basis of pharmacodynamic and 
pharmacokinetic studies conducted in patients with T1D [17]. For the first time, it is now 
possible to directly compare these 2 long-acting insulin analogues from a clinical and an 
economic perspective on the basis of randomized clinical trial data.  
 
In the following report, the validated Center for Outcomes Research (CORE) Diabetes 
Model is used to project the long-term clinical and economic benefits that might be 
anticipated with IDet treatment (either as a replacement for NPH or as an alternative to 
IGlarg) in the U.S. health system setting. Because currently available clinical data for 
these new long-acting insulin analogues have been generated from trials of less than 12 
months’ duration, the use of a computer simulation modeling approach is one of the few 
ways by which the long-term impact can be taken into consideration. By applying clinical 
trial results to simulation cohorts that closely resemble patients included in the trials, 
realistic assessments can be made in a defined cost setting. The following report 
represents a first attempt to predict the long-term clinical and economic potential of IDet 
in the U.S. diabetes market.  
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Methods 
 
Two separate analyses were undertaken and are included in this report. The first analysis 
modeled the impact of IDet usage compared with NPH insulin. Data were extracted from 
an 18 week, open-label, randomized trial that compared treatment with twice-daily IDet 
given in conjunction with mealtime insulin (aspart) versus treatment with twice-daily 
NPH supplemented with human soluble insulin 30 minutes before meals [7]. In total, 598 
patients with T1D were randomized and monitored for changes in glycemic control, 
insulin dose, body weight, and adverse events. The latter cost-effectiveness analysis, 
reported here, compares the long-acting insulins IDet and IGlarg. Model projections have 
been based on results generated in a recently completed head-to-head, randomized trial of 
IDet and IGlarg, in which IDet was administered twice-daily in combination with 
premeal insulin aspart (IAsp), and IGlarg was given once daily in combination with 
premeal IAsp [16]. Subjects were monitored over a 26 week period of treatment (6 
weeks’ titration and 20 weeks’ maintenance); changes in glycosylated hemoglobin 
(HbA1c) and body weight, hypoglycemic events, and other adverse events were recorded.  
 
Model Description 
 
Through the CORE Diabetes Model, the short-term clinical effects of IDet versus NPH 
and IDet versus IGlarg were simulated over a long-term horizon (35 years) from the U.S. 
health system perspective. The CORE Diabetes Model has been previously published in 
considerable detail [18]. Briefly, it is an interactive computer simulation model of 
diabetes that investigators developed for the purpose of determining the long-term health 
outcomes and economic consequences of interventions in type 1 or type 2 diabetes. 
Comprising 15 interdependent sub-models, the model simulates the diabetic 
complications of angina, myocardial infarction, congestive heart failure, stroke, 
peripheral vascular disease, diabetic retinopathy, macular edema, cataract, hypoglycemia, 
ketoacidosis, lactic acidosis, nephropathy, end-stage renal disease, neuropathy, foot ulcer, 
amputation, and nonspecific mortality.  
 
Each sub-model is a Markov model that uses time-, state-, and diabetes-type dependent 
probabilities derived from published sources; these are interconnected with the use of 
tracker variables. Patient cohorts can be defined in terms of age, sex, baseline risk factors, 
and preexisting complications, and disease management components can be altered in a 
disease management module. Similarly, economic data can be altered in an appropriate 
module that reflects the required setting. The CORE Diabetes Model thereby allows 
comparison of different patient populations in a variety of realistic clinical settings to 
yield long-term health and economic outcomes. Extensive validation of this model to 
ensure reliability of reported outcomes has been established in 66 separate analyses [19]. 
 
Simulation Cohorts 
 
Two separate simulation cohorts were defined according to the corresponding clinical 
trial from which clinical outcomes data were derived. Baseline characteristics of the 2 
treatment arms within a given clinical trial were pooled to generate an appropriate 
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simulation cohort; no statistical differences in baseline patient characteristics were noted 
between arms in either trial. The first cohort was based on a randomized, 18 week, 
multicenter clinical trial undertaken to compare IDet with NPH insulin in 595 patients 
with T1D [7] (Table 1). The second cohort was modeled on the 26 week, randomized, 
multicenter clinical trial recently presented by Pieber et al. [16]. In that trial, the long-
acting insulin analogues IDet and IGlarg (both given in combination with rapid-acting 
insulin aspart) were compared in intensively treated subjects with T1D (Table 1). 
 
Treatment Effects 
 
Treatment effects were extracted from the corresponding randomized clinical trials and 
were adjusted for baseline HbA1c. The between–treatment group difference in HbA1c 
was significant — a decrease of 0.5% versus 0.28% — with IDet versus NPH after 18 
weeks, respectively [7]. The risk of hypoglycemia was 21% lower with IDet than with 
NPH (p<0.036), and the risk of major hypoglycemia (defined as requiring third-party 
medical assistance) was non-significantly reduced at an event rate of 58 per 100 patient-
years with IDet versus 66 per 100 patient-years with NPH. Nocturnal hypoglycemia and 
major nocturnal hypoglycemia, however, were significantly reduced in the IDet arm by 
55% and 83%, respectively (both, p<0.008). Furthermore, a significant difference in body 
weight was observed after 18 weeks of treatment; the adjusted weight change was 1 kg 
lower in the IDet treatment group than in the NPH group (p<0.001). 
 
In the randomized trial that compared IDet with IGlarg, HbA1c decreased from 
8.76% to 8.16% (–0.71% points) and from 8.70% to 8.19% (–0.62% points), 
respectively—a nonsignificant between–treatment group difference [16]. However, a 
significant reduction in major hypoglycemic events (72%) favored IDet; an event rate of 
6.5 per 100 patient-years contrasted with a rate of 24.5 per 100 patient-years reported in 
the IGlarg treatment group (p<0.05). Episodes of nocturnal hypoglycemia were also 
significantly reduced in the IDet arm (32% lower; p<0.05). A nonsignificant difference in 
weight gain was also observed, although IDet was associated with a lower increase in 
body weight (0.52 kg) compared with the IGlarg group (0.96 kg). Although variation in 
the stability of glucose profiles was observed between arms in both trials, IDet-based 
treatment consistently exhibited reduced intra-day variability of fasting glucose levels 
compared with both NPH and IGlarg; these data were not included in the current analysis. 
 
Costs 
 
Cost analyses from a societal perspective within the U.S. health care system were 
performed, and both direct and indirect costs were taken into account. Direct costs, which 
were regarded as the sum of treatment, complication, and medication costs as listed by 
Medicare, were inflated to 2005 values (as previously reported) [20]. Indirect costs 
included those incurred through lost productivity; these were based on U.S.-specific data 
on average salaries, retirement age, and days of work missed because of complications 
(data taken from the U.S. Department of Labor, Bureau of Labor Statistics). All costs and 
clinical benefits were discounted at an annual rate of 3.0%, in accordance with 
recommendations for the U.S. setting [21]. Acquisition costs of insulin were based on 
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Table 1. Baseline demographics, complications, relevant concomitant medications, and 
management of patients in the simulated cohort 
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mean end-of-study dosing, and published Average Wholesale Price cost data (2005 Drug 
Red Book; Medical Economics Co., Inc., Montvale, NJ, USA) were used. 
 
Quality-of-Life Utilities 
 
Quality-of-life utilities were derived as previously described [18] with the exception of 
utilities associated with hypoglycemic events. For major hypoglycemic events, an event 
disutility of –0.0121 quality-adjusted life-years (QALYs) was assumed on the basis of 
recently published data [22]; for all other hypoglycemic events, a value of –0.0052 
QALYs was applied [23] Event disutilities are applied in the model to the 1 year period 
in which the event occurred, as previously outlined by Palmer et al. [18]. Subsequent 
state disutilities are applied for non-transient events that affect quality of life over a 
longer period. 
 
Sensitivity Analysis 
 
Sensitivity analysis was performed on key assumptions and variables used in the base 
case analysis: change in HbA1c, discount rate, duration of treatment effect, and costs for 
insulin and management of hypoglycemia. The impact of changes in HbA1c within the 
model was evaluated under 2 assumptions: (1) that improvements in HbA1c were 
identical in the 2 treatment groups, and (2) that they persisted for only 5 years. Through 
assignment of a variable annual discount rate of between 0% and 6%, the impact of this 
variable on costs and clinical benefits was assessed relative to the base case rate of 3.0% 
used in the simulation. Similarly, the time horizon was varied from the base case setting 
of 35 years to 5 and 10 year time horizons. Insulin detemir acquisition costs were varied 
by ±15% so that the impact of potential contractual rebate adjustments reflected within 
the U.S. setting could be assessed; sensitivity to costs associated with major 
hypoglycemic events was assessed through application of the confidence intervals 
associated with the base cost as reported by Bullano et al. [24]. 
 
Statistical Approach 
 
Analysis was performed by means of a nonparametric bootstrapping approach, in which 
the progression of diabetes was simulated in 1000 patients passed through the model 
1000 times for calculation of the mean and standard deviations of life expectancy; 
quality-adjusted life expectancy and costs were derived through second-order 
Monte Carlo simulation [25]. A total of 1000 mean values (each of 1000 patients) for 
incremental costs and incremental effectiveness in terms of quality-adjusted life 
expectancy were plotted (scatter plots) on the cost-effectiveness plane, and these data 
were used to generate an acceptability curve through calculation of the proportion of 
points below a range of willingness-to-pay thresholds. 
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Results 
 
IDet versus NPH: Life Expectancy, Quality-Adjusted Life Expectancy, and Cost-
Effectiveness 
 
Long-term projections indicated that treatment with IDet compared with NPH was 
associated with improvements in life expectancy and quality-adjusted life expectancy 
(Table 2). Life expectancy (discounted by 3.0%) was improved by 0.168 QALYs with 
IDet compared with NPH insulin. Quality-adjusted life expectancy increased with IDet 
by 0.698 QALYs; average values consisted of 8.0 QALYs (±0.09) and 7.32 QALYs 
(±0.08) for IDet and NPH, respectively. Direct medical costs increased by $10,451 in the 
IDet treatment group relative to the NPH group; however, this was partially balanced by 
reduced indirect costs of $4688 to yield a total lifetime cost increase of $5763 among 
those using IDet. In the final cost-effectiveness analysis, treatment with IDet was 
associated with an incremental cost-effectiveness ratio (ICER) of $14,974 per QALY 
gained versus NPH on the basis of direct costs. 
 
IDet versus NPH: Incremental Cost-Effectiveness Scatter Plot 
 
In the base case analysis, most points in the incremental cost-effectiveness scatter plot 
(Figure 1) fell within the upper right quadrant, indicating that treatment with IDet was 
both more effective and more costly than NPH-based therapy. When this was converted 
to an acceptability curve, it could be seen that in the base case analysis, IDet-based 
treatment was associated with a 100% likelihood that it would be cost-effective versus 
NPH, if the willingness to pay was $50,000 per QALY gained. 
 
 
Table 2. Summary of Base Case Results: IDet versus NPH 
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IDet versus NPH: Diabetes-Related Complications 
 
Treatment with IDet compared with NPH resulted in an overall reduction in diabetes-
related complications, most notably in retinopathy and nephropathy (Table 3). The 
greatest absolute reductions were projected for the cumulative incidences of proliferative 
diabetic retinopathy (PDR), end-stage renal disease (ESRD), microalbuminuria, and gross 
proteinuria, with values 0.8%, 0.8%, 2.1%, and 2.8% lower than those resulting from 
NPH treatment, respectively. Cardiovascular complication rates were generally similar 
between treatment groups, with the exception of myocardial infarction, for which the 
cumulative incidence was reduced by 0.7% with IDet compared with NPH. 
 
Sensitivity Analysis 
 
Sensitivity analysis revealed that the ICER for IDet versus NPH was most sensitive to 
changes in HbA1c. However, even when no difference in efficacy with respect to HbA1c 
was assumed between treatment groups, IDet was associated with an ICER of $20,386 
per QALY gained versus NPH (Table 4). As would be expected, reducing the time 
horizon increased the ICER, because benefits that result from improvements in glycemic 
control tend to occur later rather than earlier. Nevertheless, variations in key assumptions 
(including price of IDet, discount rate, and cost of managing hypoglycemia) had no 
impact on the relative results and yielded ICERs below the $25,000 per QALY gained 
threshold used to define “attractive” diabetes interventions [26]. 
 
IDet versus IGlarg: Life Expectancy, Quality-Adjusted Life Expectancy, and Cost-
Effectiveness 
 
Treatment with IDet was associated with lower direct medical and indirect costs, as well 
as improved quality of life and life expectancy, when compared with treatment with 
IGlarg (Table 5). Discounted life expectancy was improved by 0.087 years and quality-
adjusted life expectancy by 0.063 years with IDet. For IDet relative to IGlarg, direct 
medical costs were reduced by $2072 and indirect costs were reduced by $3103 per 
patient, resulting in overall lifetime cost savings of $5174 per patient from a societal 
perspective. In the cost-effectiveness analysis, IDet was therefore a dominant treatment 
option. 
 
IDet versus IGlarg: Incremental Cost-Effectiveness Scatter Plot 
 
In the base case analysis for IDet versus IGlarg, the incremental cost-effectiveness scatter 
plot (Figure 2) demonstrated that most points fell within the lower right quadrant, 
indicating that treatment with IDet was more effective and less costly than IGlarg-based 
therapy. However, there were a number of points in the upper right and lower left 
quadrants; when this plot was converted to an acceptability curve, it could be seen that in 
the base case analysis, IDet-based treatment had an 80% probability that it would be cost-
effective, if the willingness to pay was $50,000 per QALY gained. 
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Figure 1. Scatter plot and acceptability curve for IDet versus NPH (Base case scatter plot 
of 1000 samples of mean incremental costs plotted against mean incremental 
effectiveness (quality-adjusted life-years gained) generated for 1000 patients for IDet 
therapy versus NPH-based therapy) 
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Table 3. Cumulative incidence of diabetes-related complications: IDet vs NPH and IDet 
vs IGlarg 
 
 
 
Table 4. Sensitivity analysis on the direct incremental costs per QALY 
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Figure 2. Scatter plot and acceptability curve for IDet versus IGlarg (Base case 
scatterplot of 1000 samples of mean incremental costs plotted against mean incremental 
effectiveness (quality-adjusted life-years gained) generated for 1000 patients for IDet 
therapy versus IGlarg-based therapy) 
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Table 5. Summary of Base Case Results: IDet vs IGlarg 
 
 
 
 
 
IDet versus IGlarg: Diabetes-Related Complications 
 
IDet treatment was associated with a reduced cumulative incidence of diabetes-related 
complications, particularly of retinopathy and nephropathy, when compared with IGlarg 
(Table 3). The corresponding absolute reductions in cumulative incidence of PDR, 
ESRD, microalbuminuria, and gross proteinuria were 0.8%, 0.5%, 0.9%, and 1.3%, 
respectively, for IDet versus IGlarg. 
 
Sensitivity Analysis 
 
When IDet was compared with IGlarg, results were most sensitive to changes in 
pharmacy acquisition costs, with an ICER of $1126 for a 15% increase in the cost of 
IDet. However, variation in the other key assumptions had no impact on relative results, 
and IDet remained dominant in the U.S. setting (Table 1). 
 
Discussion 
 
We have used the validated CORE Diabetes Model to analyze long-term economic and 
clinical outcomes that can be expected with uptake of the long-acting insulin detemir into 
the intensive treatment regimen of patients with T1D within the United States. Compared 
with both intermediate-acting NPH insulin and an alternative long-acting insulin, IGlarg, 
model projections indicate that use of IDet is associated with improvements in life 
expectancy, quality-adjusted life expectancy, and cumulative incidence of diabetes-
related complications. In economic terms, IDet represents a very attractive alternative to 
both NPH and IGlarg according to generally accepted standards. 
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Long-acting insulin analogues have been developed in response to high rates of major 
and minor hypoglycemia, both daytime and nocturnal, experienced by patients with 
diabetes who use NPH. The occurrence of hypoglycemia is a frequent complication 
among intensively treated patients with T1D; it affects overall patient quality of life and 
has the potential to be a life-threatening event [27]. Weight gain associated with insulin 
use is also a considerable problem for patients with diabetes. Apart from negative effects 
on blood pressure and lipid levels [28,29], which exacerbate diabetic complications, 
increased weight often has an adverse effect on patient quality of life [30].  
 
Randomized clinical trials comparing IGlarg with NPH have demonstrated improved or 
at least equivalent glycemic control, reduced incidence of hypoglycemia, and reduced 
weight gain with the former. Additionally, recent retrospective assessments of Medicaid 
claims in the United States reported that patients who used IGlarg, when compared with 
matched reference patients with diabetes, recorded lower event rates of hypoglycemia or 
greater reductions in event rates, as well as reduced treatment costs [24,31]. These early 
data suggest that the potential benefits exhibited by long-acting insulin analogues within 
controlled settings are already being realized in clinical practice. Before IDet was 
approved by the U.S. Food and Drug Administration (FDA) in 2005, IGlarg was the only 
long-acting insulin analogue available in the United States. Preliminary trials directly 
comparing IDet and IGlarg for within-subject variability found that IDet had a 
significantly more predictable glucose-lowering effect than IGlarg, which, it was 
postulated, should result in fewer hypoglycemic events [17]. Indeed, a recently reported 
26 week long, head-to-head trial of IDet and IGlarg found a significant reduction in 
major hypoglycemic events associated with the use of IDet [16]. 
 
To gain an appreciation for the long-term potential offered by IDet, we have used the 
CORE Diabetes Model to project over 35 years the short-term benefits observed with 
IDet versus NPH or IGlarg treatment in randomized clinical trials. Treatment with IDet 
has resulted in increased life expectancy, improved quality of life, and reduced 
complication rates compared with NPH; costs associated with these improvements are 
well within the limits of general acceptability at an ICER of $14,974 based on direct 
costs. According to Klonoff and Schwartz [26], an ICER that is less than $25,000 should 
be considered a very attractive diabetes intervention.  
 
In the comparison of IDet with IGlarg, although both are long-acting insulin analogues, 
IDet was shown to result in cost savings and an improved patient quality of life, making 
it a dominant option to IGlarg treatment. The between-group difference in complication 
event rates was, as anticipated, less than that seen for IDet versus NPH. Nevertheless, 
over a 35-year time projection, these differences translated into meaningful clinical and 
economic benefits favoring IDet. Because long-acting insulin analogues offer relevant 
improvements and flexibility in diabetes care, both clinically and in terms of patient 
quality of life, interest in and uptake of these new insulins by clinicians are on the rise. 
For this reason, it becomes necessary to make timely clinical and economic decisions 
regarding their short- and long-term potential. Because the available trial data are based 
on relatively short periods of observation, use of appropriate and validated disease 
models to project long-term clinical and economic outcomes represents the best currently 
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available approach by which clinicians can make evidence-based decisions on the basis 
of long-term assessments. 
 
The present modeling study was based on randomized clinical studies conducted 
predominantly within European health care settings. Extrapolation of these findings to a 
U.S. setting has permitted the prediction of likely economic and clinical outcomes in a 
U.S. diabetes population. However, the necessity of confirming these short-term clinical 
outcomes in a typical U.S. diabetes cohort of representative ethnic diversity is 
acknowledged. With the recent completion (late in 2005) of a United States–based 
randomized trial of IDet versus IGlarg, new data can be used to further elucidate the 
relative merits of the conclusions presented here. 
 
Conclusions 
 
Among patients with insulin-dependent diabetes, basal bolus therapy with detemir was 
projected to yield improvements in life expectancy and quality-adjusted life expectancy 
when compared with either NPH or IGlarg. IDet was also associated with a reduced 
cumulative incidence of diabetes-related complications and consequently represents a 
clinically and economically attractive treatment option from a societal and reimbursement 
perspective in the U.S. setting.  
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Summary 
 
Diabetes mellitus (DM) affects over 18.2 million Americans and diabetes-related medical 
costs exceed 132 billion dollars per year, totaling more than 12% of the United States 
healthcare budget. The Diabetes Control and Complications Clinical Trial demonstrated 
that intensive insulin therapy and the control of plasma glucose can significantly reduce 
the incidence of late diabetic complications and delay the progression of existing 
conditions in type 1 diabetes (T1D). Optimal glycemic control often requires intensive 
insulin therapy to maintain a hemoglobin A1C (A1C) of less than 7% as recommended 
by the American Diabetes Association. It is estimated that more than half of the 
approximately 7 million Americans using insulin do so with suboptimal treatment and 
while administering one or two insulin injections per day. Non-adherence may be a 
contributing factor in suboptimal treatment. For a variety of reasons, many patients 
diagnosed with diabetes and treated with insulin are non-adherent.  
 
The primary objective of this study was to evaluate preference for an insulin delivery 
system comparing a disposable doser (InnoLet) to the standard vial/syringe. In a 
prospective, randomized, open-label, two-period, crossover study, 260 patients were 
enrolled (age ≥ 18 years, with type 1 or 2 diabetes, and receiving NPH or regular or 70/30 
insulin for at least 6-months). A total of 162 patients completed both treatment arms. 
Excluded were those unable to read/write English or administer their own injections, 
pregnant/lactating women, those using antipsychotics, and those with a history of alcohol 
abuse or cognitive impairment. Patients completed the eight-item Diabetes Fear of Self-
Injection Questionnaire at baseline, week 12 and week 24. Items were rated on a 4-point 
Likert scale (1 = almost never; 4 = almost always) with a maximum fear score of 32. At 
week 24, patients completed a preference survey. 
 
Of the 162 patients completing both treatment arms, 89 (55.0%) were in the vial/syringe 
to disposable doser treatment arm, 50% were female and mean age was 60 ± 11 years. 
Patients in both treatment arms displayed little significant differences in baseline 
characteristics. Patients reported significantly lower fear of self-injection after using the 
disposable doser compared to vial/syringe (mean ± SEM: 9.5 ± 0.2 vs. 11.2 ± 0.4; 
p<0.0001). Most patients (71.5%) indicated a preference for the disposable doser 
compared to the vial/syringe method (p<0.0001). 
 
The majority of patients preferred the disposable doser, and reported significantly less 
fear of self-injection using this delivery system. There are some potential limitations to 
consider. A randomization bias may have been present, patients who enrolled in this 
study were those who were actively seeking medical treatment for diabetes, insulin pens 
and cartridges are not available for all types of insulin regimens, pre-filled pens and 
cartridges may not be altered and, in general, alternative insulin delivery systems tend to 
be more costly than insulin sold in traditional vials. However, insulin may have greater 
patient acceptance and less psychological distress when administered via an alternative 
delivery system. 
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Introduction 
 
Diabetes mellitus (DM) affects over 18.2 million Americans and diabetes-related medical 
costs exceed 132 billion dollars per year, totaling more than 12% of the United States 
healthcare budget [1,2]. A portion of this budget is used to treat complications associated 
with diabetes, primarily among those whose diabetes is poorly controlled. The Diabetes 
Control and Complications Clinical Trial [3] demonstrated that intensive insulin therapy 
and the control of plasma glucose can significantly reduce the incidence of late diabetic 
complications and delay the progression of existing conditions in T1D. Optimal glycemic 
control often requires intensive insulin therapy to maintain a hemoglobin A1C (A1C) less 
than 7% as recommended by the American Diabetes Association [4]. It is estimated that 
more than half of the approximately 7 million Americans using insulin do so with 
suboptimal treatment and while administering one or two insulin injections per day [5,6]. 
Non-adherence may be a contributing factor in suboptimal treatment. For a variety of 
reasons, many patients diagnosed with diabetes and treated with insulin are non-adherent. 
Lack of diabetes education, poverty, stigma and fear associated with needles, denial, and 
lifestyle all contribute to non-adherence with insulin injections and poor glycemic 
control.  
 
In 1987, insulin pens were introduced in the United States and, through the years, 
additional alternative insulin delivery systems have become available. The development 
of alternative insulin delivery systems have offered patients improved flexibility, more 
accurate dosing, convenience and improved social acceptability with administration of 
their insulin regimen. Moreover, these benefits may have improved patients’ adherence to 
their insulin regimen. Two multicenter surveys of 1310 insulin users showed that 77% of 
patients found insulin adherence to be easier with the use of an insulin pen, and 85% of 
insulin pen users never missed a scheduled injection, as compared to 73% of the vial and 
syringe users [7]. In 1993, Plevin and Sadur [8] assessed patient acceptance of insulin 
pens and found that 98% of the patients reported that the insulin pen was easier to use 
and 91% preferred to continue using the pen. Recognizing the increasing importance of 
patient preference, we investigated through a multicenter, randomized, cross-over trial 
whether patients diagnosed with diabetes and treated with insulin therapy would prefer 
the disposable doser (InnoLet, Novo Nordisk Inc., Princeton, NJ) over the standard vial 
and syringe, as has been found among patients using insulin pens. The disposable doser is 
similar to an insulin pen in that it is a pre-filled disposable insulin delivery system. It has 
a large dial that is easy to read, with audible clicks to help patients select the correct dose 
of insulin. To use the system, patients set their dose, insert the needle and press a button. 
 
Methods 
 
Study design 
 
This was a randomized, open-label, two-period cross-over study conducted at 50 
physician offices within Arizona, California, Colorado, Oregon, Texas, Washington and 
Wyoming with patient enrollment occurring from August 1, 2003 through May 5, 
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2004. The majority of physician investigators who participated specialized in internal 
medicine (54.0%), followed by family medicine (36.0%), endocrinology (8.0%), and 
general medicine (2.0%). Conduct of this trial conformed to the human experimentation 
guidelines of the Declaration of Helsinki and title 21 parts 50 and 56 of the United States 
Code of Federal Regulations [9,10]. An institutional review board for each clinical center 
approved the protocol, and all study participants gave written informed consent. 
 
Patients 
 
Patients were eligible for inclusion if they were at least 18 years of age at the time of 
enrollment, diagnosed with type 1 or 2 DM and had an A1C value of ≤ 10%. Patients 
were required to use at least one daily injection of neutral protamine hagedorn (NPH), 
regular or 70/30 insulin, and to have been using insulin for at least 6 months. Patients 
were excluded if they were unable to read or write English, were unable to administer 
their own injections, had used an alternative insulin delivery system during the 6 months 
prior to enrollment, were pregnant or lactating (or had the intention of becoming 
pregnant), or were using antipsychotics. Patients were also excluded if they had any form 
of cognitive impairment or a history of alcohol abuse. 
 
Organization of the study 
 
All patients were identified during routine physician office visits. Three study visits were 
performed: visit 1 at baseline (week 0), visit 2 for treatment crossover (week 12), and 
visit 3 for the final visit (week 24). Patients were randomized to either the disposable 
doser or vial/syringe for approximately 12 weeks and then ‘crossed over’ to the alternate 
treatment for an additional 12 weeks (Figure 1). At visit 1 (week 0), patients who 
enrolled were randomly assigned to receive the disposable doser or vial/syringe on the 
basis of a computer-generated randomization scheme. If randomized to the disposable 
doser, the investigator, or trained staff, taught the patients how to use it. Patients were 
required to demonstrate proficiency in the use of the delivery system. In addition, the 
patients were given written instructions on the use of the device. At each visit, A1C 
testing was performed at the site using a disposable monitor, which had been waived by 
the Clinical Laboratory Improvement Amendments (CLIA) and certified by the National 
Glycohemoglobin Standardization Program (NGSP).  
 
Patients also completed the following questionnaires: Diabetes Fear of Self-Injection 
[11], Thoughts about Taking Insulin, Insulin Treatment Satisfaction Questionnaire 
(ITSQ) [12], and Problem Areas in Diabetes (PAID) [13,14] (Appendix A). During visit 
3, patients also completed the Insulin Device Preference Questionnaire (Appendix A). 
Patients were required to complete the questionnaires in the exam room prior to leaving 
the site. To obtain study medication, patients were given a pharmacy purchase card to 
present to their community pharmacy. Therefore, all patients received study medication, 
delivery systems and supplies at no charge. In addition, after each visit, patients were 
compensated for their time with a gift card of a nominal amount to redeem at a national 
chain retail store. 
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Figure 1. Treatment schedule 
 
 
 
 
 
Efficacy assessments 
 
The primary efficacy endpoint was patient preference of an insulin delivery system: 
disposable doser or vial/syringe as measured by the Insulin Device Preference 
Questionnaire. Secondary measures included patient responses to the following 
questionnaires: Diabetes Fear of Self Injection [11], Thoughts about Taking Insulin, 
ITSQ [12], and PAID [13,14] (Appendix A). To assess delivery system preference and 
patients’ thoughts about taking insulin, the Device Preference and Thoughts About 
Taking Insulin Questionnaires were developed. In addition, baseline demographics and 
clinical characteristics of patients were evaluated to describe the population, and to 
determine if there were any differences in study outcomes based on patients’ 
characteristics. The demographics evaluated included age, gender, body mass index, and 
race. The clinical characteristics evaluated included type of diabetes, duration of diabetes, 
and duration of insulin use, Charlson Co-morbidity Index (CCI), and A1C values. The 
CCI for each patient was calculated from the patient’s concomitant illnesses and was 
used as a measure of co-morbidity [15]. The CCI contains 17 categories of diseases, each 
assigned an associated weight based on the adjusted risk of one-year mortality [16]. The 
overall score reflects the cumulative increased likelihood of one-year mortality. The 
higher the score, the more severe the burden of comorbidity [15,16]. 
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Statistical analysis 
 
Due to the non-systematic distribution of missing data across study variables, the number 
of patients with missing data for each study variable is reported. All data are presented as 
mean ± standard error of the mean (SEM) or N (%; percent) and stratified by either 
treatment arm or treatment response (completion of disposable doser or vial/syringe use) 
as appropriate for the data. To compare baseline demographic and clinical characteristics 
between treatment arms, t-test and chi-square analyses were performed on non-missing 
data. Patient preference rates for each of the survey questionnaires were reported from the 
questionnaires completed during visit 2 and visit 3. To test the preference rates, a one-
sample test of proportions was used. Proportions were compared to a baseline value of 
0.50 (ie, no preference).  
 
To compare treatment effect, only non-missing pairs (ie, for patients with non-missing 
data upon completion of each treatment arm) were included in the analysis. The mean 
treatment effect was first determined within each treatment arm among non-missing 
pairs, then the un-weighted average of the two treatment arms was calculated as the 
overall treatment effect. The t-test or Wilcoxon signed rank was used to compare the 
treatment effect for continuous or ordinal variables. Logistic regression was performed to 
identify potential factors that influence a patient's preference for the disposable doser 
versus no preference for the disposable doser. The no-preference category included 
patients who reported no preference plus those who reported preference for vial/syringe. 
Variables entered into the model included: age at enrollment, gender, diabetes type and 
treatment arm. Two-way interaction terms were checked for significance and included in 
the final model if significant. Reported p-values for the preference survey questionnaire 
are one-sided, all other reported p-values are two-sided. An alpha level of 0.05 was used 
for all statistical analyses. 
 
Results 
 
A total of 260 patients were enrolled in the study. To be included in the primary analysis, 
a patient had to have met all inclusion and exclusion criteria, completed all study visits 
within the designated timeframe and completed the preference outcome (n = 162). Patient 
demographics are displayed in Table 1. Ninety-eight patients failed to meet these 
requirements and were excluded for the following reasons: one patient (0.4%) used 
insulin for less than 6 months prior to enrollment, 53 (20.4%) were lost to follow-up, 32 
(12.3%) were exposed to either delivery system for less than 9 weeks or had greater than 
a 15-week gap between visit dates, seven (2.7%) had a serious adverse event (all were 
deemed unrelated to study treatment), two (0.7%) did not complete the preference 
outcome, and three (0.7%) had a history of alcohol abuse or dementia. 
 
Delivery system preference 
 
Of the entire cohort, 71.5% of the patients reported an overall preference for the 
disposable doser (p<0.0001; Table 2). Patients reported that the disposable doser was a 
more convenient method for the administration of insulin (74.1%, p<0.0001), an easier 
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Table 1. Baseline demographic and clinical characteristics 
 
 
 
 
method for insulin administration (75.2%, p<0.0001), was more comfortable to use in 
public (72.3%, p<0.0001), was the least unpleasant method to use (67.9%, p<0.0001), 
made it easier to take all of their daily insulin doses (62.3%, p=0.0006), and made life 
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with diabetes easier (62.2%, p=0.0007; Table 3). Although not statistically significant, a 
slightly higher percentage of patients reported that the disposable doser allowed a more 
enjoyable social life (52.5%, p=0.2658), was the method of insulin administration that 
least interfered with daily activities (51.5%, p=0.3569), and provided an overall better 
quality of life (55.6%, p=0.0763). 
 
No statistical test was performed on the questions for preference of the disposable doser 
providing a more flexible method to deliver insulin, a method of insulin administration 
that provides better control over blood sugar, and a method of insulin administration that 
makes them less dependent on others, because the proportion of patients who selected the 
disposable doser as the preferred method was less than the baseline comparison value of 
0.50 (ie, no preference). The degree of patient preference (slight, some, strong, very 
strong) was examined for each subset: those who preferred the disposable doser and those 
who preferred the vial/syringe. Of the subset of patients who preferred the disposable 
doser (n = 117), 78.6% (n = 92) had a strong or very strong preference for this delivery 
system. Of the subset of patients who preferred vial/syringe (n = 36), 66.7% (n = 24) had 
a strong or very strong preference for this delivery system. Factors that influenced 
preference for the disposable doser included age and treatment arm. For each additional 
year of age increased, patients reported a decrease in their preference for the disposable 
doser (odds ratio [OR], 0.948; 95% CI 0.911–0.986). Those who were randomized to arm 
2 (vial/syringe to disposable doser) preferred the disposable doser more than those who 
were randomized to arm 1 (disposable doser to vial/syringe) (OR, 2.170; 95% CI 1.051–
4.478). 
 
Fear of Self-Injection Questionnaire  
 
Results for all of the eight items, as well as the summary score, on the Fear of Self-
Injection Questionnaire showed a statistically significant difference, where after using the 
disposable doser, patients reported a lower fear of self-injection (p<0.05; Table 4). The 
summary score for overall fear of self-injection was lower after using the disposable 
doser than after using vial/syringe (mean ± SEM: 9.5 ± 0.2 vs. 11.2 ± 0.4). 
 
Thoughts About Taking Insulin Questionnaire 
 
Results for six of the seven items, as well as the summary score, on the Thoughts About 
Taking Insulin Questionnaire showed a statistically significant difference, where after 
using the disposable doser, patients reported a lower degree of non-compliance (p<0.05; 
Table 5). The summary score for overall degree of non-compliance was lower after 
using the disposable doser than after using vial/syringe (mean ±SEM: 10.3 ± 0.3 vs. 12.0 
± 0.5).  
 
Insulin Treatment Satisfaction Questionnaire (ITSQ) 
 
There was a statistically significant difference in all transformed score categories of the 
ITSQ, as well as the overall summary score (p<0.05; Table 6). After using the 
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Table 2. Patient preference for insulin administration delivery system stratified by 
randomization 
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disposable doser, patients had higher insulin treatment satisfaction in the areas of 
convenience of regimen (p<0.0001), lifestyle flexibility (p=0.0006), glycemic control 
(p<0.0001), hypoglycemic control (p<0.0001), insulin delivery system satisfaction 
(p<0.0001) and overall satisfaction (p<0.0001) compared to after using vial/syringe. The 
transformed summary score for overall insulin treatment satisfaction was higher after 
using the disposable doser than after using the vial/syringe (mean ± SEM: 79.0 ± 1.3 vs. 
70.4 ± 1.7; Table 7).  
 
Problem Areas in Diabetes (PAID) 
 
Results for 17 of the 20 items, as well as the summary score, on the PAID questionnaire 
showed a statistically significant difference, where after using the disposable doser, 
patients reported a lower amount of problem areas in diabetes (p<0.05; Table 8). The 
summary score for the overall problem areas in diabetes was lower after using the 
disposable doser than after using the vial/syringe (mean ± SEM: 20.8 ± 1.5 vs. 26.1 ± 
1.9). 
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Table 3. Comparison* of overall preference for the disposable doser upon study 
completion 
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Table 4. Responses to Diabetes Fear of Self-Injection Questionnaire upon completion of 
disposable doser versus vial/syringe 
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Table 5. Responses to Thoughts About Taking Insulin Questionnaire upon completion of 
disposable doser versus vial/syringe 
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Table 6. Responses to Insulin Treatment Satisfaction Questionnaire upon completion of 
disposable doser versus vial/syringe 
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Table 7. Mean difference comparisons* of transformed scored responses to Insulin 
Treatment Satisfaction Questionnaire upon completion of disposable doser versus 
vial/syringe 
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Table 8. Responses to Problem Areas in Diabetes questionnaire upon completion of 
disposable doser versus vial/syringe 
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Discussion 
 
The primary objective of this study was to evaluate patients’ preference for an insulin 
delivery system by comparing a disposable insulin doser to standard vial and syringe. We 
have shown that in the real world setting, after using both delivery systems, patients 
reported a greater preference for the disposable insulin doser. The goal of insulin therapy 
is to return blood glucose levels to normal or near-normal levels. It has been extensively 
documented that glycemic control may prevent both short-term and long-term effects of 
poorly controlled blood glucose [1–3]. However, for long-term regimens, such as insulin 
therapy, to be effective, patients must be willing to adhere to their treatment plan. While 
there are many factors that affect adherence, factors that may enhance patients’ 
willingness to adhere include ease and convenience of administration, minimization of 
lifestyle disruptions, and the ability to be confident in the skills necessary to manage the 
regimen.  
 
We found factors that contributed to patients’ preference for the disposable doser 
included its convenience, ease of use, comfort of use in public and social settings, 
lessening fear of self-injection, lessening feeling of being overwhelmed by diabetes and 
making life with diabetes easier. Our findings of 71.5% overall preference for the 
disposable doser are consistent with the results of a previous clinical trial that showed 
patients’ preference for use of an alternative insulin delivery system over vial and syringe 
[7,8]. Furthermore, a two-sided test was conducted and there was no significant 
difference in the study findings. While we found many factors that may contribute to 
patients being more adherent to their insulin treatment regimen, we did not find a 
significant difference in A1C concentrations between the two treatment groups during the 
study observation period. While a few of the patients had a change in their insulin 
regimen between study visits, the majority did not and generally, patients switched their 
insulin delivery system rather than the type, frequency and/or dose of insulin.  
 
The design of this study required that patients used insulin therapy for at least 6 months; 
however, the majority of patients had been using insulin therapy for 5 or more years. 
Therefore, it is reasonable to assume that these patients had mastered the manual 
dexterity and hand–eye coordination necessary to administer insulin via vial and syringe. 
However, patients reported that using the disposable doser to administer insulin 
consumed even less time, made it easier to give the correct amount of insulin, caused less 
pain, and postponed or missed insulin doses occurred less often. These enhanced 
efficiencies may result in greater patient acceptance of insulin therapy, more accurate 
insulin administration, fewer insulin administration errors and missed doses, and thereby 
may delay or prevent the onset of long-term complications of diabetes. 
 
Limitations 
 
There are some study limitations to consider. Although patients were randomized, there 
were some differences in baseline characteristics between the patients within the two 
treatment arms. Therefore, logistic regression was performed to adjust for age, gender, 
type of diabetes, and treatment arm. For the majority of patients, only the delivery system 
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changed so any potential drug or efficacy bias that would affect preference was removed. 
However, a randomization bias may have been present. To correct this potential bias, 
Koch’s method was used when performing tests of treatment effect; however, one cannot 
be certain if it was completely eliminated. While our findings were statistically 
significant, we cannot be certain that patients’ preference for an insulin delivery system 
would result in an improvement in their clinical status. Additional research exploring the 
clinical significance of each of the delivery systems would be helpful.  
 
In addition, patients who enrolled in this study were those who were actively seeking 
medical treatment for diabetes. It is not known if these findings would be similar for the 
general population of patients treated for diabetes. This study had a large proportion of 
patients with T2D. Therefore, our study finding may not be generalizable to the entire 
insulin-dependent population. Finally, some disadvantages exist with the use of 
alternative insulin delivery systems. Insulin pens and cartridges are not available for all 
types of insulin regimens, pre-filled pens and cartridges may not be altered and, in 
general, alternative insulin delivery systems tend to be more costly than insulin sold in 
traditional vials. 
 
Conclusions 
 
In real-world clinical practice settings, after using both the disposable doser and vial and 
syringe, patients in this study preferred the disposable doser to administer their insulin 
therapy. The importance of patient preference should not be underestimated. When 
prescribing insulin therapy, physicians may consider asking patients which delivery 
system they would prefer. An alternative insulin delivery system may offer greater 
patient acceptance of insulin therapy and, as was found in our study, improved treatment 
satisfaction. These findings may be clinically significant, given the potential health gains 
that can be obtained through improved diabetes self-management. Further research is 
needed to examine long-term use of the alternative insulin delivery systems.  
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Summary 
 
Successfully managing diabetes is a complex process that includes addressing issues of 
drug efficacy, safety and treatment satisfaction. Additionally, the combined impact of 
patient/disease characteristics and treatment outcomes on treatment satisfaction is not 
well understood. The purpose of this study was to examine the impact of age, weight, 
gender, co-morbid conditions, diabetes history, treatment burden, efficacy (HbA1c) and 
side effects (weight gain, hypoglycemic events) on patients' appraisal of treatment 
satisfaction using linear regression models. Data from a multi-center, randomized clinical 
trial comparing the efficacy/safety of biphasic insulin aspart 70/30 (BIAsp 70/30) vs. 
glargine (Glar) among insulin naïve type 2 patients were analyzed. Subjects were 
between ages 18–75, with baseline HbA1c > 8% and BMI ≤ 40 kg/m2 (N = 233). 
Treatment satisfaction was assessed by the Insulin Treatment Satisfaction Questionnaire 
(ITSQ).  
 
When factors were examined independently, multiple significant relationships (age, 
comorbidity, hypoglycemic events, and weight gain) with overall and/or domains of 
treatment satisfaction were found. However, when all significant relationships were 
examined together, only neuropathy, treatment efficacy, and number of hypoglycemic 
events maintained their previous significance. By examining predictors independently, 
significant relationships were identified. However, not all findings remained significant 
when examined in combination with each other. Thus, to more accurately characterize the 
impact of factors on treatment satisfaction, a more comprehensive approach may be 
necessary. By improving patient treatment satisfaction, the efficacy of treatments, as well 
as critical treatment outcomes such as compliance and cost of care should be improved.  
 
Introduction 
 
Successfully managing diabetes is a complex process and must address not only issues of 
drug efficacy and safety but also treatment satisfaction. Weaver and colleagues [1] 
defined treatment satisfaction as the patient's view of the treatment process and its 
associated outcomes based on predefined criteria. Treatment satisfaction is a key patient-
reported outcome as it has been found to impact patient compliance [2,3], cost of care 
[4,5], and self-management behaviors [6]. Treatment satisfaction has also been shown to 
significantly differ between the array of drug treatment options available to clinicians for 
a given patient [7,8]. It may at times be more sensitive to change than quality of life, and 
has the ability to distinguish treatments with equivalent efficacy [9]. Persons with 
diabetes who perceive injecting insulin as burdensome may experience more negative 
health outcomes [10], whereas patients who are satisfied with their treatments are more 
likely to maintain positive physical and psychological health [11]. 
 
Understanding the elements of treatment satisfaction for diabetes is especially important, 
given the ever increasing range of treatment options for diabetes patients as treatment 
satisfaction expectations have been shown to be dynamic and changing with the 
introduction of new therapies [12]. Overall treatment satisfaction in diabetes consists of 
the patient's appraisal of 3 main treatment-related parameters: side effects, 
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burden/inconvenience, and efficacy [13,14]. In diabetes, appraisal of side effects may 
predominantly include factors such as weight gain or the occurrence of hypoglycemic 
events. Appraisal of inconvenience or burden may take into consideration number of 
injections or type of delivery device. The gold standard for assessing efficacy is generally 
considered to be improvement in HbA1c level, although it is unclear if diabetes patients 
are aware of their exact values when not enrolled in a clinical trial. Additionally, patient 
and disease characteristics such as age, gender, time with diabetes, and prevalence and 
incidence of co-morbid conditions may act as mediators that influence these appraisals. 
Static factors such as patient and disease characteristics are generally constant or fixed at 
any given point in time. Characteristics such as age, gender, level of education, ethnicity 
and duration of diabetes have been shown to account for some of the differences in 
patients' treatment satisfaction with their diabetes care when provided by 
endocrinologists compared to generalists [15].  
 
However, data on the relationship of these factors to treatment satisfaction is oftentimes 
conflicting, and many significant relationships do not endure when examined in 
combination with other important factors. For example, studies have found that greater 
satisfaction is associated with decreasing age, while others have indicated that younger 
patients are less satisfied with their treatment [16-18]. The occurrence of diabetes-related 
complications has been found to be associated with lower treatment satisfaction with 
diabetes medication, however, this association was no longer found when age, therapy 
and HbA1c level were also taken into consideration [17]. Insulin-treated patients have 
been found to have significantly greater treatment satisfaction than non-insulin treated 
patients with diabetes, though this significant difference was also lost after adjustments 
were made for age, gender, body mass index and duration of diabetes [19]. When 
examining treatment outcome factors which influence the appraisal of treatment 
satisfaction in diabetes, the most universal finding is that treatment satisfaction has 
generally been shown to be greater for those treatments that are most efficacious 
[13,17,20]. Additionally, clinical wisdom assumes that patients prefer treatments with 
few injections and few side effects such as weight gain or hypoglycemic events, although 
the data supporting these assumptions is not extensive and is contradictory [1].  
 
For treatments with equal efficacy and no significant differences in weight gain or 
occurrence of hypoglycemic events, significant differences in treatment satisfaction have 
not been found [21]. Despite significant improvement in treatment satisfaction after 7 
months of efficacious treatment (improved HbA1c) with decreased hypoglycemic events 
and increased weight, a significant relationship between weight gain, HbA1c and 
treatment satisfaction has not been found [22]. Interestingly, fewer number of daily 
injections has been shown both to improve treatment satisfaction and to have no impact 
on treatment satisfaction [23,24]. Further, continuous subcutaneous insulin infusion has 
been shown to be both superior to multiple daily injections, as well as to have no impact 
in determining patient treatment satisfaction [25,26]. Thus, it remains unclear what part 
of our beliefs about the relationships between patient/disease characteristics, clinical 
wisdom and treatment satisfaction in diabetes is myth versus reality.  
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The purpose of this study was to examine, in the context of a randomized clinical trial 
(RCT), the correlative relationship between treatment satisfaction, patient/disease 
characteristics, and key treatment outcomes that impact the appraisal of treatment 
satisfaction. By understanding the myths versus the realities of these relationships, 
clinicians will be in a better position to identify patients at risk for decreased treatment 
satisfaction and tailor treatment plans to maximize treatment satisfaction. By improving 
patient treatment satisfaction, the efficacy of diabetes treatments as well as other critical 
treatment outcomes such as compliance and cost of care is likely to be improved.  
 
Methods 
 
Procedures 
 
Baseline and end of study (28 weeks) data from the INITIATE trial, a multi-center (25 
U.S. sites) open-label RCT comparing the efficacy and safety of twice-daily (BID) 
biphasic insulin aspart 70/30 (BIAsp 70/30) vs. once-daily, bedtime (QD) glargine (Glar) 
among insulin naïve type 2 diabetes (T2D) patients failing oral medication were 
analyzed. Eligible subjects had T2D inadequately treated, controlled on oral antidiabetic 
agents (OADS), were insulin naïve, and male or female between the ages of 18–75 with 
baseline HbA1c > 8% and BMI ≤ 40 kg/m2. Patients with a history of recurrent, severe 
hypoglycemia, hepatic or renal insufficiency, cardiac disease, acute or chronic metabolic 
acidosis, active proliferative retinopathy or intolerance to metformin were excluded from 
the study. 
 
The first phase of the study was a 4 week run-in period with metformin with patients with 
a fasting blood glucose level of ≤ 140 mg/dL, or any single value ≤ 170 mg/dL 
considered a run-in failure. Patients who successfully completed the run-in period were 
then randomized to receive equal doses of BIAsp 70/30 within 15 minutes before 
breakfast and dinner in addition to their current metformin, or Glar at bedtime in addition 
to their current metformin treatment. Subjects were told to perform daily blood glucose 
self-monitoring before breakfast and dinner. Insulin doses were titrated weekly for the 
first 12 weeks, then every 2 weeks thereafter according to a predefined titration algorithm 
based on blood glucose levels for the 3 days preceding a visit. Post-randomization, 
subjects were seen in the office weekly for the first month, and then again at weeks 8, 12, 
16, 20, 24 and 28. Phone visits were conducted for weeks in which there was no office 
visit. Patients in the INITIATE trial signed informed consent forms and the study 
complied with FDA Good Clinical Practices. The study protocol had IRB approval. 
 
Measures 
 
The following data were derived from and/or generated during the trial and were used for 
the present analyses: 
 
• Patient characteristics and diabetes history including age (as a continuous 
variable), sex, ethnic group, time with diabetes (at baseline as a continuous 
variable), body mass index (BMI) and co-morbid conditions (classified as 
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diabetes-related condition and as total number of conditions). These data were 
collected at the baseline visit. 
 
• The Insulin Treatment Satisfaction Questionnaire (ITSQ) [11]: a validated 
measure consisting of 22 items that comprehensively assess treatment satisfaction 
for persons with diabetes on insulin. The measure was developed as a patient-
reported outcome based on interviews with patients and clinical experts regarding 
treatment satisfaction as well as information in the literature. Satisfactory factor 
structure and internal consistency as well as adequate test-retest reliability, 
construct and discriminant validity for the ITSQ have been demonstrated [11]. In 
addition to an Overall score, the items make up five domains of satisfaction: 
Inconvenience of Regimen (IR-5 items), Lifestyle Flexibility (LF-3 items), 
Glycemic Control (GC-3 items), Hypoglycemic Control (HC-5 items) and Insulin 
Delivery Device (DD-6 items). All items are scored on a seven-point Likert-like 
response scale ranging from "not at all" to "extremely" (as worded appropriately 
for item). Items in the Glycemic and Hypoglycemic Control subscales are worded 
so that the respondent is asked about the relevant symptoms of their control such 
that a clinical understanding of either is not required. The ITSQ is scored by 
transforming all items to a scale of 0–100 with the higher score indicating better 
treatment satisfaction. For each subscale, the sum score is divided by number of 
items. Missing values are imputed based on the mean of the non-missing items. 
The ITSQ was administered after 28 weeks of treatment. 
 
• Diabetic treatment effect status assessed after 28 weeks of treatment: 
 
- HbA1c level 
 
- Hypoglycemic episodes classified as total number, by timing of event (classified 
as day or night), and by type of event (classified as symptomatic or not) 
 
- BMI classified as BMI group (< 25 as normal, between 25 and 29.9 as 
overweight, and ≥ 30 as obese) and by absolute value change (classified as 
improved or worsened) 
 
 
Statistical strategy 
 
According to an a priori statistical analysis plan, for each statistical test performed, the 
relationship between the factors of interest, overall satisfaction and satisfaction within 
each domain of the ITSQ was examined by linear regression with list-wise entry (all 
variables entered as a block to test interaction with treatment satisfaction as the 
dependent variable). Statistical significance was considered to be achieved with a 
minimum p value of 0.05. 
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Examining the relationship between patient and disease characteristics and treatment 
satisfaction 
 
First, in order to confirm successfully randomized cohorts, differences between treatment 
groups for baseline patient and disease characteristics were examined by ANOVA or chi 
square as appropriate for each characteristic. Next, a list-wise linear regression analysis 
was performed to examine baseline predictors of treatment satisfaction assessed at week 
28. The model included all demographic and diabetes history variables collected at 
baseline (age, gender, ethnicity, duration of diabetes diagnosis, BMI, and number/type of 
diabetes-related co-morbid conditions). Independent linear regression models were 
assessed for each of the ITSQ subscales and the Overall score. The relationship of total 
number of co-morbid conditions and treatment satisfaction (each subscale and Overall) 
was examined by Pearson correlations. Additionally, the relationship between types of 
diabetes-related co-morbid conditions and treatment satisfaction was examined by 
independent linear regression (list-wise) analyses of the diabetes-related co-morbid 
conditions found in this sample and treatment satisfaction. 
 
Examining the relationships between treatment outcomes and treatment satisfaction 
 
The relationship between the number of minor hypoglycemic events and treatment 
satisfaction was assessed by Pearson correlation (2-tailed). Type of event (symptomatic 
or not) and time of event (day or night), cumulative over the treatment period, and 
treatment satisfaction were examined by linear regression analyses independently for 
each subscale and Overall ITSQ score. The relationship between BMI change during 
treatment and treatment satisfaction (Overall and all subscales) was first examined by 
performing an ANOVA, controlling for baseline weight, using change in BMI group 
from baseline to week 28. An independent ANOVA, controlling for baseline weight, 
examined the relationship between absolute changes in BMI, comparing those who had 
improved BMI to those whose BMI had worsened over the 28 weeks. The relationship 
between HbA1c levels at week 28 and treatment satisfaction was examined by Pearson 
correlation coefficients. The relationship between treatment group and treatment 
satisfaction was examined by ANOVAs for the total ITSQ score and each of its domains. 
 
Examining the combined impact of significant factors 
 
Lastly, as outlined in the statistical analysis plan, to understand the larger picture of the 
impact of demographic and treatment effect variables on treatment satisfaction, a 
regression analysis was performed on all of the above factors that were found to have a 
significant relationship to treatment satisfaction at week 28. Variance and goodness-of-fit 
was examined by the R2. 
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Results 
 
Sample description 
 
A total of 233 patients with T2D, a slight majority of which were male (52.9%) and 
Caucasian (51.7%) with an average age of 52.15 (± 10.34) years, were randomized into 
the INITIATE study. Two hundred and nine (209) of these subjects had treatment effect 
data and 197 of these completed the ITSQ and were included in these analyses. The 
average duration of diabetes diagnosis was 8.29 years (± 5.24), and mean baseline HbA1c 
was 9.71% (± 1.47%). 
 
Statistical findings 
 
INITIATE trial clinical results 
 
The INITIATE trial demonstrated that patients receiving BIAsp 70/30 were significantly 
more likely to have achieved HbA1c targets vs. Glar (66% vs. 40% of patients to HbA1c 
< 7%, p<0.01, and 42% vs. 28% of patients to HbA1c ≤ 6.5%, p<0.05, respectively), and 
significantly improving total HbA1c reduction (-0.43%; p<0.01 between arms). Post-
prandial glucose excursions at lunch and supper were also significantly more tightly 
controlled (p<0.05), though an increase in minor hypoglycemia and weight gain occurred 
(both p<0.05) [27]. 
 
Examining the relationship between patient and disease characteristics and treatment 
satisfaction 
 
There were no significant differences found between treatment groups for any of the 
baseline patient or disease characteristics, indicating that randomization of subjects to 
treatment groups used in the present analyses was successful. As shown in Table 1, 
presence of diabetes-related co-morbid conditions at baseline was significantly predictive 
of overall treatment satisfaction as well as for Lifestyle Flexibility and in the 
Hypoglycemic and Glycemic Control subscales. Age was also predictive of treatment 
satisfaction related to Lifestyle Flexibility. The number of total co-morbid conditions in 
the sample ranged from 0 to 7 with a mean of 1.70 (± 1.50) and a median of 1.00. The 
diabetes-related co-morbid conditions identified in this sample were retinopathy, 
nephropathy, neuropathy, and macro-angiopathy. There were no significant relationships 
between total number of co-morbid conditions and treatment satisfaction. However, 
neuropathy was a significant predictor of treatment satisfaction (overall and in all 
subscales), indicating that pain is broadly associated with satisfaction outcomes. One 
other noted predictor was retinopathy, which was significant for the Device Satisfaction 
subscale. The relationship between types of diabetes-related co-morbid condition and 
treatment satisfaction is shown in Table 2.  
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Table 1: Impact of Demographics and Diabetes History on Insulin-related Treatment 
Satisfaction  
 
 
 
 
 
Table 2: Impact of Diabetic-related Co-morbid Conditions on Treatment Satisfaction 
 
 
 
 
 
Examining the relationships between treatment outcomes on treatment satisfaction 
 
A total of 1,073 hypoglycemic events, of which 1,072 were minor events, were reported 
over the 28 weeks of treatment. Hence, the analysis is based on minor hypoglycemic 
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events only. The number of minor hypoglycemic events per patient was found to be 
significantly associated only with the Hypoglycemic Control subscale (r = -0.263, 
p<0.001). However, as shown in Table 3, the time of a hypoglycemic event was found to 
be highly predictive of overall treatment satisfaction and for each subscale, with daytime 
events resulting in decreased treatment satisfaction. There were no significant impacts for 
the type of hypoglycemic event. The majority of patients (81%) did not change BMI 
group (normal, overweight or obese) during the treatment period, and no significant 
relationships between BMI group change and treatment satisfaction were found. The 
absolute BMI change ranged from -2.57 (decrease) to +6.83 (mean 1.61 ± 1.62) with the 
majority of the population (85.5%) increasing in BMI levels. 
 
For those 14.5 % of patients who had a decrease in BMI, there was a systematic 
improvement in treatment satisfaction across all scores, although only the difference for 
the Lifestyle Flexibility subscale was significant (p<0.05). The lack of statistical 
significance may be due to the small number of patients who did change BMI group 
power (19%). Pearson correlation coefficients showed a significant relationship between 
HbA1c and treatment satisfaction. While associations were low, the relationship of 
HbA1c level to treatment satisfaction was significant for the Overall score (r = -0.16, 
p<0.05), Inconvenience of Regimen (r = -0.15, p<0.05), Glycemic Control (r = -0.23, 
p<0.001), and Device Satisfaction (r = -0.17, p<0. 05). No significant differences were 
found in the total ITSQ score or any of the domains during comparisons between 
treatment groups, indicating in part the potential that an increase in number of daily 
injections (BID vs. QD) may not negatively affect treatment satisfaction. 
 
 
Table 3: Impact of Hypoglycemic Events on Treatment Satisfaction  
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Examining the combined impact of significant factors 
 
As shown in Table 4, when all previously identified significant relationships were 
examined together, neuropathy continued to have the broadest impact on treatment 
satisfaction (Overall and in all 5 subscales). Improved treatment efficacy (HbA1c) 
maintained the previously identified significant impacts on overall treatment satisfaction 
and in 3 subscales. The number of hypoglycemic events remained significant only for the 
Hypoglycemic Control subscale, however the timing of the hypoglycemic event 
significantly impacted overall satisfaction and 3 subscales rather than the previous 5 
(Glycemic Control and Inconvenience of Regimen were no longer significant). The 
impact of age, weight gain and the number of co-morbid conditions were no longer 
significant. The R2 for the model was 0.123, suggesting that these combined factors 
account for 12% of possible variance of factors that may impact treatment satisfaction. 
 
 
Table 4: Impact of Significant Treatment Variables on Treatment Satisfaction  
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Discussion 
 
Clinical wisdom and common sense would presume, and research has at times supported 
the idea, that there is a negative impact of unfavorable treatment characteristics, burden 
of treatment and side effects on patient-reported treatment satisfaction. However, we did 
not find a significant relationship between the number of minor hypoglycemic events, 
weight gain or treatments with 1 vs. 2 daily injections with overall treatment satisfaction. 
The relationship of weight gain to treatment satisfaction was restricted only to Lifestyle 
Flexibility. This significant finding may be due to the nature of the items in the Lifestyle 
Flexibility domain, as 2 of the 3 items in that subscale concern eating times and meals. 
The timing of the hypoglycemic event (minor hypoglycemic events that occurred during 
the day vs. nocturnal episodes) did have a significantly negative impact on overall 
treatment satisfaction. However, it should be noted that it remains unclear if daytime 
hypoglycemic events are also more "feared" or problematic for patients, as nighttime 
events may be more difficult to identify or respond to and if they are major events they 
may have a greater potential for serious health consequences. It may also be noteworthy 
that minor diurnal events may be more bothersome to daily functioning, and therefore 
more negatively influence treatment satisfaction. On the contrary, minor nocturnal events 
such as patients' activity levels are likely to be higher during daytime hours. As there was 
only 1 severe hypoglycemic event during the study, we were not able to examine the 
relationship between major events and treatment satisfaction.  
 
Also, contrary to common wisdom, no significant differences in treatment satisfaction 
were found between treatment groups despite the fact that BIAsp 70/30 was administered 
twice a day (with a pen device) and Glar was administered once a day (with a syringe) as 
a fixed characteristic of the treatment arm. This finding suggests that number of daily 
injections may not impact overall treatment satisfaction. However, due to the design of 
this study, it is difficult to separate out the effect of the number of daily injections versus 
the delivery device itself. It may be that the increased number of daily injections required 
for BIAsp 70/30 is balanced by a reported preference for the pen device over syringe [28-
30]. It may also be that having 1 vs. 2 injections per day is not as important a factor of 
treatment satisfaction as the distress experienced by patients going from being insulin 
naïve (0 injections per day) to having begun injections on a daily basis [31]. Given that 
there is evidence suggesting that BIAsp 70/30 is also efficacious with once-daily 
injections [32], additional research should continue to examine the impact of once-daily 
injections with a pen versus syringe on overall satisfaction, as well as specifically for 
device satisfaction.  
 
Regarding the belief that treatment efficacy is the primary driver of treatment 
satisfaction, BIAsp 70/30 was found to have superior efficacy (improvement in HbA1c) 
to Glar in the INITIATE trial, evidence that is supported in a subsequent clinical trial 
[33]. Although there is no data available to confirm that patients knew their HbAlc levels, 
doses were regularly titrated based on blood glucose levels and patients self-monitored 
their blood glucose levels twice daily. Further, HbAlc level was found to be significantly 
related to Overall Satisfaction suggesting that subjects were aware of treatment efficacy 
either by information from the physician or by how they felt. Thus, it is highly likely that 
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the patients were aware of their HbA1c values, and able to use this factor when 
appraising their treatment satisfaction.  
 
Despite superior efficacy, treatment satisfaction was equivalent between the 2 treatment 
groups. This finding may be explained by the Decisional Balance Model of Treatment 
Satisfaction, whereby Overall treatment satisfaction is determined by the balance 
between the positive value of treatment and the negative harms and inconveniences of the 
medication [3]. Thus, the appraisal of treatment satisfaction for a treatment such as 
BIAsp 70/30, with superior efficacy when compared to Glar, but increased minor 
hypoglycemia and weight gain, may be equivalent. The Balance Theory model and our 
findings in the present analysis are supported by those in recent trials where competing 
insulin preparations which demonstrate disparate side effect and efficacy profiles have 
caused non-significant differences in treatment satisfaction [34]. The Balance Theory 
model may also help explain the lack of significant differences in overall treatment 
satisfaction in pen vs. syringe device studies, even when there is clearly stated preference 
for the pen device, if treatments have equivalent efficacy and safety [28]. It should be 
noted that the ITSQ overall score is not a truly independent rating of overall treatment 
satisfaction as it is the sum of the subscale items rather than a separate item assessing 
overall satisfaction. Post-hoc analyses with this study data have shown that the 
correlations between subscales and the overall score are all above 0.77 and a regression 
analysis of subscales on the Overall score, found all subscales were significantly 
associated with the Overall score at the 0.01 level, indicating a balance of the subscale 
weights contributing to the Overall score.  
 
We believe that in order to fully understand the impact of variables on treatment 
satisfaction, the impact on both subscales and Overall treatment satisfaction should be 
identified. Understanding the relative weight of subscales in the overall assessment may 
be valuable as this can help identify subscales of greater importance given a particular 
treatment or patient characteristic. Future studies may find it helpful to include a truly 
independent measure of overall satisfaction to further understand the contribution of 
subscales to overall satisfaction. In this study we have examined both "simple" regression 
models looking at similar types of factors (e.g. demographic and patient characteristics) 
as well as more "complex" multivariate models allowing us to test if significance of 
variables from the like factor model is maintained when "competing" against a wide 
spectrum of influences. This incremental approach to the importance of factors provides a 
more compressive picture of these factors and allows us to refine our understanding of 
their influence treatment satisfaction. 
 
It should be noted that although statistically significant relationships were identified in 
the study, the amount of variance accounted for in some of the models was small to 
moderate. Further, as with all statistical significance, it is unclear what the relationship is 
between the statistical and clinical significance of the findings and it is often difficult to 
separate out the unique contributions of variables which may be related, such as age and 
co-morbidity. Older T2D patients are more likely to have diabetes related co-morbid 
conditions and these conditions may negatively impact a patient's ability to self-manage 
their disease, creating a barrier to positive outcomes. Thus, it is important to understand 
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the unique contributions of each of these factors to overall as well as domains of 
satisfaction. For example, although age did not have a significant impact on Overall 
satisfaction, neuropathy – a painful diabetes related condition – was the strongest 
predictor for decreased treatment satisfaction overall and across subscales. Although it 
may be difficult for physicians to reduce neuropathy-related pain in diabetes, lessening of 
pain has been found to play only a partial role in explaining treatment satisfaction for 
people with chronic pain. Several studies have found that provider-patient interaction 
factors such as confidence, trust and positive communications are also important for 
improving satisfaction [35-37]. Thus, improving provider-patient relationships for 
persons with diabetes and neuropathy may help improve their treatment satisfaction in 
general and lead to improved outcomes. This study did not examine the impact of non-
diabetes related co-morbid conditions on treatment satisfaction and we suggest that this 
relationship be examined in future studies.  
 
Diabetes related retinopathy was also a significant indicator for the Device Delivery 
subscale, indicating that visual impairments and the sensory experience should be taken 
into consideration in choosing an insulin delivery device for a given patient. When pen 
devices have been compared head-to-head (FlexPen vs. Humalog Pen vs. syringe), 
significant improvements in patient preferences have been found in favor of the devices 
which improve the readability of the dose scale and user confidence [28,38]. The auditory 
feature of pen devices has also been shown to affect the patient's confidence in selecting 
the correct dose [39], suggesting that auditory impairments also be considered when 
exploring treatment options. These findings may also help clinicians identify patients 
who are most at risk for poor treatment satisfaction, so that the clinicians can develop 
targeted treatment plans for these patients. Certainly, patients with neuropathy or frequent 
daytime hypoglycemic events should be targeted for a discussion regarding their potential 
dissatisfaction with treatment. Additionally, their compliance and diabetes self-
management behavior, critical factors for diabetes treatment success, should be assessed 
to identify if these behaviors have been negatively affected by their dissatisfaction.  
 
Finally, although cost of treatment was not examined in this study, it should be noted that 
biphasic insulin has been projected to be cost-effective therapy vs. basal insulin alone for 
long-term treatment [40,41]. Given the superior efficacy and equivalent patient-reported 
treatment satisfaction between these treatments, it may be reasonable for clinicians to 
consider the estimated improvements in quality-adjusted life expectancy along with 
potential cost savings associated with complication reductions. Understanding the 
complex and multidimensional nature of treatment satisfaction as well as the interaction 
between factors that may impact how persons with diabetes appraise their treatments is 
still evolving. This study has begun to examine factors that may impact these 
relationships; considerably more research will be required to further unravel the myths 
and the realities of treatment satisfaction in diabetes.  
 
There are some shortcomings of this study that should be noted so that future research 
can address these issues. First, although satisfaction with previous treatments may 
significantly impact satisfaction with new treatments [42], the reality is that it is often 
difficult or unfeasible to assess. The lack of baseline treatment satisfaction also prevents 
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the assessment of responsiveness of a measure to differences in treatment. These 
methodological challenges present limitations both in the broader treatment satisfaction 
literature and in this study. As the subjects were insulin naïve at baseline, previous insulin 
treatment satisfaction could not be measured. However, the absence of any differences in 
baseline demographic or health characteristics in the sample in combination with the 
study entry criteria requiring all subjects to have failed OADs, suggests that baseline 
differences in treatment satisfaction would not have been significant. Furthermore, a 4 
week run-in period prior to the addition of the study insulin ensured that all randomized 
subjects were stabilized on an identical OAD regimen at baseline.  
 
It is also known that RCT populations are generally not representative of the entire 
population. Therefore, it would be very informative to examine these relationships in a 
more representative diabetic population such as in a clinic-based study. Additionally, 
although this study examined potential baseline patient/disease characteristics and key 
treatment outcomes that may influence treatment satisfaction, data on other important 
ongoing treatment factors such as burden and compliance were not collected. There may 
also be other diabetes as well as non diabetes related co-morbid conditions not reported in 
this sample, which may impact treatment satisfaction. These additional influences should 
be considered when looking at the broader spectrum of variables that may or may not 
impact treatment satisfaction. Inclusion of these variables or other potential drivers of 
treatment satisfaction may have increased the amount of variance in predicting treatment 
satisfaction in this study. 
 
Conclusions 
 
Using baseline and end of study treatment effect data from a randomized controlled trial 
comparing the efficacy of BIAsp 70/30 (administered BID via pen device) and Glar 
(administered QD via syringe), and by correlating it to measured responses in the ITSQ, 
we examined the relationship between treatment satisfaction, patient/disease 
characteristics, treatment outcomes, and treatment groups. By assessing these factors 
independently, certain significant relationships were identified. However, not all of these 
significant findings survived when examined in combination with each other. Thus, in 
order to more accurately characterize the impact of patient/disease characteristics and 
treatment outcomes on treatment satisfaction, a more comprehensive approach at 
capturing data on all potentially relevant variables is necessary. This approach can 
enhance our understanding of factors that exert enduring or broader impacts on treatment 
satisfaction.  
 
The perfect drug for diabetes would improve efficacy with no side effects, and the perfect 
patient with diabetes would be otherwise healthy. However, given the real world, 
clinicians will need to balance the advantages and disadvantages of various treatments 
and patient types, and aim to more fully understand the myths and realities of patient-
reported treatment satisfaction to identify the optimal treatment for a given patient. 
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adherence in diabetes 
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Summary 
 
We conducted a systematic literature review using a comprehensive list of relevant search 
terms (1990–2005) to identify studies on adherence among patients with diabetes, and its 
economic effect. A lack of adequate treatment adherence (36%–87%) among patients 
with diabetes was confirmed, primarily measured by medication possession ratio (MPR). 
Adherence varied among oral agent−only (36%–87%) versus concomitant or insulin-only 
(54%–81%) regimens. Economic consequences of adherence were a decrease in health 
care costs, ranging from 8.6% to 28.9%, with an approximate 10% increase in MPR, 
mostly in the form of a 4.1% to 31.0% decrease in hospitalization. Increased cost sharing 
was associated with a 9% to 23% decline in medication use. 
 
Introduction 
 
Diabetes is a chronic medical condition that currently affects nearly 21 million people in 
the United States, comprising 7% of the entire population [1]. Commensurate with this 
high prevalence rate and its increasing trend, the national economic burden of treating 
diabetes in 2002 was approximately $132 billion, representing 19% of total personal 
health care expenditures in the United States [2]. This figure represents a significant and 
steady increase in diabetes-attributable health care costs; the corresponding figure in 
1997 was just $44 billion. In light of the rising health care costs for management of 
diabetes, numerous studies demonstrate the benefit of improving glycemic control in the 
form of increased cost savings. The decrease in overall health care costs is largely 
attributable to the benefits of improved health by lowering or normalizing blood glucose 
levels [3−7]. 
 
The goal of effective diabetes management, according to the American Diabetes 
Association (Alexandria, VA), is to achieve tight glycemic control, characterized as a 
hemoglobin A1c level of less than 7% [8]. Studies have shown that effective management 
of diabetes rests heavily on adequate adherence to treatment therapy [9−21]. The present 
study sought to synthesize and analyze published levels of adherence with diabetes 
medications including oral anti-diabetic drugs (OADs) and insulin, and to report the 
effect of adherence on overall health care costs through a systematic literature review. A 
secondary goal was to identify information gaps and areas of research where additional 
work would contribute to the literature. 
 
Methods 
 
Literature Search 
 
A systematic literature search was conducted to identify articles containing information 
on adherence to diabetes treatment regimens primarily among patients with Type 2 
diabetes (T2D), and its association with relevant health care costs. To this end, electronic 
MEDLINE and PubMed searches were conducted in various phases. Such important 
factors contributing to diabetes medication adherence as patient preference, mode of 
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administration, and medication copayment were included in the search strategy, as were 
searches on the effect of adherence and clinical and economic outcomes.  
 
For adherence data, search terms included: “diabetes” combined with “adherence,” 
“compliance,” “persistence” or “nonadherence.”  
 
For costs associated with diabetes medication compliance, search terms included: 
“diabetes” combined with “adherence,” “compliance,” “persistence,” or “nonadherence” 
in combination with “costs,” “economics,” “resource utilization,” “hospitalizations,” 
“physician visits,” “direct costs,” “indirect costs,” or “cost analyses.”  
 
For identifying articles examining the effect of cost sharing on diabetes medication 
adherence, search terms included: “diabetes” combined with “adherence,” “compliance,” 
“persistence,” or “nonadherence” in combination with “cost sharing” or “copayments.”  
 
All search terms were limited to Medical Subjects Headings (MESH) terms, English-
language abstracts, human subjects, and the years 1990 to 2005. From the initial 
electronic search, 975 article abstracts were screened, comprising 139 article abstracts for 
costs associated with nonadherence, 832 article abstracts for adherence/compliance data, 
and four articles related to cost sharing. In addition to the MESH term search, a keywords 
search was conducted using “diabetes,” “epidemiology,” “prevalence,” “incidence,” 
“compliance,” “costs,” “economics,” “cost sharing,” and “copayments.” A total of 1,216 
articles were identified with these keywords.  
 
Supplemental searches were conducted with additional resources, including E-medicine 
along with comprehensive Internet searches using well-known search engines (e.g., 
Google). The search through these additional resources yielded 20 articles. All abstracts 
and articles were imported into a master reference database after eliminating duplicate 
references. Of the total 2,211 articles identified (975 studies identified through the 
electronic searches with MESH terms described above, 1,216 identified with the 
keywords, and 20 articles found through additional search engines), 21 papers that met 
the subject criteria were retrieved and included for the literature review. Although the 
search terms were as thorough as possible, several relevant articles that were additionally 
identified from these 21 papers were missing in this electronic search. In addition to the 
electronic searches, six articles were identified by manual review of the bibliographies of 
the references retrieved, thereby yielding the total number of 27 references. 
 
Results 
 
The results of the review were disaggregated into three categories for analysis: (1) 
quantitative and qualitative information on adherence to diabetes medications (N = 13), 
[9–21]; (2) the effect of adherence on overall health care costs (N = 7) [5, 22−27]; and (3) 
the effect of medication copayment on levels of adherence and overall health care costs 
(N = 7) [28−34]. Descriptive statistics (e.g., means, ranges) and the results of inferential 
analysis (e.g., odds ratio, hazard ratio, and regression coefficients) were identified from 
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the studies and presented wherever appropriate, and analysis was performed by class of 
medication (OAD, insulin) to the extent possible. 
 
Adherence to Oral Anti-diabetic Drugs and Insulin Therapy 
 
A total of 13 papers were identified and included for analysis in this section. Excluding 
one literature review paper [35], which reported adherence rates of 20 papers from 1993 
to 2003, and one quantitative review paper [36], which compared adherence levels of 
diabetes with those of other chronic diseases, most studies on drug adherence in diabetes 
were conducted on OADs (N = 8) [9,12,13,15−19]. In addition, four articles (30.8%) 
addressed individuals who were taking either OADs or insulin therapy [11,14,20,21].  
 
Morris and colleagues [10] described adherence rate of insulin therapy alone. A 
systematic literature review by Cramer [35] summarized oral as well as insulin 
medication adherence rates. The paper identified research addressing the association 
between adherence rates and glycemic control. Much attention was given to studies that 
focused on and supported electronic monitoring tools to estimate levels of adherence; 
therein resides the difference between their review and this study’s examination of levels 
of adherence. The present review extends Cramer [35] by including two additional 
studies (Guillausseau and colleagues [18], and Hertz and co-workers [20]), by focusing 
the analysis on both retrospective and prospective studies, by comparing adherence rates 
of OADs with those of insulin, and by presenting a comprehensive review of the 
economic consequences of suboptimal adherence and the effect of cost sharing on 
adherence (in T2D patients only). To reiterate, the review of these papers was conducted 
specifically to provide background information for the primary research goal, which was 
to identify, synthesize, and analyze published literature that discussed the effect of levels 
of adherence to diabetes medications on overall health care costs, and to then identify key 
areas of future research.  
 
Follow-up period in these 13 studies varied greatly, ranging from two to 120 months. The 
mean ages of the study populations were greater than 50 years, indicative of a Type 2 
population. Adherence rates among the retrospective studies (N = 8) for OADs ranged 
from 36% to 87% (Table 1). Of note, this range is similar to that (36%−93%) estimated 
by Cramer [35]. A recent meta-analysis identified in the literature search offered an 
overview of 569 studies conducted from 1948 to 1998 reporting adherence levels to 
medical treatments for a variety of conditions including diabetes [36]. The composite 
score of the average adherence level in patients with diabetes was obtained from 23 
studies and was reported at 67.5% (95% confidence interval [CI], 58.5%–75.8%). This 
was a substantially lower rate than those found in other medical conditions, including: 
human immunodeficiency virus (88.3%), arthritis (81.2%), gastrointestinal disorders 
(80.4%), and cancer (79.1%) [36]. Adherence to medical treatments prescribed by non-
psychiatrist physicians was measured and performed using such techniques as pill counts, 
medical record/chart, self-report, physical test, and electronic monitoring. This meta-
analysis underscores two points of interest: (1) although their reported adherence of these 
medications all reside somewhere in the upper range of 36% to 87% found in the review 
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of individual papers, (2) diabetes was isolated as the condition with the most suboptimal 
rate, suggesting the presence of unique barriers to adherence in these patients.  
 
The lower boundary rate estimate of adherence of 36% was observed by Dailey and 
associates [9]. This adherence rate was defined as the total days of drug supply during the 
follow-up period divided by the number of days in the follow-up period. This low 
number may be explained by two factors: (1) the study population consisted of Medicaid 
enrollees initiating diabetes medication treatments and (2) the study focused on patients 
receiving multiple drugs from two or more classes of anti-diabetic medications, or poly-
pharmacy. In comparison with the 36% adherence observed in patients with poly-
pharmacy, adherence among patients receiving monotherapy (drug regimen with a single 
class of anti-diabetic medication) was 49% [9]. In confirmatory data reported by Donnan 
and colleagues [16], 35% of patients with diabetes receiving single drug regimens were 
greater than 90% adherent, whereas the corresponding figure was only 27% for patients 
with diabetes receiving poly-pharmacy. However, Melikian and co-workers [19] found 
no statistically significant difference in adherence rates between patients on monotherapy 
and poly-therapy. This lack of difference may again be attributable to the study 
population selected for the study, which was a newly diagnosed subject group having a 
follow up of only six months. It is not surprising that patients in both groups would have 
been optimally adherent to their prescribed medications at the initiation period of diabetes 
treatment. Furthermore, the relatively short follow-up may not have fully captured the 
effect of any occurrence of chronic complications that might affect medication 
adherence; that is, factors that commonly generate differences in adherence rates between 
these two groups may not yet have developed.  
 
An average adherence rate, defined by medication possession ratio (MPR), was estimated 
to be 79.2% among patients with diabetes prescribed OADs for the first time (N = 
85,888) [13]. The most interesting and notable result emerging from this study was the 
decline in adherence rate as length of therapy increased, indicating that long-term 
adherence with diabetes oral medication therapy is low. Once-daily diabetes medication 
regimens were associated with a higher adherence level compared with twice-daily 
treatment regimens (61% vs. 52%, respectively) [15]. Even though the once-daily patient 
cohort exhibited a greater number of mean pills per day, adherence was 8.5% higher than 
the twice-daily patient cohort; adherence was found to be more strongly associated with 
an easier-to-maintain/schedule dosing regimen rather than the number of tablets per dose. 
Guillausseau [18] reported adherence rates of 46% among patients with T2D (N = 
11,896) treated with OADs in a prospective analysis. Adherence was estimated using self 
reports through data collection with a questionnaire and was categorized into three levels: 
(1) no omission, (2) omission one to three times a month, and (3) omission once a week. 
The study found that once-daily therapy was associated with an approximate 60% 
adherence rate as compared with 48% for twice-daily, which further fell to 38% when 
medications were administered 3x. A prospective study by Winkler and co-workers [17] 
measured adherence through self-reports, pill counts, and a medication event–monitoring 
system among 19 patients with T2D. Adherence was defined as the percentage of days in 
which the dose was taken as prescribed. Results showed an overall adherence rate of 
78.6%, though again, once-daily regimens exhibited better adherence as compared with 
 
102 
Table 1: Studies of patient adherence to oral anti-diabetic agents 
 
 
 
 
 
more frequent dosing (93.6% vs. 57.8%, respectively). Overall, these findings illustrate 
the critical importance of convenience and ease of drug administration in improving 
adherence rates of OADs.  
 
Four studies examining adherence levels among patients with diabetes who were 
prescribed either oral medications or insulin therapy reported adherence rates ranging 
from 54% to 81%, excluding one persistence study that reported a rate of 27% (Table 2) 
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[11,14,20,21]. Schetman and associates [14] reported that medication type, be it insulin 
or OADs, was not correlated with adherence after adjusting for age, race, income, 
frequency of glucose testing, and frequency of visits in their regression model. A 
retrospective study found a mean adherence rate of 62% to 81% for a large cohort (N = 
199,000) of patients with diabetes initiating treatment with either oral medications or 
insulin [11]. Adherence, measured by MPR, was found to be higher among oral 
medication patients (N = 52,469; 81%) as compared with patients taking insulin (N = 
27,274; 62%). Brown and associates [21] estimated persistence rather than adherence and 
demonstrated the persistence rate for each subsequent year post-diagnosis among a large 
cohort of patients with diabetes (N = 693) for a period of 10 years. Persistence in this 
study was calculated by the number of times that each member changed his or her drug 
regimen, which was considered a modification of the regimen, during the nine years after 
the year of diagnosis. The persistence rate was 27.3%. Mean adherence (88.3% [95% CI, 
85.9%–90.6%]) among patients previously taking oral medications (i.e., sulfonylureas) 
who then switched to insulin was slightly higher than that of patients taking sulfonylureas 
alone (87.4% [95% CI, 86.7%–88.2%]) [12].  
 
Hertz and colleagues’ [20] findings are somewhat at odds with this study, as adherence 
was found to be lower among patients using insulin compared with those taking OADs 
(30.8% for insulin vs. 63.9% for sulfonylurea users, 63.8% for biguanides, and 67.1% for 
thiazolidinedione users) (OR = 3.00; 95% CI, 2.30–3.91). They found the overall 
adherence rate, estimated using MPR, among patients with either medication type to be 
53.8%. This study population, however, was treatment-naïve, with patients newly 
prescribed anti-diabetic medications over three years (1997–2000). Three forces may 
explain the contrasting results observed in these two studies: (1) medication-naïve 
patients initiating insulin may have experienced a more inconvenient mode of 
administration, leading to inadequate adherence levels; (2) variation in disease severity 
among patients requiring insulin therapy versus OADs alone may indicate that patients 
were either more motivated to be adherent or they were less able to adhere consistently; 
and (3) patients taking OADs commencing insulin therapy are likely to experience tighter 
glucose control versus continued OAD-only therapy, which may improve health-related 
quality of life and increase willingness to comply.  
 
The lone study estimating adherence rate of insulin alone was, not surprisingly, 
conducted among young Scottish patients (N = 89; mean age, 16 yr) with T1D. In this 
study, an adherence index was created using the insulin dose and cumulative supply of 
insulin preparations [10]. This adherence index, similar to MPR, calculated the days of 
insulin coverage using two variables: (1) medically recommended insulin dose and (2) 
cumulative supply of insulin prescriptions. The latter variable was obtained from data 
that have an actual purchased amount of insulin. Based on the calculated days of supply, 
the study found the adherence rate to be 72% (i.e., 28% of the 89 study patients obtained 
less insulin than the prescribed doses). Adherence rates of OADs and insulin therapy 
have varied, because of a difference of applied methods among very diverse study 
populations. Only four studies [11,14,20,21] comparatively assessed adherence rates of 
OADs and insulin therapy on similar populations, and just one study was performed 
solely on patients with diabetes treated with insulin [10]. Whether the adherence level of 
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patients to insulin therapy after previous use of oral medications is higher or lower than 
that of patients to OADs is largely inconclusive and requires further inquiry. Studies 
estimating adherence for diabetes have so far relied mainly on such techniques as MPR, 
whereas a few have reported persistence rates, defined as switch or discontinuation of 
initial medication.  
 
 
Table 2: Retrospective Database Studies of Patient Adherence to Oral Anti-diabetic 
Medications or Insulin 
 
 
 
 
 
Economic Consequences of Suboptimal Levels of Diabetes Medication Adherence 
 
Seven studies were identified that elucidate increased health care costs owing to patients’ 
inability to adhere to prescribed diabetes medications [5,22–27]. They were exclusively 
retrospective database studies, including a longitudinal cohort investigation. A summary 
of these studies is provided in Table 3. An administrative claims data study revealed an 
association between levels of adherence to OADs and subsequent hospitalization among 
individuals with T2D [22]. Approximately 29% of patients who were prescribed an anti-
hyperglycemic agent were nonadherent. Nonadherence was defined as a MPR of less 
than 80%. When the MPR dropped below 80% of that observed in the preceding year, the 
rate of hospitalizations related to diabetes significantly increased, specifically from 4.1% 
to 14.8% in response to a decrease of adherence rate from 100% to less than 40%. The 
results of this study suggest that the effect of suboptimal adherence substantially 
increases diabetes-related hospitalization in the following year and adversely affects the 
quality of life of these patients. A further study compared two distinct populations: (1) 
individuals with T2D alone and (2) those with both diabetes and diagnosed 
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cardiovascular disease (CVD), a population more prone to substantial health care 
utilization. Patients with diabetes alone who were no more than 75% and 76% to 95% 
adherent had a 31% and 19% greater chance of a hospital/ emergency room (ER) 
admission than those with greater than 95% adherence, respectively [23]. However, 
patients who were no greater than 75% and 76% to 95% adherent in the diabetes plus 
CVD cohort exhibited a 44% and 51% greater chance of ER/hospital admission, 
respectively, as compared with those with better than 95% adherence. Although the 
difference between these two cohorts was expected, the results between levels of 
adherence within the cohort of patients having diabetes plus CVD were surprising; this 
outcome could be explained by the possibility that patients who were no greater than 75% 
adherent in this cohort may have had an increased susceptibility to further co-morbidities 
unrelated to medications captured in the study. Still, this study confirms a lower level of 
adherence among patients with concomitant co-morbidity than that among patients with 
diabetes alone, creating a negative effect on overall health care costs and suggesting the 
importance of achieving tight glycemic control to inhibit the negative effect of 
uncontrolled diabetes on CVD.  
 
Outcome measures, such as health care costs and utilization, were found to commonly be 
measured after a lag time of 360 days from the date the patient was identified. Where 
medication adherence rates initially increase, one might expect that medication costs 
would also initially rise. Hepke and co-workers [24] reported that medical care costs 
steadily increased at an adherence level of 20% to 39%; however, once this level was 
reached, overall medical care utilization started to decrease through reduced use of ER 
and hospital inpatient resources. A shortcoming of using a one-year lag time in patients 
with diabetes is that the effect of co-morbidity is readily missed, owing to the fact that 
diabetes is a chronic medical condition, and most complications develop over time.  
Sokol and co-workers [25] compared a diabetes population with three stratified cohorts, 
each having a different chronic medical condition, such as hypertension, 
hypercholesterolemia, and congestive heart failure. Among these conditions, only for 
diabetes and hypercholesterolemia was a high level of medication adherence associated 
with lower overall costs for the one-year period after patient identification. The short-
term increase in medication costs related to a higher adherence level was offset by the 
increased savings in overall health care costs for these two medical conditions. This 
analysis differed, however, from Hepke and colleagues’ [24] study examining the 
quantity of overall health care cost savings achieved through increased adherence (a 
difference in total costs at the 80%–100% adherence level of $2,830, $4,570 for the study 
by Sokol and co-workers [25], and $7,400 for that by Hepke and associates [24]). The 
investigation by Sokol’s group [25] examined those who were receiving prolonged 
medication before the analysis period and thus demonstrated a higher cost savings 
because of the cumulative effects of maintained adherence.  
 
Adherence and its effect on overall health care costs were also studied among a low-
income population (North Carolina Medicaid program). Patients receiving 
thiazolidinedione (TZD) therapy, who had better treatment adherence calculated using 
MPR in comparison with patients receiving other OADs (13% increase in MPR, p<0.01), 
experienced a 16.1% decrease in total annual health care costs (p<0.01) in the post-
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medication start year [26]. A period of 365 days was used as the lag time for the analyses. 
Interestingly, adherence rates in this population were substantially lower than the general 
population; 60% for the TZD group versus 50% for other OADs was found to be lower 
than the rates reported in other studies. A five-year retrospective longitudinal cohort 
study using prescription refill patterns as a major outcome measure of adherence 
confirmed the findings obtained from the above five short-term database studies [27]. A 
random-effects log linear regression model was employed to observe the association 
between mean adherence and a host of confounders including categorical MPR. Other 
predictor variables included: age, gender, Charlson co-morbidity index, total health care 
costs, smoking status, and total days in hospital. Increased anti-diabetic MPRs proved to 
be the strongest predictor of decreased total annual health care costs (i.e., 8.6%–28.9% 
decrease in annual costs with every 10% increase in MPR). 
 
The above six studies illustrate that higher levels of medication adherence result in 
increased cost savings accrued because of decreased hospitalizations. Interestingly, one 
study revealed cost savings to be associated with a decrease in primary care and specialist 
physician visits rather than a decrease in hospitalizations/ER visits, though this was likely 
because of the length of the follow-up (5 years), where reduced specialty visits may have 
arisen because of reductions in co-morbidity associated with improved glycemic control 
[5]. This study demonstrated higher hospitalization rates only among higher levels of 
adherence; the primary outcome measure was the number of primary care and specialty 
visits among patients with improved and unimproved glycemic control, without 
ascertaining whether higher levels of adherence to treatments directly improved glycemic 
control. Economic consequences of suboptimal adherence levels to diabetes were found 
to be significant, with increasing overall health care costs in the form of higher 
hospitalization and ER visit rates.  
 
Effect of Medication Copayment on Medication Adherence among Patients with Diabetes 
 
Few studies have shown the effect of copayment alone for prescription medications on 
patient treatment adherence among patients with diabetes, though several have shown 
that greater cost-sharing reduces spending on prescription drugs (Table 4) [28−34]. Each 
of these studies covers either the general population regardless of specific disease or 
patients with diabetes. None of the studies narrowly focus on patients undergoing insulin 
treatments. A recent assessment of 528,969 individuals enrolled in health insurance plans 
found that doubling copayments reduced the use of nonessential medications (including 
antihistamines and anti-inflammatories) and, to a lesser extent, essential medications used 
to treat chronic diseases including diabetes [31]. With regard to diabetes medications, a 
25% decrease in response to copayment doubling was observed. These results suggest 
more essential drugs are less price sensitive, providing a reference figure for price 
sensitivity of insulin therapy. As this study did not assess insulin, one may posit that the 
price sensitivity of insulin treatment would actually be lower than the 25% decrease seen 
with oral medication. Similarly, the effect of prescription drug cost sharing on use of 
essential and less essential drugs among elderly patients (N = 93,950) and welfare 
recipients (N = 55,333) was studied in Canada, whereby the rate of adverse events 
associated with discontinuation or reductions in drug use owing to increased cost sharing 
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Table 3: The Effect of Levels of Patient Adherence on Health Care Costs 
 
 
 
 
 
was estimated [32]. Increased cost sharing resulted in reduced utilization of essential 
medications, including those for diabetes, and a subsequent higher rate of serious adverse 
events and ER visits. Interrupted time-series analysis of data for a period of 17 months 
after introduction of medication coinsurance and cost sharing for the year 1996 was 
performed. The results showed a decrease in use of essential drugs by 9.1% (95% CI, 
8.7%–9.6%) among elderly persons and by 14.4% (95% CI, 13.3%–15.6%) among 
Medicaid beneficiaries, respectively. Rate of serious adverse events, estimated per 10,000 
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person-months, increased from 5.8 before introduction of the cost-sharing policy to 12.6 
post-introduction among elderly persons, compared with 14.7 to 27.6, respectively, 
among welfare recipients. Similarly, an increase in ER visits owing to reductions in use 
of essential drugs was also noticed between both cohorts (from 32.9 to 47.1 / 10,000 
person-mo. among elderly persons, and from 69.6 to 123.8 / 10,000 person-mo. among 
welfare recipients).  
 
Decreased medication utilization and expenditures were noted as a result of a three-tier 
prescription copay [33]. An increase in copayments from 20% to 30% yielded a 
significant decrease in medication adherence (83.7% vs. 66.7%, respectively) among 
patients with diabetes (N = 66). However, this decrease did not compromise any other 
complications [30]. One primary reason was that the copayment change explored in this 
study was not sufficient to trigger a substantial decrease in medication utilization which 
would increase any complications. Finally, lack of insurance coverage for patients with 
diabetes (N = 405) for their testing supplies led to underuse of diabetes medications, 
thereby leading to poorer glycemic control (HbA1c 7.1% vs. 7.4%; p=0.03) [34]. 
However, these results should be treated with caution because of the cross-sectional 
nature of the study, thus limiting inferences on causal associations.  
 
A patient survey reported less use of diabetic medications because of varied insurance, 
linked with different cost-sharing levels [28]. Nine percent of Veterans Administration 
(VA) patients showed an underuse of medications compared with other sources of 
insurance, including private insurance (18%), Medicare (25%), and no insurance (40%) 
(p<0.0001). These results are significant, because patients enrolled in the VA had 
relatively comprehensive drug coverage as compared with some private insurances and 
Medicare. Lack of medication coverage, thereby generating increased out-of-pocket 
expenditures on medications, led patients to discontinue buying their prescribed 
medications, ultimately resulting in low adherence. These studies were characterized by 
the absence of an income variable; the majority of patients included in these studies 
would likely have been less affluent and therefore more price sensitive. After adjusting 
for levels of income, the effect of copayment on resource utilization in a general 
population may have been lessened. Financial constraints on patients in terms of 
increased medication copayments have been found to reduce patients’ ability to adhere to 
diabetes medications.  
 
Discussion 
 
This systematic review confirms that adherence rates to diabetes medications — OADs 
and insulin — are suboptimal among patients with diabetes. Only one study, which was 
focused on T1D in adolescent patients, reported an adherence level of 72%, though 
factors facilitating this adherence rate remain unverified. It is perhaps equally as 
influential that these patients likely received strong parental monitoring, that exogenous 
insulin is an absolute necessity for them, and that copayment/cost sharing is generally a 
more indirect factor in adherence for these patients. Whether adherence level of patients 
to insulin therapy is higher or lower than that of patients to OADs was found to be 
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Table 4: Effect of Cost-Sharing on Patient Medication Adherence and Overall Health 
Care Costs 
 
 
 
 
 
inconclusive, although all studies concluded the significantly negative effect of 
suboptimal adherence levels to diabetes medications, as well as the financial constraints 
imposed by increased copayments, on overall health care costs. Results of adherence 
rates to both OADs and insulin varied owing to a diversity of applied methods, with 
differing follow-up periods among study populations. One study reported a persistence 
rate (27.3%) that was lower than the lowest adherence rate (36%) obtained in the present 
literature review. This low persistence rate resulted from a different method of 
calculation of therapy persistence compared with traditional estimation of adherence. The 
results of the present review are consistent with those of other surveys, where adherence 
to medications for different medical conditions have been found to be approximately 75% 
[39−41]. 
 
Studies targeting younger populations are almost completely lacking in the literature. One 
might expect research to be focused on adults with T2D, who are more prone to costly 
co-morbidities and who constitute the majority of the population with diabetes (and are 
therefore most burdensome for providers). Analyses in which the mean age of the study 
population was 50 to 59 years revealed adherence levels between 61% and 80% 
[11,14,15,20], whereas those whose study populations had a mean age of 60 to 68 years 
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demonstrated adherence rates between 54% and 79% [12,13,16,17,19]. These results 
suggest that age is a critical demographic variable in predicting adherence and that future 
studies focusing on younger populations may have adherence rates similar to or higher 
than 61% to 80%. Nichols and co-workers [42] demonstrated this strong association 
between age and adherence to diabetes medications. This is significant, because diabetes 
is more prevalent among elderly patients who are more prone to have multiple medical 
conditions for which they receive numerous concomitant medications. Multiple co-
morbidities, which collaboratively may exacerbate disease progression, and an aging 
body (presence of ocular and visual disease, arthritis, and other disorders afflicting 
manual dexterity, etc.) may have a bearing on the level of adherence. Access to therapies 
and modes of administration aiming to ease burden of care and self-management in these 
patients may prove valuable in improving outcomes.  
 
A shortcoming concerning adherence estimates was that most of the studies on adherence 
to diabetes medications have classified adherence levels based on prescription refill 
patterns or MPRs using claims data. Different categories or levels of medication 
adherence have been defined based on MPR (e.g., > 80%, 20%–80% and < 20%). 
Although MPRs provide an intensity measure of drug utilization over a certain period, it 
fails to assess therapy duration. For example, it is possible that with a higher MPR, one 
group may have a shorter time to treatment discontinuation compared with another group. 
Therefore, more sophisticated methods of defining medication adherence, including 
survival analyses — such as time to treatment discontinuation — have the potential to 
complement adherence studies that use MPR. Measuring adherence and persistence 
through these sophisticated methods was lacking in the literature review. These studies 
most commonly divided the adherence rates calculated by MPR into different categories, 
estimating the health care costs and utilization in each category. Across several studies, 
MPRs greater than 80% were used to define adherent patients [9,10−13,15], whereas 
others employed a separate threshold (e.g., 90%, categorization into 3 levels, etc.) 
[16,18]. Of note, Wagner and colleagues [5] found cost savings only in sub-populations 
exhibiting improved glycemic control, rather than on an aggregate level; however, the 
sources of improved glycemic control were unclear in the study. 
 
Findings from the literature illustrated that savings are significantly different between 
patients with the lowest adherence rates and patients with the highest adherence rates. 
Studies determining the effect of adherence over a longer period of time on subsequent 
health care costs are generally lacking in the literature, as effect of adherence over a 
period of one year after patient identification was the common finding, perhaps because 
of limitations of available longitudinal databases. An increase in cost-sharing as a result 
of copayment or other changes in insurance status triggered a decrease in use of even 
essential medications such as diabetes, thereby leading to increased adverse events and 
subsequent health care costs. Particularly, low income patients and patients suffering 
several co-morbidities are most vulnerable to experience devastating effects on their drug 
utilization in response to an increase in copayments or any other cost-sharing program. 
 
It is commonly held by providers that oral medications, because of their ease of 
administration, would induce better adherence levels compared with injection-based 
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insulin therapy, potentially delaying insulin prescriptions. In the long run, it may well 
serve patients if this perception is taken more in balance with clinical evidence 
establishing that insulin therapies, when taken correctly, pose the greatest potential for 
pharmaceutical intervention to more tightly control hyperglycemia and curb advanced co-
morbidity through inhibiting disease progression, in addition to data showing that 
adherence may actually be improved after initiating insulin among patients taking OADs 
[12,37,38,46–48]. The literature review shows that as patients are prescribed increasing 
numbers of OADs and/or are kept on OAD therapy for prolonged periods, adherence is 
increasingly suboptimal without any beneficial effect on disease progression [46]. A 
sensible approach might constitute initiating insulin sooner to improve glycemic control, 
delay disease progression, and thereby increase the probability of better outcomes leading 
to overall cost reductions. Furthermore, as improved glycemic control has been shown to 
benefit health-related quality of life among patients with T2D [49], potential 
improvement in willingness to adhere is an additional factor for consideration.  
 
Injectable insulin is recognized as inconvenient to administer because of fear of self 
administration/needle phobia [43] and because insulin treatment regimens may range 
from one to four daily doses (or more), depending on severity and type of disease, and the 
capability of the patient to manage his or her dosing schedule [44,45]. The review 
showed no stark differences in comparative adherence rates between patients treated with 
insulin and with OADs. They do indicate that, as with OADs, adherence to conventional 
insulin therapy may be characterized as suboptimal, and its attributes mentioned above 
may contribute to many of the poor outcomes observed in patients with T2D. Adopting 
modes of insulin administration that ease the burden of injections, increase patient 
preference and satisfaction, and reduce time of self-management instruction (decreased 
provider burden) may present a promising approach at diminishing costly outcomes.  
 
As insulin pens have been shown to improve patient satisfaction and treatment preference 
leading to improved quality of life, they may represent a specific method to improve 
adherence [50,51]. Studies that assess persistence and adherence to insulin pens and 
related economic consequences are lacking in the literature, and thus, future studies 
comparatively evaluating these outcomes among patients receiving oral medications and 
insulin administered by syringe would contribute considerably to this field of literature.  
 
The results of this systematic review should be interpreted carefully, with the following 
three caveats: (1) the data on medication adherence are predominantly applied to specific 
adult populations; (2) several studies have analyzed prevalent populations of patients 
with diabetes with longer disease duration as opposed to newly diagnosed populations; 
the former population typically incurs higher resource utilization and health care costs 
because of more advanced disease progression, coupled with other co-morbidities; and 
(3) adherence was measured in disparate fashion, often with a threshold of 80% MPR 
defining adherence, categorizing adherence levels into several classes, whereas other 
studies used a persistence measure (i.e., percentage of patients who switched or 
discontinued). 
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Conclusions 
 
Poor adherence among patients with diabetes is a major and established problem in 
contrast with other chronically managed diseases including arthritis, and gastrointestinal 
diseases [36], and costs associated with nonadherence to diabetes medications are 
similarly significant. This review on the effect of suboptimal levels of diabetes adherence 
on overall health care costs showed that patients adhering to prescribed therapy (OADs 
and insulin) incurred fewer overall health care costs. The consequences of suboptimal 
adherence to diabetes medications are of critical importance, both from a clinical and an 
economic standpoint.  
 
According to the Centers for Disease Control and Prevention, the number of Americans 
with T2D that cannot be controlled by exercise and a healthy diet has increased 
significantly from 5.8 million in 1980 to 18.2 million in 2005 [52]. A high number of 
these patients will eventually require treatment with medications accompanied by 
reasonable access and sustained self-management in order for success to be realized in 
controlling the progression of this debilitating disease.  
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Health and economic impact of conversion to an 
insulin analog pen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Cobden D, Lee WC, Balu S, Joshi AV, Pashos C. Health Outcomes and 
Economic Impact of Therapy Conversion to a Biphasic Insulin Analog Pen Among 
Privately-Insured Patients with Type 2 Diabetes Mellitus. Pharmacotherapy.  2007 
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Summary 
 
The purpose of this study was to evaluate claims-related treatment adherence, health care 
resource utilization, and associated costs of therapy conversion from an insulin vial and 
syringe to a premixed biphasic insulin analog pen device among privately insured 
patients with Type 2 diabetes mellitus (T2D). A retrospective, longitudinal, intrapatient 
(before and after) analysis was conducted within the PharMetrics database of medical 
and pharmaceutical claims from 57 commercial health plans across the United States. A 
total of four hundred eighty-six adult patients with a confirmed diagnosis of T2D who 
converted from an insulin analog vial and syringe (233 patients) or a human insulin vial 
and syringe (253 patients) to a biphasic insulin analog pen device between July 1, 2001 
and December 31, 2002 were included. All patients had no previous use of the pen 
device. Primary endpoints were medication possession ratio (MPR), a measure of 
adherence; hypoglycemic events; associations between treatment adherence and 
hypoglycemic events, and adherence and all-cause health care costs; and all-cause–
attributable, hypoglycemia-attributable, and other diabetes-attributable costs.  
 
After conversion to the pen device, MPR increased significantly from 59% to 68% 
(p<0.01). A significant decrease in the likelihood of experiencing a hypoglycemic event 
was also observed after conversion (odds ratio [OR] 0.40, 95% confidence interval [CI] 
0.27–0.61, p<0.05), with hypoglycemic occurrences reduced nearly two thirds among 
subjects with optimal adherence indicated by an MPR of 80% or greater (incidence rate 
ratio [IRR] 0.36, 95% CI 0.11–0.76, p<0.05). Significant decreases in hypoglycemia-
attributable emergency department visits (OR 0.36, 95% CI 0.16–0.84, p<0.05) and 
physician visits (OR 0.39, 95% CI 0.20–0.77, p<0.05) were observed. Total mean all-
cause annual treatment costs were reduced by $1748/patient (p<0.01), hypoglycemia-
attributable costs were reduced by $908/patient (p<0.01), and other diabetes-attributable 
costs were reduced by $643/patient (p<0.01). Patients with an MPR of 80% or greater 
were associated with significant reductions in all-cause health care costs (OR 0.55, 95% 
CI 0.31–0.80, p<0.05).  
 
Our study demonstrated that privately insured patients with T2D may exhibit 
considerable improvements in clinical and economic outcomes after insulin therapy 
conversion from vial and syringe to a premixed biphasic insulin analog pen device. 
 
Introduction 
 
In 2005, an estimated 21 million people across the United States were affected by 
diabetes mellitus, a chronic medical condition characterized by elevated blood glucose 
levels [1]. Its worldwide prevalence is expected to approach 366 million, or 4.4% of the 
global population, by 2030 [2], with T2D constituting greater than 90% of all diagnosed 
cases [1]. The national economic burden of treating diabetes was estimated at $132 
billion in 2002, with direct medical costs representing nearly 70%, or $92 billion, of the 
total cost [1]. Diabetes-related health outcomes and complication events, having the 
potential for substantial financial consequences, may be significantly influenced by level 
of glycemic control, differences in the safety profiles of appropriate treatments, access to 
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therapy per health plan benefit designs, and issues related to proper self-management 
over the long-term duration of the disease [3–10]. In particular, recent reports have 
identified hypoglycemia, an acute complication and safety concern commonly associated 
with intensive diabetes care, as a major contributor to elevated diabetes-related costs for 
patients treated in public and private managed care settings [11,12].  
 
Although glycemic control has been established as the cornerstone of successful diabetes 
treatment, most patients with T2D in the United States are not achieving recommended 
hemoglobin A1c (A1C) targets, despite advancements in insulin molecular design, 
delivery systems, and recommendations for antidiabetic therapy [13–15]. To this end, 
adequate patient self-management has been identified as a critical component for 
successful short- and long-term treatment of diabetes and its complications [16–19], 
including the acute and potentially fatal complication of hypoglycemia [16]. Recent 
health policy initiatives and recommendations aiming to curb the progression of T2D 
have included earlier initiation of either premixed biphasic or basal insulin (human or 
analog) for patients with T2D who have failed diet and exercise as well as oral anti-
diabetic therapy [18,20–23]. Insulin administration has traditionally occurred through the 
use of a vial and syringe; however, several disadvantages with this therapeutic approach 
have been noted. These include difficulty of transportation, intimidation of use with 
regard to anxiety about self-injection, fear of injection (needle phobia) and associated 
pain, lengthy training time on initiation, and social embarrassment. These factors have all 
been suspected to impact lifestyle flexibility and to negatively influence treatment 
adherence, patient self-management behavior, and achievement of euglycemia [24–26].  
 
Insulin delivery systems, including pen devices, may be useful tools for clinicians aiming 
to overcome the barriers to treatment adherence for patients using a vial and syringe. 
Most pen devices are structured such that the insulin cartridge and syringe are combined 
in a single unit, which has led to reported improvements in portability, dosing accuracy, 
mealtime flexibility, and convenience of delivery [25,27]. Increased patient preference 
and treatment satisfaction, which may be particularly important due to their demonstrated 
impact on patient compliance [28], cost of care [6,29], patient self-management behaviors 
[30], and adherence to treatment, have also been reported for pen devices, including 
modern premixed insulin analog pens [24,28,31–36]. Furthermore, patients who perceive 
their insulin injection to be burdensome may experience more negative health outcomes 
than those who do not feel such burden [37], and those who are satisfied are more likely 
to maintain positive physical and psychological health [38]. Additional advantages of 
prefilled insulin pens include improved user confidence, ease of training, patient 
acceptance of therapy, and greater stability during injection (handling) [25,27,39–41].  
 
Considering these positive effects, the increasing use of insulin pens as opposed to 
traditional insulin delivery devices may lead to better health-related quality of life 
[42,43]. Effective and safe long-term treatment of diabetes may depend a great deal on 
patients’ adherence to drug therapy and level of proper self-management, particularly as 
modern and novel class therapies become available and are increasingly used [44]. As 
recent, randomized, controlled, clinical trials support the efficacy and safety of modern 
insulin analog therapies, including premixed insulin, versus preexisting human and basal 
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insulin treatments [45–48], and given that significant differences for patient-reported 
outcomes exist among anti-diabetic therapies, potentially influencing adherence and 
subsequent health outcomes, it is important to evaluate the real-life effectiveness and 
economic impact of therapy conversion among such therapies. This may be especially 
noteworthy in the established framework of a strong correlation between poor diabetes 
treatment adherence and an increased risk for hospitalizations and associated costs, with 
claims-related hypoglycemic event rates having already been found to significantly vary 
for conventional versus modern insulin formulations [49–51]. 
 
To this end, and to the best of our knowledge, this study is a first attempt to evaluate the 
impact that conversion to a premixed biphasic insulin analog pen from preexisting insulin 
preparations administered with vial and syringe may have on health and economic 
outcomes in routine clinical practice. The study is intended to be an in-depth follow-up 
analysis to previously reported data [52] that examined a similar range of primary 
endpoints among patients with T2D who were converting to insulin pen delivery devices. 
However, the present analysis extends the methodological and statistical approach to 
include an assessment of the potential correlation of diabetes treatment adherence to an 
impact on patient health care costs, and specifically evaluates a subset of patients 
converting to the biphasic insulin aspart (BIAsp) 70/30 pen device from a more refined 
and transparent set of pre-conversion insulin formulations. 
 
Methods 
 
Data Source 
 
This study used the PharMetrics Database (PharMetrics, Inc., Watertown, MA), which 
contains a fully integrated and adjudicated set of medical and pharmaceutical claims for 
all covered services for more than 40 million lives from 57 commercial health plans 
across the United States (at the time of data acquisition). It is composed of a broad, 
representative sample of national, commercially-insured health care beneficiaries on a 
variety of measures, including geographic dispersion, age, sex, and health plan structure. 
As the database includes a continuously enrolled managed care population, longitudinal 
retrospective assessment of medical practice patterns and health care resource utilization 
is permissible. Descriptive information on patients’ dates of coverage, sex, geographic 
region, and age is included in the enrollment file, whereas the medical file contains 
details on claims for physician office visits, outpatient services, and hospital stays.  
 
Specifically, the information available includes dates of service, medical diagnoses, and 
procedures performed, coded using International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) and Current Procedural Terminology 
Version 4 codes. Documentation of each prescription filled, including records of the 
dispensing date, National Drug Code, quantity of drug, and number of days supplied, is 
contained in the outpatient pharmacy file. Each of these files is linked through a unique 
patient identification number, allowing integration of individual patient records across the 
entire analytic file to create episodes of care over time. The database is fully compliant 
with the Health Insurance Portability and Accountability Act of 1996 [53]. 
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Study Design and Cohort Selection 
 
This was a retrospective, longitudinal, intra-patient (before and after) analysis similar to 
that used in recently published database research aimed at assessing the clinical and 
health outcomes, as well as costs, of various therapy conversions from a third-party payer 
perspective [52,54,55]. A cohort of patients with a confirmed diagnosis of T2D who 
converted to the BIAsp 70/30 pen device (contains 70% insulin aspart protamine 
suspension and 30% insulin aspart injection) (NovoLog Mix 70/30 FlexPen; Novo 
Nordisk Inc., Princeton, NJ) for the first time (i.e., index event) and who had previously 
been treated with either human or analog insulin administered by vial and syringe were 
identified as the study group.  
 
Characteristics of the cohort in the 6-month period before the index event (pre-index 
period) were compared with those in the 2-year or longer period after the index event 
(post-index period). The primary study endpoints included treatment adherence and 
claims-identified hypoglycemic events (i.e., those requiring third-party intervention). 
Associations between adherence and hypoglycemic events, and the subsequent 
relationship between health care costs and adherence, were analyzed. The overall study 
cohort was entirely composed of and divided into four sub-cohorts by type of pre-index 
drug for further analysis: (1) NPH insulin users, (2) human premix insulin users, (3) 
insulin glargine users, and (4) premixed analog insulin users. Data were collected for the 
period from January 1, 2001–April 30, 2005. Patient inclusion criteria consisted of age 18 
years or older, multiple diagnostic claims for T2D (i.e., ICD-9-CM code 250.xx, 
excluding type 1 subcodes), and first use of BIAsp 70/30 pen therapy that started between 
July 1, 2001, and December 31, 2002. These patients were identified by National Drug 
Code and assigned an index date (i.e., the date of the first prescription for the pen device).  
 
All patients included in the study were required to have longitudinal data characterized 
by at least 6 months of continuous enrollment before the index date and at least a 2-year 
length of follow-up after the index date. First use of BIAsp 70/30 pen therapy was 
determined by the absence of its prescription during the 6 months before the index date. 
Data were collected longitudinally from the index date to first occurrence of either 
discontinuation of the index drug or to the end of the study period (April 30, 2005). 
 
Statistical Analysis 
 
Descriptive statistics were calculated, with categorical variables reported as percentages. 
Patient demographic and clinical characteristics between groups were analyzed with use 
of the Pearson x2 test. For continuous variables, means ± SDs and medians (ranges) were 
generated. The Student t-test was used to analyze mean differences among the sub-
cohorts. An a priori level of significance of 0.05 was set for all of the analyses. Clinical 
characteristics (i.e., patient co-morbidities, complications related to diabetes) were 
assessed over the 6 month pre-index period. Co-morbid conditions and complications 
associated with diabetes were comprehensively chosen for consideration after having 
been identified from the literature. Those conditions included cardiovascular disease, 
diabetes-related infections, other metabolic diseases, nephropathy, neuropathy, 
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retinopathy, obesity, lower-extremity amputation, depression, and hypoglycemic events. 
Specifically, metabolic complications such as hypoglycemic coma (ICD-9-CM code 
251.0), other specified hypoglycemia (251.1), unspecified hypoglycemia (251.2), 
postsurgical hypoinsulinemia (251.3), and disturbances of branched-chain amino acid 
metabolism (270.3) were included. These conditions were tracked by using primary and 
secondary ICD-9-CM diagnosis codes. Binary indicator variables (1 = yes, 0 = no) were 
used to signify the presence or absence of these medical conditions during the pre-index 
period.  
 
Adherence to diabetes treatment before and after the index event was evaluated by using 
the medication possession ratio (MPR). The MPR, an indicator used commonly in 
database-related outcomes research to assess levels of optimal or suboptimal adherence 
[56–58], is defined as the sum of the days’ supply of drug divided by the number of days 
between the first fill and the last refill plus the days’ supply of the last refill. This 
indicator allows for a representation of the proportion of time during the follow-up period 
that a patient was in possession of a supply of their index drug. This designation of MPR 
usually results in a ratio of 1 or less, due to time gaps in refilling the drug; MPR values 
greater than 1 were adjusted to 1. An MPR value of less than 80% was defined as poor 
adherence (conversely, > 80% was defined as optimal adherence). The statistical 
significance of differences in MPR between cohorts was assessed with use of a t-test.  
 
Annualized odds ratios (ORs), quantities used to compare whether the probability or 
likelihood of a certain event differs between two groups, were estimated by using person-
time and event-time analyses with adjustment for varying lengths of follow-up. 
Hypoglycemic events before and after the index event were estimated with the OR, 
including associated data on health care resource utilization (e.g., physician visits, 
hospitalization, emergency department visits). Having tested for overdispersion of the 
model (i.e., conditional variance is greater than the mean), Poisson regression was used 
as an appropriate multivariate regression model for these count data, which followed a 
Poisson distribution [59–61]. The outcome variable of the Poisson regression model was 
the count of hypoglycemic events in the post-index period. A stepwise and systematic 
approach to building the statistical models was taken. Variable advancement in the 
Poisson regression models was driven on a theoretical background.  
 
In model 1, associations between hypoglycemic count and baseline demographics (age, 
sex, and geographic region), study cohort, and clinical variables (co-morbid conditions or 
complications of diabetes) were analyzed. Model 2 involved addition of the main variable 
(level of adherence). In addition to observing the association between adherence and 
hypoglycemic count, this model also helped in analyzing the impact of adding the 
adherence variable on the coefficients of the baseline demographic and clinical variables. 
The third model (model 3) introduced two variables that are closely related to drug 
adherence: log-transformed post-index treatment duration and preindex hypoglycemic 
count. Addition of these two variables helped us in analyzing their impact on the 
adherence coefficient. Although geographic region was one of the independent variables 
in all three models, as a location fixed-effect model was considered, estimates for 
geographic region were not reported. Incident rate ratios (IRRs) were derived by 
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exponentiating the parameter estimates from the model. Payments made by third-party 
payers to health care providers for utilization of health care resources (i.e., the actual 
reimbursement amount) were used to compute total health care costs.  
 
Since administrative claims were collected over several years, all costs were adjusted for 
inflation to 2005 dollars by using the medical care consumer price index [62]. 
Hypoglycemia-attributable costs were computed by summing the amounts paid for all 
claims related to hypoglycemic events (ICD-9-CM codes 250.8, 251.0, 251.1, and 251.2). 
Other mutually exclusive diabetes-attributable costs were computed by totaling the 
amounts paid for claims related to T2D (ICD-9-CM codes 250.0x–250.7x and 250.9x, 
where x = 0 or 2). Overall diabetes-attributable and hypoglycemia-attributable costs were 
further stratified into emergency department, hospitalization, outpatient visit, physician 
visit, and pharmacy costs. The Wilcoxon rank sum test was used to test for significance 
of the cost difference before and after the index event as the cost data gave rise to non-
normal and skewed distributions.  
 
For analyzing associations between study sub-cohorts (the main independent variable) 
and total cost in the post-index period (dependent variable) after adjusting for baseline 
demographics, clinical co-morbidities, level of adherence, and post-index treatment 
duration, a generalized gamma regression model was used as an appropriate multivariate 
regression approach. Stepwise models were created similar to the Poisson regression 
models described above. Similar to the Poisson regression models, variable advancement 
in the gamma regression models was driven on a theoretical background. In model 1, 
associations between total cost in the post-index period and baseline demographic and 
clinical variables were analyzed. Model 2 of the gamma regression involved the addition 
of the main variable (level of adherence). In addition to observing the association 
between adherence and total post-index period cost, this model also helped in analyzing 
the impact of adding the adherence variable on the coefficients of baseline demographic 
and clinical variables. Model 2 also included another important variable that is related to 
drug adherence: log-transformed post-index treatment duration. The third model (model 
3) introduced one variable that would have an impact on total post-index cost: total pre-
index (baseline) cost. Addition of this variable related to total post-index period cost 
helped in analyzing the impact of this variable on the adherence coefficient. Although 
geographic region was one of the independent variables in all three models, since a 
location fixed-effect model was considered, estimates for geographic region were not 
reported, as with the Poisson models. Odds ratios with 95% confidence intervals (CIs) 
were derived from the model and presented. All statistical analyses were performed by 
using SAS, version 9.1 (SAS Institute Inc., Cary, NC). 
 
Results 
 
Patient Characteristics 
 
The overall study population consisted of 486 patients newly beginning treatment with 
the BIAsp 70/30 pen device. Subjects previously treated with an insulin analog vial and 
syringe (233 patients [47.9%]) and subjects previously treated with human insulin vial 
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and syringe (253 patients [52.1%]) constituted two general sub-cohorts within this study 
group. Of those treated with human insulin during the pre-index period, 112 (44.3%) had 
been prescribed NPH insulin and 141 (55.7%) were prescribed premixed biphasic human 
insulin. Of patients using an insulin analog vial and syringe during the pre-index period, 
132 (56.7%) and 101 (43.3%) were prescribed insulin glargine and a premixed biphasic 
insulin analog, respectively. The mean ± SD age of the study population was 45.1 ± 13.7 
years; most subjects (56.4%) were male (Table 1). Generally, patients had an elevated 
prevalence of diagnosed co-morbid conditions: metabolic disease (48 [9.9%]), 
nephropathy (48 [9.9%]), neuropathy (46 [9.5%]), retinopathy (41 [8.4%]), and 
cardiovascular disease (39 [8.0%]).  
 
Previous insulin analog users were significantly younger than previous human insulin 
users (mean ± SD age 43.5 ± 14.2 vs. 46.7 ± 13.1 yrs, p=0.04), with the proportion of 
subjects older than 45 years also significantly lower compared with that age group among 
the previous human insulin users (47.2% vs. 56.9%, p<0.05). Male subjects constituted a 
higher proportion of the previous analog insulin vial and syringe sub-cohort than previous 
human insulin cohort (61.8% vs. 51.4%, p=0.02). However, no significant differences 
were observed with respect to level of individual co-morbid conditions or diabetes-
related complications, with the exception of metabolic diseases (12.9% vs. 7.1%, 
p=0.04). 
 
Treatment Adherence 
 
Adherence (measured by MPR) increased significantly after conversion to the pen device 
((mean ± SD) MPR: 68 ± 31% vs. 59 ± 30%, p<0.01). Furthermore, the percentage of 
individuals exhibiting an adherence rate of 80% or greater was significantly higher in the 
post-index period compared with the pre-index period (56.2% vs. 35.4%, p<0.01). These 
improvements in MPR were also observed across the two general pre-index sub-cohorts 
(previous insulin analog users MPR 71 ± 32% vs. 59 ± 28%, p<0.01, and previous human 
insulin users MPR 66 ± 30% vs. 59 ± 29%, p<0.01). Among individuals who were 
prescribed an insulin analog in the pre-index period, premixed biphasic analog users 
(MPR 72 ± 33% vs. 60 ± 29%, p<0.01) and insulin glargine users (MPR 68 ± 31% vs. 57 
± 26%, p=0.01) showed a similar increase in treatment adherence after conversion. 
Among individuals who were prescribed human insulin in the pre-index period, NPH 
users showed a 6% increase in adherence (MPR 65 ± 29% vs. 59 ± 27%, p=0.03), 
whereas previous premixed human insulin users showed an 8% increase in adherence 
(MPR 68 ± 32% vs. 60 ± 28%, p=0.01). 
 
Hypoglycemic Events 
 
Thirty-two subjects were found to have 44 hypoglycemic events during the pre-index 
period, and 30 individuals had 64 hypoglycemic events during the post-index period 
(Table 2). The percentage of individuals experiencing a hypoglycemic event, after 
controlling for differences in length of follow-up, was reduced by 74% (OR 0.26, 95% CI 
0.15–0.44, p<0.05).  
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Table 1. Baseline demographic and clinical characteristics 
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Table 2. Hypoglycemic events in the 486 patients 
 
 
 
 
 
Similarly, the likelihood of experiencing a hypoglycemic event was reduced by 60% (OR 
0.40, 95% CI 0.27–0.61, p<0.05). Model 3 of our Poisson regression estimated that the 
frequency of hypoglycemic events in subjects with an MPR of 80% or greater decreased 
by nearly two thirds (IRR 0.36, 95% CI 0.11–0.76, p<0.05). Pre-index insulin analog 
users showed the highest reduction in hypoglycemic events after converting to the BIAsp 
70/30 pen device. Previous glargine users and premixed biphasic analog users showed a 
similar reduction of approximately two thirds of subjects experiencing a hypoglycemic 
event (OR 0.36, 95% CI 0.15–0.87, p<0.05 for previous glargine users, and OR 0.37, 
95% CI 0.16–0.82, p<0.05 for previous pre-mixed biphasic analog users). Human insulin 
users in the pre-index period showed a slightly smaller, yet still significant, reduction in 
hypoglycemic events after conversion. Previous NPH users and premixed human insulin 
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users showed a comparable 58% reduction in the annual number of subjects experiencing 
a hypoglycemic event (OR 0.42, 95% CI 0.18–0.95, p<0.05 for previous NPH insulin 
users, and OR 0.43, 95% CI 0.19–0.98, p<0.05 for previous pre-mixed human insulin 
users).  
 
Hypoglycemic events that required resource utilization are summarized in Table 2. 
Significant decreases in hypoglycemic event–related emergency department visits (OR 
0.36, 95% CI 0.16–0.84, p<0.05) and physician visits (OR 0.39, 95% CI 0.20–0.77, 
p<0.05) were observed, although hypoglycemic event–related hospitalizations (OR 0.73, 
95% CI 0.32–1.67) and outpatient visits (OR 0.42, 95% CI 0.12–1.49) were non-
significantly reduced, similar to previous reports [52]. Significant factors were found to 
be associated with hypoglycemic events in the post-index period examined in a Poisson 
multivariate context. The full analysis (model 3) revealed no significant difference in the 
occurrence of hypoglycemic events in the post-index period among individuals who were 
previously prescribed NPH insulin (IRR 1.00, 95% CI 0.99–1.01), premixed insulin 
analogs (IRR 0.90, 95% CI 0.58–1.23), and insulin glargine (IRR 0.86, 95% CI 0.55–
1.28) when using premixed human insulin vial and syringe users as the baseline 
comparison group. Several co-morbid conditions and complications did emerge as 
significant characteristics of subjects experiencing hypoglycemia in the post-index 
period: neuropathy (IRR 1.93, 95% CI 1.27–3.18, p<0.05), nephropathy (IRR 3.53, 95% 
CI 2.19–5.12, p<0.05), cardiovascular events (IRR 1.77, 95% CI 1.12–3.06, p<0.05), and 
other metabolic diseases (IRR 5.47, 95% CI 3.98–8.29, p<0.05). 
 
Health Care Costs 
 
Annually adjusted mean all-cause health care costs/patient decreased significantly after 
conversion to the BIAsp 70/30 pen device ($16,004 vs. $14,256, p<0.01; Table 3). 
Hypoglycemia-attributable costs decreased by $908 from the pre-index period to the 
post-index period ($1528 vs. $620, p<0.01), mainly reflected in significant annualized 
mean savings in associated emergency department costs of $67 ($95 vs. $28, p<0.01), 
hospitalization costs of $585 ($895 vs. $310, p<0.01), physician-visit costs of $96 ($160 
vs. $64, p<0.01), and pharmacy costs of $177 ($321 vs. $144, p<0.01). Reductions in 
hospitalization and emergency department costs were mainly due to decreases in the 
mean annual number of associated emergency department visits (7.7 vs. 5.0 visits, 
p<0.01) and hospital length of stay during those visits (9.9 vs. 6.0 days, p<0.01).  
 
Other diabetes–attributable costs decreased by $643 in the post-index period compared 
with the pre-index period ($8699 vs. $8056, p<0.01), reflected mainly in mean per-
patient reductions of $114 in associated emergency department visits ($276 vs. $162, 
p<0.01), $877 in physician visits ($1522 vs. $645, p<0.01), and $433 in pharmacy costs 
($4068 vs. $3635, p<0.01; Table 3). Similar to the hypoglycemia-attributable emergency 
department cost reductions, decreases in the cost of diabetes-attributable emergency 
department resource utilization were driven by a significant annual mean decrease in 
emergency department visits after conversion (10.1 vs. 7.2 visits, p<0.01; Table 3).  
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Examination of pre-index and post-index diabetes-attributable pharmacy costs, stratified 
by the cost of insulin and the cost of oral anti-diabetic drugs, revealed a significant 
increase in the cost of insulin in the overall study cohort ($2278 vs. $2617, p<0.01); 
however, analyses of each of the individual sub-cohorts did not show significant 
increases after conversion. During the post-index period, a reduction in the cost of oral 
anti-diabetic drugs ($772) was observed in the overall cohort ($1790 vs. $1018, p<0.01) 
as well as within each sub-cohort, significantly so for three of the four groups (previous 
glargine insulin: $484 vs. $248, p=0.04, premixed biphasic insulin analog: $483 vs. 
$251, p=0.04, premixed biphasic human insulin: $422 vs. $253, p=0.03, NPH insulin: 
$401 vs. $266, p=0.06; Table 4).  
 
Factors potentially associated with post-index all-cause total health care costs were 
examined in a generalized linear gamma regression context (Table 5). Using premixed 
human insulin as the pre-index baseline sub-cohort comparator, the most extensive model 
(model 3) revealed significantly lower all-cause health care costs in the post-index period 
among individuals who had been prescribed insulin glargine (OR 0.81, 95% CI 0.67–
0.95) and a premixed insulin analog (OR 0.79, 95% CI 0.68–0.90) during the pre-index 
period, with previous NPH insulin vial and syringe users showing a non-significant 
increase in all-cause health care costs (OR 1.20, 95% CI 0.90–1.59). Several co-morbid 
conditions and complications emerged as significant characteristics of subjects 
experiencing higher health care costs during the post-index period: neuropathy (OR 1.26, 
95% CI 1.11–1.43, p<0.05), nephropathy (OR 1.72, 95% CI 1.51–1.99, p<0.05), 
cardiovascular events (OR 1.49, 95% CI 1.30–1.51, p<0.05), other metabolic diseases 
(OR 1.14, 95% CI 1.06–1.24, p<0.05), retinopathy (OR 1.23, 95% CI 1.09–1.38, p<0.05), 
and depression (OR 1.84, 95% CI 1.68–2.04, p<0.05). 
 
Discussion 
 
Clinicians treating patients with T2D have a wide array of appropriate 
pharmacotherapeutic options available, with each having individual effects on clinical 
effectiveness, safety, treatment satisfaction, and other patient-reported outcomes affecting 
patient self-management behavior [17,24–26,31–34,39]. Therefore, assessing the effects 
on health and economic outcomes that individual therapy classes may have in routine 
clinical practice is important. Of particular importance may be distinguishing these 
outcomes not only among delivery methods but also among classes of anti-diabetic 
therapies given the current and ever-increasing range of treatment options and given that 
patient perceptions of care have been shown to be multifactorial and variable between 
conventional and modern therapies [44].  
 
This study aimed to provide an extended and more focused methodological approach to 
data recently reported on the health economic sequelae of conversion to insulin pen 
devices among a larger cohort [52]. We attempted to achieve this first by examining the 
impact of conversion to the pen device of a specified class of insulin from a refined, 
stratified variety of pre-existing vial and syringe preparations, and then by including an 
assessment of the potential impact that treatment adherence with this pen may have on 
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Table 3. All-cause-attributable, hypoglycemia-attributable, and other diabetes-
attributable resource utilization and costs associated with switching to or adding analog 
insulin pen therapy 
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Table 3. (continued – far right column) 
 
 
 
 
 
Table 4. Comparison of pre-index and post-index diabetes-related pharmacy acquisition 
costs  
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Table 5. All-cause-related treatment costs: a generalized linear gamma regression model  
 
 
 
 
 
patient health care costs in a multivariate context of other clinical and patient 
characteristics. In using a data source providing observational perspective within 
privately-insured community practice settings, the analytic approach supplements clinical 
trial data (from a controlled setting) comparing BIAsp 70/30 pen with the defined variety 
of sub-cohort pre-index insulin formulations in this study. This thereby allowed a first 
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attempt to offer insight to clinical and policy decision-makers of the potential impact that 
therapy conversion to a dual-action insulin analog may have on treatment adherence, 
occurrence of hypoglycemic events, resource utilization, costs, and the correlative effects 
therein.  
 
Optimal treatment adherence, one of the primary endpoints measured by an MPR of 80% 
or greater, was significantly improved during the post-index period compared with the 
pre-index period (68% vs. 59%, p<0.01). This positive impact on MPR for conversion to 
the BIAsp 70/30 pen was more pronounced than was observed in a more general, 
inclusive insulin pen cohort previously reported [52], highlighting a potentially 
distinctive benefit associated with the pre-mixed, dual-action insulin analog. 
Furthermore, the present analysis revealed more prominent all-cause-attributable, 
hypoglycemia-attributable, and other diabetes-attributable cost reductions on conversion 
when compared with the larger pen group ($1748 vs. $1590, $908 vs. $788, and $643 vs. 
$600, respectively) [52]. That hypoglycemia-attributable cost reductions accounted for 
58.5% of the total reduction in diabetes-related health care resource use reinforces the 
notion that hypoglycemia is a major contributor to diabetes-attributable costs, and also 
suggests that improved adherence associated with reductions in hypoglycemia-
attributable events may have a positive influence on total diabetes-attributable resource 
use in the short term. Hypoglycemia should therefore be an important factor to focus on 
for improving patient safety and containing costs during medical decision-making.  
 
The number of hypoglycemic events during the post-index period also decreased 
significantly (OR 0.40, 95% CI 0.27–0.61, p<0.05); this reduction, in parallel to the 
results for MPR and health care costs, was found to be higher than the previously 
reported [52] OR of 0.50 (95% CI 0.37–0.68, p<0.05). The utilization of specific health 
care resources associated with hypoglycemic events declined: emergency department 
visits (OR 0.36, 95% CI 0.16–0.84, p<0.05) as well as physician visits (OR 0.39, 95% CI 
0.20–0.77, p<0.05). However, no significant change was noted in hypoglycemia-
attributable hospitalizations (OR 0.73, 95% CI 0.32–1.67) or outpatient visits (OR 0.42, 
95% CI 0.12–1.49), which were mutually exclusive from the emergency department and 
physician visits. This may be an indication that patients experiencing hypoglycemia 
severe enough to warrant third-party intervention may be more prone to receive care 
specifically within the emergency department or from a physician rather than through 
treatment provided within other hospital units or settings of outpatient care. These 
outcomes data specific to use of the BIAsp 70/30 pen device may also reinforce its 
previously documented benefit in hypoglycemia versus human insulin and may provide 
impetus to further test for causality regarding improved patient-reported treatment 
preference and satisfaction and a positive impact on adherence [31,32,42,45–48].  
 
The Diabetes Audit and Research in Tayside Scotland/Medicines Monitoring Unit 
(DARTS/ MEMO) collaborative study found that the presence of inadequately controlled 
diabetes-related complications is associated with a negative impact in terms of the acute 
occurrence of hypoglycemia [63]. Similarly, our findings highlight the significantly 
negative impact that various diabetes-related co-morbidities and complications may have 
on hypoglycemic events and costs; patients were significantly more likely to experience 
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hypoglycemia if they had concomitant metabolic disorders (IRR 5.47, 95% CI 3.98–8.29, 
p<0.05), nephropathy (IRR 3.53, 95% CI 2.19–5.12, p<0.05), cardiovascular events (IRR 
1.77, 95% CI 1.12–3.06, p<0.05), or neuropathy (IRR 1.93, 95% CI 1.27–3.18, p<0.05). 
Note that although not statistically significant, post-index hypoglycemic event 
occurrences were lower among subjects who received analog insulin in the pre-index 
period compared with those who received human insulin. 
 
T2D has a well-established and progressive correlation with many long-term 
complications, such as dysfunction or failure of the peripheral nerves, vision, and the 
renal and cardiovascular systems [64,65]. Increased and suboptimally controlled plasma 
glucose level is a strong indicator of increased risk for these complications [4,8]; 
however, monitoring patient self-management and hypoglycemia, not only A1C values, 
should constitute an essential component to diabetes care. Although the present analysis 
did not evaluate A1C laboratory values as an outcome measure, and therefore no 
conclusions can be made regarding glycemic control for this study group, previous 
research suggests that improvements in treatment adherence are significantly correlated 
to improved glycemic control [66,67] and that this may considerably ameliorate 
complication events, increased resource utilization, and the financial consequences of 
T2D [49–51], particularly related to hypoglycemia and hospitalizations. As such, the 
results in this analysis demonstrating a correlation between increased MPR and reduced 
hypoglycemia may be hypothesis-generating for future research evaluating a causal 
relationship between treatment adherence and A1C, data that would represent an 
important contribution to managing T2D.  
 
Hypoglycemia, one of the primary obstacles to successfully controlling diabetes, is a 
potentially serious complication that is most often associated with insulin and insulin 
secretagogues, and may discourage providers from starting more intensive therapy 
[68,69]. Large epidemiologic studies such as the Diabetes Control and Complications 
Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have 
shown that intensive diabetes care, particularly with insulin, although providing 
significant improvements in glycemic control, is associated with increased rates of 
hypoglycemia [70,71]. Without the inclusion of A1C as an outcome measure in the 
results of the present analysis, it is not possible to conclude whether the reduction in 
hypoglycemia observed in patients converting to the BIAsp 70/30 pen was correlated to 
or independent of A1C; however, the possibility exists that a reduction in hypoglycemia 
was associated with elevated A1C levels (loss of glycemic control). Nevertheless, 
reductions in hypoglycemic events and the potential benefits therein on health-related 
quality of life may lead to a reduction in the ensuing fear of recurrent hypoglycemia [72], 
which may facilitate a greater likelihood of sustained adherence and tighter glycemic 
control over the course of long-term management of T2D. This too, however, requires 
further research and confirmation. 
 
Symptoms and levels of severity of hypoglycemia can vary considerably from patient to 
patient, potentially leading to unreported or unidentified occurrences of the condition 
[68,69,73]. The coded hypoglycemic events in the claims data used to estimate resource 
utilization in the present analysis were likely to be of a more severe nature, as some 
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patients may either not detect or have a higher tolerance for the effects of minor events, 
which may therefore not require a third party and go unreported. An MPR value of 80% 
or greater was associated with fewer hypoglycemic events (IRR 0.36, 95% CI 0.11–0.76, 
p<0.05). This result is very similar to that previously observed [52], thereby reinforcing 
the possible association between improved adherence and reduced hypoglycemia over an 
annually adjusted time period.  
 
A reduction in diabetes-attributable pharmacy costs in association with an increased level 
of adherence after conversion to the BIAsp 70/30 pen device was observed, although a 
significant increase was seen in the contribution that total insulin costs had to overall 
diabetes-attributable pharmacy costs over time (from 56.0% to 72.0%). It may be 
noteworthy that beneficiaries’ diabetes-attributable pharmacy costs analyzed here were 
the actual reimbursed amount and that it was not possible to ascertain manufacturer 
rebates. Future research on the impact of disparities in copayment and rebate levels as 
they pertain to received health care benefit designs and health economic outcomes may 
help further create efficiencies and equality in access to care. Nonetheless, the cost for 
oral anti-diabetic drugs in the present analysis was significantly reduced by 
$772/patient/year, which was higher than the $664 observed in the more generalized pen 
cohort [52]. This cost reduction may be an indication that the association between 
improved MPR and, subsequently, improved short-term outcomes (hypoglycemia) may 
have led physicians treating patients in the study group to reduce the prescribed number, 
strength, or daily dose of oral anti-diabetic drugs. It is also equally possible, however, 
that providers chose to reduce dosing or to discontinue oral anti-diabetic drugs in the 
post-index period due to changes in treatment protocols, incident co-morbid conditions, 
or other unidentifiable reasons, or to simply reduce patient copayments or pill burden.  
 
As mentioned, one important factor to be considered when interpreting the results of the 
current study is the impact that patient copayments or other financial barriers to accessing 
pen devices, including prior authorization, may have had [74–76]. Given the evidence 
that less favorable tier assignment may induce suboptimal adherence [19], and the fact 
that insulin analogs and pen devices are typically placed on less favorable managed care 
formulary tiers compared with human insulin and insulin vials, the finding of improved 
MPR despite a likely increase in cost-sharing after conversion to pen therapy may be 
particularly noteworthy [76]. Consideration of the level of cost-sharing to the patient (i.e., 
drug copayment) might also highlight in more detail a variable impact on adherence and 
the true pharmacy costs to a third-party payer, and may also provide insight to 
characteristics of optimal health plan benefit designs in terms of facilitating improved 
adherence and cost containment for patients with diabetes.  
 
Limitations of MPR and Claims Analyses 
 
Limitations inherent to this and other claims data analyses require mentioning. First, 
although MPR is well established in the literature as an appropriate measure of treatment 
adherence, the ability to analyze the continuity of treatment usage with this value is 
limited. Particularly, when calculating MPR, important aspects in evaluating drug intake 
such as drug sharing or wastage are notable to be included. Although efforts were made 
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to reduce potential skewing effects in our calculation of MPR, the drugs in the present 
analysis are dispensed in disparate volumes (i.e., 10-ml vials and a 15-ml box of pens [3 
x 5 ml] per prescription), potentially affecting refill gaps.  
 
Second, although MPR provides insight as to whether a patient was adequately or 
inadequately in possession of the correct amount of drug, it is not possible to confirm 
with claims data that patients are correctly or accurately administering their drugs. Third, 
although efforts were made to use appropriate multivariate analyses to adjust for 
differences in demographic and clinical characteristics, data on race or income were 
absent, which may have revealed notable effects on clinical and economic outcomes and 
resource use. Fourth, although the data source used in this analysis contained a study 
population that was well-dispersed geographically and covered by a variety of private 
managed care structures, prudence should be taken in generalizing these results across 
populations receiving health benefits in other countries or within public health insurance 
systems, as potentially confounding factors regarding treatment paradigms and access to 
therapy may be unobserved or missed.  
 
Fifth, data were not available regarding over-the-counter drugs, which may have included 
testing supplies related to diabetes care. However, whether the requirement for or actual 
adherence to such resource use would differ between the pre-index and post-index drug 
therapies is unknown. A sixth limitation may be that although the Poisson and 
generalized linear model multivariate analyses adjusted for occurrence of pre-index 
hypoglycemic events and log-transformed pre- and post-index treatment duration, it is not 
possible to exclude the potential for clinicians to have converted to BIAsp 70/30 pen 
therapy specifically to ameliorate problems with pre-index hypoglycemia, or that any of 
the reported benefits were sustained over a longer follow-up period than was observed.  
Also, with all retrospective claims database analyses, the possibility exists for miscoding 
of events or for missing data, and thus the potential to either inflate or underestimate any 
outcomes results. Finally, these study findings are those from a retrospective 
observational approach, evaluating data from a community practice rather than within a 
randomized controlled setting. Thus, the data allow examination of associations between 
patient or treatment variables and outcomes, but limit the ability to draw conclusions 
regarding causality. 
 
Conclusion 
 
Patients with T2D who receive private health care insurance coverage may exhibit an 
improvement in treatment adherence and be associated with reductions in the resource 
use and related costs of treating hypoglycemia after insulin therapy conversion from vial 
and syringe to a premixed biphasic analog pen device. Facilitating optimal levels of 
adherence among patients with T2D may be significantly associated with reducing not 
only the likelihood of hypoglycemia, but also health care costs, particularly through 
reduced emergency department and physician visits.  
 
Future research is warranted and should address the potential effects that disparate health 
plan benefit designs may have on health and economic outcomes for patients with 
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diabetes, while further exploring the potential correlation among improved MPR, reduced 
hypoglycemia, and A1C laboratory values.  
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Summary 
 
Type 2 diabetes (T2D) treatment involves complex interactions between biological, 
psychological and behavioral factors of care, requiring multifaceted efforts in clinical 
practice and disease management to reduce health and economic burdens. We aimed to 
quantify correlations amongst these factors and characterize their level of inclusion in 
economic analyses that are part of informed medical decision-making. A comprehensive, 
stepwise systematic literature review was performed on published articles dated 1993-
2008 using medical subject heading and keyword searches in electronic reference 
libraries. Data were collected using standardized techniques and were analyzed 
descriptively. 
 
A total of 97 manuscripts fulfilling all inclusion criteria were reviewed, including 16 on 
economic models (17% of articles). Most studies were retrospective (41/97; 42%) and 
from managed care perspectives (66%). Oral anti-diabetic drugs were a central focus, 
appearing in 83% of studies. Behavioral factors, particularly medication adherence and 
persistence, are well-researched (n=65) and may influence diabetes outcomes, 
cardiovascular risk, mortality rates, and treatment-specific resource use (eg, 
hospitalizations) and costs (≤ $3400 annually per patient). However, they are absent from 
current economic models.  
 
Strong correlations exist between patient behaviors, perspectives of care, health outcomes 
and costs in T2D. Their inclusion in pharmacoeconomic modeling, notably the influence 
on clinical effectiveness of variation in self-management between treatments, should 
ultimately lead to more accurate estimates of comparative cost-effectiveness, and thereby 
improve value-based resource allocation and patient access to appropriate therapy.  
 
Introduction 
 
The health and economic burden of Type 2 diabetes (T2D) is rapidly growing in rural, 
urban, developing and industrialized nations alike. Costs doubled in India from 1998 to 
2005 [1], rose 395% in the U.S. over the last decade [2,3] and are projected to exceed 
$550 billion in China by 2015 [4]. Lifestyles, dietary choices and ageing populations 
have contributed to a 400% increase in number of diagnoses among adolescents to the 
elderly [5,6,7,8]. This trend will likely continue: U.S. prevalence is estimated to triple by 
2050 (to 50 million patients) [5], and prevalence and costs in the U.K. are projected to 
increase 20-30% and 40-50%, respectively, in the near future [6].  
 
Payers and policymakers have aggressively responded to this crisis through disease 
management and reimbursement reform [9], where pharmacy benefits are a common 
focal point for cost containment [10]. Although adjusting formularies and increasing 
copayments can lead to short-term cost savings [11], this may jeopardize patient 
acceptance of prescribed therapy, resulting in poor clinical outcomes and higher costs 
over the long-term [10,12-14]. The difficulty of minimizing costs while maximizing 
clinical effectiveness has broadened the definition of value in healthcare and led to 
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mainstream use of economic models, particularly in evaluating diabetes and other chronic 
diseases [15,16]. 
 
Diabetes economic models traditionally employ data from large clinical trials and 
epidemiological studies to calculate disease progression and future costs. These have 
historically been driven by: (1) biological/clinical parameters (eg, HbA1c change, 
complication risks) [17] and (2) treatment- and demographic-specific effects (to estimate 
the cost-effectiveness of competing therapies in defined populations) [18]. However, 
biological/clinical mechanisms alone may explain as little as 6-8% of variation in 
resource use and costs among T2D patients, leaving potential for large margins of 
uncertainty to exist in current economic evaluations [19,20,21]. Despite increased use of 
models to inform disease management, most patients are still not achieving target HbA1c, 
indicating the need to conduct economic evaluations that more accurately predict what 
will actually happen in real-world clinical practice [5,22].  
 
One worthwhile focus to achieving this goal can be found in psychological and 
behavioral patient factors, namely self-management and perceptions of care. These 
factors have been defined in terms of (1) medication adherence and persistence, and (2) 
satisfaction, preferences, psychological wellbeing, and related patient-reported outcomes 
(PROs) [23,24]. Various studies have observed that these factors can affect metabolic 
control, hypoglycemia, diabetes-related resource use and healthcare costs [25-28]. 
 
The primary aim of this study was to review the literature regarding the clinical and 
economic impact of correlations between psychological and behavioral factors of care 
among T2D patients. Furthermore, we examined the extent to which these factors have 
been included in T2D economic models to date. 
 
Methods 
 
Data Sources  
 
We performed a comprehensive systematic literature review based on standard 
methodology [29] among published, peer-reviewed articles in electronic reference 
libraries (EMBASE, MEDLINE (PubMed) and CENTRAL). Article bibliographies were 
searched for references that were undetected electronically. 
 
Search Strategy  
 
A four-step approach was taken (see Figure 1): (1) preliminary screening of articles, (2) 
formal abstract review, (3) full-text retrieval with bibliography screen and (4) manuscript 
critique with population of table shells in electronic databases. Each paper was evaluated 
independently by a trained researcher. 
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Figure 1. Stepwise literature search strategy 
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We examined the impact of the following psychological and behavioral factors on 
clinical and economic outcomes: 
 
 self-management 
 
 patient perceptions of care 
 
 direct and indirect correlations of these factors 
 
Rigid inclusion criteria on study populations, content matter and formatting were applied 
(see Table 1). Studies were required to satisfy all criteria. 
 
 
Table 1. Article selection criteria 
 
 
 
 
 
Applied MeSH terms were: “Type 2 diabetes mellitus” combined with “patient 
compliance” or “economics” or “treatment costs” or “decision modeling” or “patient 
acceptance of healthcare” or “aversion therapy” or “treatment failures” or “medication 
self” or “patient satisfaction” or “patient preference” or “quality of life” or “self 
management”. 
 
Free text keyword combinations were: “Type 2 diabetes” combined with “therapy 
conversion” or “adherence” or “persistence” or “compliance” or “MPR” or “patient-
reported outcomes” or “treatment satisfaction” or “wellbeing” or “economic model” or 
“therapy switch” or “treatment substitution” or “therapy conversion” or “treatment 
alteration” or “therapy burden” or “treatment addition” or “therapy replacement” or 
“treatment modification”. 
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Data Extraction & Critical Appraisal  
 
Electronic data tables captured relevant information. Pre-defined metrics were populated 
concurrently alongside critique of individual articles (see Table 2).  
 
 
Table 2. Metrics of data collection 
 
 
 
 
 
Data Analysis  
 
Descriptive statistics were calculated to aggregate and report main attributes of reviewed 
articles. The substantial heterogeneity of research designs, populations and outcome 
measures found in collected articles precluded formal meta-analysis.  
 
Results 
 
Initial searches generated over 5500 candidate abstracts. After eliminating duplicates and 
screening for general subject matter, 816 studies were entered into a master reference 
database. Formal abstract review applying all content and formatting criteria resulted in 
the selection of 133 full articles. A search of references within these 133 articles yielded 
6 additional references, raising the total to 139 manuscripts. A second critique (formal 
review of 139 manuscripts) yielded 97 articles satisfying all criteria. Most excluded 
studies were disqualified by lacking correlations of multiple (≥ 2) measures of interest or 
because therapeutic interventions were not explicit.  
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Table 3. Breakdown of characteristics for full-text articles (n = 97) 
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Psycho-behavioral factors of T2D  
 
We evaluated psychological and behavioral factors as follows:  
 
 self-management: medication adherence; treatment persistence 
 
 patient perceptions of care: treatment satisfaction; psychological wellbeing;  
preferences 
 
Medication adherence or persistence was analyzed in 67% of articles (n=65) across 
treatment groups, primarily in observational/uncontrolled settings and defined by 
medication possession ratio (MPR; for adherence) and treatment duration/continuation 
(for persistence). 
 
Patient perceptions of care were addressed in 31 articles (32%), usually captured with 
validated PRO instruments. Correlations involving treatment modification and economic 
or clinical outcomes occurred in 36% of articles (n=35), and correlations among 3 or 
more psychological and behavioral factors were analyzed in 27 papers (28%).  
 
Medication Adherence  
 
Thirteen articles measuring self-management correlated adherence with costs or resource 
use, nearly all retrospectively using medical records or administrative claims data. 
Although adherence was measured in numerous ways, including prospectively and cross-
sectionally via questionnaire and electronic monitoring, calculating MPR (describing the 
proportion of days in possession of prescribed medication) was most common. Cutoff 
levels > 80% were frequently used to define optimal adherence. 
 
Twenty articles demonstrated statistically significant, inverse correlations between 
adherence and glycemic or cardiovascular outcomes. Poor adherence has been associated 
with up to a 3.4% rise in HbA1c. Conversely, optimal adherence promotes a greater 
likelihood of achieving target HbA1c; patients achieving an HbA1c ≤ 7% on oral anti-
diabetic drugs (OADs) have averaged 15% greater adherence (vs. patients > 7% HbA1c) 
[30,31], and may achieve 0.1% absolute HbA1c reductions for every 10% relative 
increase in adherence [24]. Amongst patients whose initial HbA1c is above target, up to 
8% more patients who maintain good adherence (vs. poor) may reach HbA1c ≤ 7% within 
6 months [32]. Additionally, increased adherence to diabetes medications over 2 years 
may contribute to LDL cholesterol reductions (-12.4 mg/dl) and likelihood of improved 
hypertension (by 56-60%) [33,34], although it remains unclear the extent to which 
increased adherence to OADs and insulin may individually have on cardiovascular 
outcomes. 
 
Additional studies where patients were stratified into levels of adherence found that those 
with optimal adherence show a greater reduction in HbA1c (by up to 1.4%) than patients 
with poor adherence [35]. Incrementally, 10-25% relative increases in drug adherence 
over 1 year may decrease HbA1c by 0.05-0.2% among indigent, minority and caucasian 
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populations alike [36-38]. The ability to achieve glycemic control through treatment 
intensification/positive clinical inertia may depend on – or at least be predicted by – the 
degree of adherence to previous medication [39]. Insulin users with an MPR > 80% had a 
0.7% lower mean HbA1c (6.6% vs. 7.3%) than insulin users with an MPR < 80%. In 
addition, insulin users with an optimal MPR also showed 30% greater adherence to 
cardiovascular medication [40,41]. Among highly uncontrolled patients, adherent patients 
may reduce HbA1c by 2.1% more (11.2% to 8.3%; p<0.01) than non-adherent (11.4% to 
10.6%; p=NS) after 1 year; 84% of those who reduced HbA1c > 2% were in the adherent 
group [42]. 
 
Other studies correlated MPR for T2D medications with major hypoglycemia and 
cardiovascular outcomes (comprehensive BP, CHF and LDL cholesterol) [25,26,43]. 
Two studies, one a prospective clinical trial, also examined the relationship between risk 
of mortality and adherence among T2D patients. The chance of death was 81% higher 
amongst patients with poor adherence [43], and patients with physician-rated “very bad” 
adherence had 2.7 times higher risk of mortality than patients with “rather good” or “very 
good” adherence [44]. 
 
Three studies highlighted the importance of optimal T2D medication adherence in 
comparison to other chronic diseases. Diabetes adherence may significantly influence 
annual healthcare costs and risk for hospitalization (by 2.5 fold), whereas adherence to 
cardiovascular medication for hypertension, dyslipidemia and heart failure may not 
[45,46]. Furthermore, a 10% decline in adherence to OADs may increase HbA1c (by 
0.14%) and LDL cholesterol (by 4.9 mg/dl), whereas adherence to ACE-inhibitors may 
not significantly affect clinical outcomes [47]. 
 
Numerous studies have examined the possible impact of adherence on resource use and 
costs (see Table 4). One reported that after 1 year, patients were more adherent to OADs 
versus insulin, requiring fewer physician visits and incurring 35% lower hospitalization 
costs, 18% lower total healthcare costs and 25% lower T2D-related costs [48]. Another 
study stratified patients according to MPR and also found that higher MPR levels were 
associated with lower costs: patients with an MPR < 75% incurred the highest annual 
patient costs ($5706), patients with an MPR of 75-95% incurred $5314, and patients with 
an MPR > 95% incurred the lowest costs ($4835) [49]. It was reported that each 20% 
increase in adherence may contribute to an approximate $1500 reduction in costs [45]. 
Similarly, 8.6% to 28.9% decreases in annual costs were found for every 10% MPR 
increase for OAD-treated patients [50], although studies in minority populations suggest 
only a 2% reduction in healthcare costs for the same degree of MPR improvement 
[36,51]. 
 
This correlation between MPR and costs appears true for insulin regimens as well. An 
8% increase in MPR during conversion to pen devices from a vial/syringe may be 
associated with $1400 and $1800 annual reductions in T2D-related and overall healthcare 
costs, respectively. These cost differences were primarily attributed to 56% and 61% 
drops in emergency room and physician visits, respectively, and patients having an MPR 
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> 80% experienced fewer hypoglycemic events (by 67%) and incurred lower total costs 
(by 45%) [25,26]. 
 
 
Table 4. The economic impact of between-treatment differences in diabetes medication 
adherence  
 
 
 
 
 
Treatment Persistence  
 
Ten articles (10.3% of total) analyzed persistence to therapy, defined as treatment 
duration without modification, or rate of discontinuation. 
  
Treatment attributes were found to influence persistence. Based on 352,955 patient days 
of follow-up, higher dosing of anti-diabetic medications predicted early discontinuation 
by up to 2 fold, and patients initiating therapy through self-injection (insulin 
monotherapy) versus an OAD were 33% less persistent over 1 year, and up to 3 times 
more likely to be non-persistent (OR 3.00 [95% CI: 2.30-3.91]) [52]. In contrast, 
treatment by an endocrinologist may predict greater persistency, and patients may exhibit 
an 8-9% increase in OAD persistence with use of extended-release tablets and/or once-
daily dosing versus twice-daily administration [53,54]. Regardless of treatment, however, 
OAD persistence decreases consistently after 1 year (by about 50%) and varies widely, 
ranging from 31% to 65% [52,55]. Similarly, low rates of persistency have been reported 
for insulin use, at 32% over a 12 month period [52]. 
 
Several studies illustrated the economic impact of persistence. One analyzed a U.S. 
Medicaid population to reveal that 10% greater persistence in OAD patients may reduce 
annual healthcare costs by 16% [56]. Long-term assessment of these patients revealed 
that a 4% increase in persistency may reduce annual costs by up to 20% [57]. Another 
demonstrated that improved persistency may improve HbA1c, and reduce sick days and 
costs by $1200-1800 per patient [58]. However, persistency and costs are not always 
inversely related; short-term cost reductions can occur in non-persistent patients 
inasmuch as they do not use/seek treatment [59]. 
  
Additional research links persistency to psychological wellbeing; 23% of depressed T2D 
patients discontinue, switch or augment therapy, 7% higher than non-depressed [60]. 
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Furthermore, a 6% decrease in OAD persistence was reported to predict onset of 
depression, and depressed patients (vs. non-depressed) are 72% more likely to modify 
therapy and 89% more likely to augment OADs, increasing pharmacy costs. 
 
Patient Perceptions of Care  
 
We focused on three primary areas of patient perceptions: treatment satisfaction, 
psychological wellbeing and preferences. Of the 31 articles that evaluated these outcomes, 
23% (n=7) analyzed interrelations of ≥ 3 psychological or behavioral factors. 
 
Treatment Satisfaction  
 
Strong associations were discovered between clinical outcomes and level of satisfaction 
with treatment attributes and treatment-related health events [24,61,62]. 
  
Among 50 patients new to insulin, improved satisfaction correlated with improved HbA1c 
(-1.43%), lipid profile and frequency of hypoglycemia over 7 months, even as BMI 
increased (+1.1 kg/m2) [63]. Extensive analysis of 233 patients in a multi-country 
randomized controlled trial comparing device and syringe-based insulin revealed that 
domain-specific and overall treatment satisfaction was highly associated with: (1) 
reduced HbA1c (-0.4%), (2) achieving target HbA1c ≤ 7%,  (3) neuropathy, (4) retinopathy, 
(5) frequency, timing and severity of hypoglycemia, (6) age and (7) weight change (BMI 
reductions ≥ 2.57 kg/m2) [23]. Pearson coefficients revealed a statistically significant 
association between HbA1c and 3 different satisfaction domains, including treatment 
attributes (device subscale). Additional evidence reaffirms this correlation across diverse 
geographical locations and populations [64].  
  
Similar to adherence, the correlation between treatment satisfaction and clinical outcomes 
may partly drive changes in resource utilization. Improved satisfaction has been 
associated with reduced utilization of emergency room and preventive services by up to 
63% [65]. Related analyses demonstrate that increased satisfaction may improve 
persistence and thereby lower HbA1c [66,67]. 
  
Psychological Wellbeing  
 
Of 11 articles focusing on relationships between psychological wellbeing and health 
economic outcomes, 9 (82%) studied the extent to which depressive symptoms and 
mental distress were correlated with measures of self-management. 
  
Cross-sectional analysis of 5104 patients and 3827 care providers revealed that poor 
psychological wellbeing was correlated with suboptimal adherence to preventive 
treatments [68]. Two studies that together examined over 1000 patients reported similar 
results: up to 67% of T2D patients may be depressed, and these patients show a 130% 
increased frequency of missed medication doses per week [69,70]. Furthermore, the 
prevalence of severe/major depression in T2D patients may range from 19-33%, and may 
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have a particularly strong impact on medication adherence in male and minority 
populations [71,72]. 
  
Two studies demonstrate that increasing severity of depressive symptoms incrementally 
affects adherence to both preventive and later-stage therapies [73,74]. These studies also 
found that elevated depression may reduce adherence by 8%, increase the use of 
emergency department and specialty care services, and increase primary care, ambulatory 
and total healthcare costs by 51%, 75% and 86%, respectively.  
  
Depressive symptoms may also affect T2D progression through inadequate glucose 
control and increased BMI due to an inability or unwillingness to maintain adherence 
[75,76]. Interestingly, psychological distress may even account for greater variation in 
long-term and transient glycemic control than biological mechanisms [77]. For patients 
with substantially elevated HbA1c, restoration of glycemic control may actually improve 
psychological wellbeing [78].  
 
Patient Preference  
 
The impact of choice and acceptance of treatments, which varies considerably in T2D 
[79], was reviewed in 4 studies. 
  
A randomized, crossover clinical trial evaluating insulin devices showed that differences 
in patient preference and stated desire to continue treatment were important factors in 
reducing HbA1c [80]. Observational analysis of 445 T2D patients revealed that 
medication side effects may significantly reduce patient preference for treatment and 
result in non-adherence [81]. An additional study utilized willingness-to-pay 
methodology to correlate T2D preferences to economic outcomes, illustrating that 
preference was a strong indicator of likely future adherence and pharmacy costs [82]. 
Another found massive preference among elderly patients for an insulin injection device 
versus vial/syringe (82% vs. 18%), which was associated with a reduced need for 
nursing/caregiver assistance and an average daily cost savings of approximately $80 [83]. 
 
Current T2D Economic Models  
 
Sixteen articles described the structure of T2D-related economic models (Table 5). Most 
modeling approaches are recent (70% developed after 2002) and have been used to 
evaluate the cost-effectiveness of OADs. Considerable diversity exists, but there is a 
fairly even distribution between model types: 6 models (38%) primarily involve 
simulations with regression-weight risk equations validated against randomized 
controlled trials or large epidemiological studies, 3 employ linear-state transitions (eg, 
decision-analysis), and the remaining 7 are open-state transition models (e.g., recurrent 
and/or inter-linked Markov states).  
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Table 5. Characteristics of type 2 diabetes economic modeling assessments (n = 16) 
 
 
 
 
 
The time horizons examined in base-case scenarios also varied, although most (38%; n=6) 
simulated entire patient lifetimes, projecting outcomes until death. Three models (19%) 
had short-term (≤ 10 years) or long-term (> 10 years) horizons, and the rest (n=10) had 
no implicit default or intended scenario. 
 
Primary Model Drivers  
 
Input variables were arranged into five categories: (1) patient demographics, (2) baseline 
and continuous clinical lab values, (3) changes in treatment regimens (modification), (4) 
patient perceptions of care, and (5) measures of self-management (adherence or 
persistence). 
  
Most models incorporated demographic factors when projecting outcomes. Clinical lab 
values, as either intermediate predictive outcomes or absorbing states (ie, achieving 
target=end simulation), influenced risk adjustment in all models. The majority focused on 
HbA1c, however, post-meal and fasting blood glucose also appeared as clinical drivers, 
such as in accounting for patients’ ability to reach intermediate dual control (HbA1c+post-
meal) [84]. 
  
Twenty-five percent (n=4) of models allowed some level of treatment modification, as 
observed in one short-term (3 year) decision analysis where estimation of outcomes for 
1st-line OAD strategies permitted transition to OAD or insulin combinations based on 
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achieving glycemic control [85]. Other models utilize similar factors such as time-to-
impaired glucose tolerance under specified treatments [86,87], or stratifying regimens 
based on treatment patterns [88]. However, most models apply single, fixed treatments, 
often over lifetimes. 
  
Patient perceptions of care and measures of self-management were absent as input 
variables in identified models. 
 
Interventions and Study Types  
 
Sizeable emphasis was placed on OADs, appearing in >80% of modeled applications, at 
times in combination with insulin (Table 6). For example, the Centers for Disease 
Control model of T2D progression employs epidemiological risk data to allow choice of 
simulating insulin or sulfonylurea [86]. 
 
 
Table 6. Identified economic models by therapeutic intervention and study type (n = 16) 
 
 
 
 
 
Overall, cost-effectiveness evaluations were most prevalent (≥80% depending on 
therapy). Only 2 cost-minimization analyses and zero cost-benefit approaches were 
identified. 
 
Discussion 
 
We reviewed 97 articles to (1) investigate the clinical and economic impact of 
correlations between psychological and behavioral factors of care in T2D, and (2) 
characterize their application in current economic evaluations used to inform medical 
decision-making. Our results indicate that medication adherence, persistence, treatment 
satisfaction, patient preferences and psychological wellbeing are interrelated, well-
studied and directly or indirectly affect clinical outcomes, health events, resource use and 
costs. These results suggest that psychological and behavioral factors can play a critical 
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role in determining the value of healthcare interventions, beyond the impact of biological 
mechanisms alone. 
  
Relationships between psycho-behavioral factors, and health economic outcomes are 
multifaceted throughout stages of treatment and disease progression, and studies have 
often analyzed them in triplets, with one factor mediating relationships between the other 
two. For example, patient willingness to self-manage may be explained by satisfaction 
with or preference for treatment, which is influenced collectively by that treatment’s 
attributes and biological response. These attributes may include actual and perceived 
efficacy (e.g., HbA1c, BMI), side effects (e.g., hypoglycemia, neuropathy, weight gain), 
device usability, route and frequency of administration, and dosage. 
  
Similarly, psychological wellbeing may influence self-management, treatment 
satisfaction and clinical outcomes; satisfied patients are less likely to become depressed, 
and may therefore be more likely to exhibit better adherence, persistence and, 
subsequently, health status and costs [62,90-94]. Furthermore, self-management can 
mediate the relationship between psychological wellbeing and glucose control. Depressed 
patients are more likely to be unable or unwilling to properly self-manage and thereby 
experience poor HbA1c control. Conversely, poor HbA1c control can reduce psychological 
wellbeing and decrease the likelihood of adherence. Additionally, treatments which 
increase satisfaction and decrease depression may help patients achieve glycemic control 
and reduce resource use and costs [95-98].  
  
From these observations, we developed a conceptual, cyclical framework describing the 
nature of relationships between psycho-behavioral factors and health economic outcomes 
in T2D (see Figure 2). Adherence and persistence with treatment, which may be 
explained by a patient’s psychological wellbeing on that treatment, may readily influence 
clinical outcomes (namely HbA1c). Glycemic control is a primary determinant of short 
and long-term health events and subsequent resource use and costs. Changes in resource 
use and costs may in turn affect decisions on healthcare benefits, influencing copayment 
levels, patient access and ultimately, self-management (since higher copayments may 
further reduce adherence/persistence). Patient satisfaction and preferences, which are 
sensitive to treatment attributes, clinical response and health events at various stages of 
treatment and disease progression, may affect self-management, psychological wellbeing 
and costs, and thereby impact all elements of the loop. 
 
There are several areas where further research and innovation in diabetes economic 
modeling are warranted. Firstly, models to date have assumed that changes in HbA1c and 
health outcomes are determined solely by changes in clinical risk and biological 
mechanisms. Although ample studies exist, no models yet address the potential impact of 
patient self-management, satisfaction or preferences on glycemic control, health 
outcomes or costs. 
 
Secondly, although we found studies demonstrating considerable variation in adherence 
and persistence for T2D treatments, even over short-term (1-2 year) periods, these are 
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Figure 2. Conceptual framework for psycho-behavioral factors and health economic 
outcomes in type 2 diabetes. 
 
 
 
 
 
either absent as a modifiable factor, or assumed to be perfect (100%) and constant, in 
current models, often over patient lifetimes. Our review illustrates that this does not .  
reflect reality, and that there is sufficient evidence to incorporate additional heterogeneity 
in self-management when evaluating cost-effectiveness across numerous treatments and 
populations. 
   
Thirdly, treatment changes were only allowed in 25% of the models we reviewed; 12 out 
of 16 assumed all patients remain on baseline treatment for the entire duration of 
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simulations. However, we found substantial data demonstrating that (1) T2D treatment 
modification occurs frequently, even over short-term periods, and (2) costs related to 
these changes may be strongly determined by factors such as adherence, persistence, 
satisfaction and psychological wellbeing.  
  
Fourthly, models assumed constant dosing, although in reality, dosing can widely vary 
according to numerous factors, including clinical response and patient behavior. By 
applying fixed dose and treatment type (with fixed levels of adherence and persistence), 
variation in health event rates is not fully captured, and effects on pharmacy costs 
become fixed, misrepresenting true budgetary impact and misinforming what should be 
expected in real-world scenarios. 
  
Although detailed proposals for methodological innovation fall outside the scope of our 
analysis, it is worthwhile to note that current mechanisms exist whereby psycho-
behavioral parameters could potentially be incorporated into modeling. These may be 
employed directly or indirectly to address interrelations depicted in our conceptual 
framework, particularly between medication adherence and: (1) clinical effectiveness 
(e.g., HbA1c); (2) mortality rates; (3) resource use; and (4) subsequent healthcare costs. 
  
For example, where adequate evidence exists, equation-based modeling could incorporate 
regression functions to predict future HbA1c levels, where medication adherence (as an 
independent and user-identified input variable alongside other modifiable factors such as 
age, gender, etc.) would adjust HbA1c (the dependent variable) and subsequent health 
economic outcomes, such as hospitalization rate, over time. With this approach, 
improved adherence could be programmed to more accurately predict glycemic response 
for a target population (ie, better controlled HbA1c), thereby reducing complications, 
lowering costs and generating improved cost-effectiveness ratios. Furthermore, structural 
models (those with temporal linear or open-state transitions, as in Markov or discrete 
event modeling), could utilize added transient states to adjust outcomes based on grouped 
or cutoff levels of adherence (e.g., 80-100%, 60-79%, etc.). 
 
It is also worthwhile to note the importance of sensitivity analysis when incorporating 
psycho-behavioral parameters into modeling. Univariate or multivariate analysis of 
uncertainty around these factors would increase the robustness and validity of modeled 
results. For example, one could use documented levels of mean adherence as a baseline 
default input, and subsequently perform sensitivity analysis around these levels and their 
relative impact on outcomes (including incremental effectiveness, resource use, costs, 
and comparative cost-effectiveness). This could be accomplished through standard error 
techniques or by utilizing upper- and lower-bound limits (derived from literature or 
expert opinion) within probabilistic / 2nd order Monte-Carlo simulation. Conducting 
sensitivity analysis would be especially important when the underlying mechanisms 
linking psycho-behavioral parameters to health economic outcomes are less clear or 
unknown (e.g., in utilizing medication adherence to adjust mortality rates / modeled 
survival and quality-adjusted life year (QALY) estimates). 
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Many forthcoming T2D medications will be differentiated by attributes that largely 
influence psychological and behavioral factors (e.g., route of administration, dosing 
frequency, device convenience). This further underscores the importance of developing 
techniques to better understand how to determine the value of interventions based on the 
economic impact of these factors. 
 
 It is important to note several limitations to our review: 
 
 we were only able to identify, retrieve and analyze data in the public domain 
 
 we included only peer-reviewed articles 
 
 we utilized a pre-defined list of (1) terms, (2) publication dates and (3) data 
sources 
 
The potential impact of these limitations include: (1) overlooking important data in grey 
literature, textbooks and scientific conferences, which might limit the completeness of 
our review; (2) reporting and publication bias, where certain types of results are more 
likely to be reported or published than others.  
  
Additionally, since many of the studies in our review were performed retrospectively 
using observational data, some of their findings may simply reflect statistical associations 
and not cause-effect relationships (e.g., for persistence and costs). However, we also 
reviewed prospective, controlled studies that demonstrate causality elsewhere (e.g., for 
adherence and glycemic control). All in all, we believe that psychological and behavioral 
factors have at least a plausible direct relationship with clinical and economic outcomes 
as depicted in our conceptual framework.  
 
Conclusions 
  
In summary, we found clinical outcomes, resource use, and costs to be strongly 
associated with psychological and behavioral factors of care among T2D patients. Better-
informed decision-making in T2D will require future research on integrating the 
complexity of these relationships in economic evaluations to reduce uncertainty in 
modelled results and more accurately reflect real-world treatment. Successful efforts to 
this end are likely to improve clinical practice and patient health through cost-effective 
allocation of healthcare resources. 
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Modeling the economics of medication adherence 
in Type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Cobden D, Niessen LW, Rutten FFH, Redekop WK. Modeling the 
Economic Impact of Medication Adherence in Type 2 Diabetes: a Theoretical Approach. 
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Summary 
 
While strong correlations exist between medication adherence and health economic 
outcomes in Type 2 diabetes (T2D), current economic analyses do not adequately 
consider them. We propose a new approach to incorporate adherence in cost-
effectiveness analysis. Our study describes a theoretical approach to incorporating the 
effect of adherence when estimating the long-term costs and effectiveness of an anti-
diabetic medication. This approach was applied in a Markov model which includes 
common diabetic health states. We compared two treatments using hypothetical patient 
cohorts: injectable insulin (IDM) and oral (OAD) medications. Two analyses were 
performed, one which ignored adherence (analysis 1) and one which incorporated it 
(analysis 2). Results from the two analyses were then compared to explore the extent to 
which adherence may impact incremental cost-effectiveness ratios. 
 
In both analyses, IDM was more costly and more effective than OAD. When adherence 
was ignored, IDM generated an incremental cost-effectiveness of $12,097 per QALY 
gained versus OAD. Incorporation of adherence resulted in a slightly higher ratio 
($16,241/QALY). This increase was primarily due to better adherence with OAD than 
with IDM, and the higher direct medical costs for IDM. Incorporating medication 
adherence into economic analyses can meaningfully influence the estimated cost-
effectiveness of T2D treatments, and should therefore be considered in healthcare 
decision-making. Future work on the impact of adherence on health economic outcomes, 
and validation of different approaches to modeling adherence, is warranted. 
 
Introduction 
 
Type 2 diabetes (T2D) presents a substantial health economic burden globally, and its 
prevalence and costs are only forecasted to increase in the coming years [1-3]. 
Medication adherence, especially for patients with chronic diseases such as T2D, has 
long been viewed as a critical lever for improving outcomes and containing costs. Recent 
studies conclude that more than $100 billion is spent each year in the U.S. on 
hospitalizations that could have been avoided with optimal medication adherence [4]. 
Indeed, growing evidence suggests that suboptimal T2D medication adherence eventually 
results in higher HbA1c levels, complication rates, and costs. Conceptual frameworks 
have been developed to describe these interrelations and their effect on reimbursement 
policies [5-8]. 
 
In order to make appropriate judgments about resource allocation and cost-sharing 
(namely involving pharmaceuticals), decision-makers have progressively relied on health 
technology assessment and economic evaluation. The long-term impact of diabetes 
treatment on clinical outcomes, health events, quality-of-life, and costs is often 
mathematically modeled since notable complications may occur years after onset of 
diabetes [9]. However, current models used in T2D economic analysis do not adequately 
address, or explain incorporation of, real-world factors which influence medication 
adherence. These factors are wide-ranging and include patient preferences and behaviors, 
healthcare system factors, practice guidelines and patterns, and treatment characteristics 
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[8,10]. The exclusion of these factors can lead to inaccurate estimates on the cost-
effectiveness of diabetes therapies, and thereby result in misinformed reimbursement 
decisions affecting patient access to treatment. 
 
Several diabetes medications now in development have been criticized for being too 
similar to each other and not offering significant clinical benefit over existing therapies 
[11]. However, most of these new therapies and delivery systems differ greatly in other 
“non-clinical” ways, such as their route of administration, dosing schedule/convenience, 
and device ergonomics, all of which may influence patient preferences and behaviors 
(hence, medication adherence) [5,6,8]. This highlights the increasingly important role that 
adherence could play in the health technology assessment of new anti-T2D therapies as 
they reach the market. In particular, this is noteworthy for injectable diabetes medications 
(IDM) (ie, insulin) versus oral anti-T2D medications (OAD), since needle phobia, 
multiple daily injections, and varied dosing schedules (e.g., meal timing) are inherently 
associated with IDM and may adversely affect adherence [5]. 
 
There is substantial opportunity to improve the methods used to estimate the cost-
effectiveness of T2D medications by considering medication adherence [8,9]. The 
objective of this study was to develop and apply an approach to integrate adherence in an 
economic model of diabetes [8]. In doing so, we compared the cost-effectiveness of IDM 
versus OAD before and after adjustment for adherence, hypothesizing that incorporation 
of medication adherence would reduce the cost-effectiveness of IDM versus OAD, since 
patients on IDM generally exhibit poorer adherence than OAD patients. 
 
Methods 
 
We developed a novel approach to modeling medication adherence among T2D patients 
using conventional health economic techniques and software (MS Excel and TreeAge Pro 
2009). To test our approach, two separate economic analyses were conducted in a 
Markov / Monte Carlo format to provide a preliminary estimate of the impact of 
medication adherence on incremental cost-effectiveness ratios (ICERs): 
  
 Analysis 1: base-case modeling of IDM vs. OAD  
 
 Analysis 2: adherence-adjusted modeling  
 
Markov modeling in healthcare consists of developing a structure of a specified number 
of health states related to a given disease. Over time, patients will have a certain chance 
(or transition probability) to move from one health state to another [12]. This approach is 
particularly well-suited for modeling chronic diseases, such as T2D, where numerous 
health states / complications exist and are repeatable, previous history of complications 
may impact future events, and where a long-term perspective for downstream outcomes 
is relevant. Monte Carlo simulations commonly serve as the analytic / mathematic engine 
to a Markov structure, as was done in our analyses. This allows for transition 
probabilities into and out of health states to be applied, including sensitivity analysis, 
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whereby assumptions on reasonable variation for transition probabilities and the effects 
of random error may be accounted for [13]. 
 
Base Case Model 
 
The model we developed  consists of major health states that define the natural history of 
T2D, and are consistent with those seen in previous models (see Figure 1) [10,14]. These 
states include the various diabetes complications, such as end-stage renal disease 
(ESRD), lower-extremity amputation, cardiovascular and coronary artery disease (CVD / 
CAD), nephropathy, stroke, neuropathy, retinopathy, and major hypoglycemia. 
 
In this model, patients receive either IDM (insulin in our example) or OADs, chosen as 
mutually-exclusive comparators because of the inherent differences between them which 
readily impact adherence. Patients on both therapies begin at a baseline HbA1c that is 
either < 7% or ≥ 7%, and through subsequent annual iterations, may (1) remain in a 
‘healthy’ state with controlled (< 7%) or uncontrolled (≥ 7%) HbA1c, (2) progress 
between T2D complication states (with controlled or uncontrolled HbA1c), or (3) die. 
Probabilities for patients to move from one complication state to another are based on 
HbA1c over time, since patients with controlled HbA1c are much less likely to develop 
complications [10,14]. Treatment effects (mean of -1.2% HbA1c and -0.8% HbA1c for 
IDM and OAD, respectively, to reflect greater potency of insulin use) were applied to 
assumed baseline HbA1c means of 8.1% and 6.8% for patients modeled to HbA1c ≥ 7% 
and < 7%, respectively [14,15]. An annual increase in HbA1c – or “creep up” effect – of 
+0.14% per year was applied to initial levels of glycemic control to reflect the natural 
progression of underlying biological mechanisms affecting glycemic control over time, 
such as beta-cell loss and reduced insulin sensitivity [10,14]. In the base case scenario, 
approximately 50% fewer IDM patients were, on average, likely to have baseline HbA1c 
< 7% versus OAD patients, as those who are prescribed IDM frequently have further 
progressed, and/or more difficult to control, T2D [14-16]. In both analysis 1 and analysis 
2, the Death state may be transitioned to after any/all previous health state(s), and reflects 
all-cause mortality as well as adjustment for severity of T2D/CVD risk over time.  
 
A lifetime (up to 35 year horizon), U.S. third-party payer perspective was taken starting 
from the time of T2D treatment initiation [10]. Cohort characteristics and transition 
probabilities were derived from large epidemiologic studies, clinical trials, and recent 
national surveillance data [10,14,15]. Modeled output included life expectancy (LE), 
quality-adjusted life expectancy (QALE), cumulative incidence of T2D complications, 
direct medical and pharmacy costs, total lifetime costs, and ICERs. 
 
Simulated Cohorts and Assumptions 
 
The demographic and clinical characteristics used in the patient cohorts reflected those of 
typical U.S. T2D populations, including the percentage of patients receiving specific 
OADs and IDM, the percentage of patients with baseline HbA1c<7% (for OADs 46.6% , 
for IDM , 26.8%), age (mean of 51.1 years), gender (51.6% male), race/ethnicity (62.1% 
white, 17.4% black, 15.4% Hispanic, 5.1% other), presence of risk factors (e.g., smokers:  
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Figure 1. Base case model of fundamental T2D health states. 
 
 
 
 
 
 
 
18.8%), and presence of preexisting complications [10, 14-16]. 
 
The magnitude and duration of mean treatment effects  remained consistent among IDM 
and OAD sub-classes, and were extracted from large, long-term epidemiologic studies 
and literature reviews [10,14,15]. Applied risk factors included BMI, total cholesterol, 
systolic blood pressure, triglycerides, and smoking [10].  
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Quality-of-life (QoL) utilities and disutilities for T2D health states were derived from 
previous studies [10,14]. Mean pharmacy costs based on average 30 day wholesale price, 
and direct medical costs such as hospitalizations, were collected from published data and 
inflated to 2009 USD$ [5,6,10,15,17]. Of the patients who received IDM, it was assumed 
that 70% of them were given human insulin and 30% analog insulin. Within the OAD 
cohort, 70% of the patients were assumed to receive generic metformin +/- sulfonylurea, 
and 30% non-generic thiazolidinediones. This was done in Analyses 1 and 2 to 
incorporate consistency for drug costs, and to approximate the use of generics in a real-
world U.S. scenario [18,19]. A 3% discount rate for future costs and health was applied 
as a base case assumption, however, a range of 0-6% was allowed during sensitivity 
analyses to address a range of variation in present value of benefits over time [10].  
 
Adherence-adjusted Model and Theoretical Approach 
 
As depicted in Figure 2, adjustments for adherence involved revisions to the degree of 
modeled glycemic control, risks of subsequent diabetes complications, and costs using 
current evidence on the impact of real-world medication adherence. Applied rates of 
adherence were primarily determined using Medication Possession Ratios (MPR)), and 
were derived from large observational studies [5-7,18-22]. Just as the target of HbA1c < 
7% was applied to model the impact of glycemic control in analysis 1, MPR (≥ 80%) was 
added and applied to model the influence of optimal versus suboptimal (MPR < 80%) 
adherence in analysis 2. New health states were created, where categorical levels of MPR 
were combined with categorical HbA1c control, thereby enabling MPR to directly 
influence the likelihood of a patient moving to, and remaining in, either of the HbAlc 
categories (HbA1c < 7% or HbA1c ≥ 7%), and hence, experience downstream T2D 
complications and costs. For example, recent data suggest that OAD and IDM patients 
with MPR≥80% are more likely to achieve HbA1c < 7%, have reduced incidence of 
hypoglycemia and related resource use, and incur lower healthcare costs [5,7,18-22].  
 
Specifically, revised transition probabilities in the adherence-adjusted model include 
means and distributions regarding adherence to anti-T2D treatment, likelihood of 
achieving HbA1c<7%, and likelihood of major hypoglycemia. Up to 13% and 6% of 
patients on OADs and IDM, respectively, were allowed to exhibit MPR ≥ 80% (ranges: 
36-93% OADs, 54-86% IDM). The chance of achieving target HbA1c was approximately 
28% greater for patients with MPR ≥ 80%, and the chance of major hypoglycemia was 
64% lower for patients with MPR ≥ 80% (74% chance overall, but only 47% chance for 
optimal adherence; OR: 0.36, p<0.01) ; [5,7,18-22]. Medication adherence in both groups 
was modeled to worsen over time, at -0.3% per year [6,14]. 
 
Statistical and Sensitivity Analyses 
 
Probabilistic sensitivity analyses, wherein a range of distributions (uncertainty) for values 
of all input parameters are applied simultaneously, were conducted using cohort-level 
Monte Carlo simulation and bootstrapping. The progression of T2D was simulated in a 
1000 x 1000 manner (each cohort of 1000 patients was simulated 1000 times), producing 
individual candidate bootstrap samples. The average costs and health for each cohort 
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Figure 2. Adherence-adjusted approach at modeling T2D. 
 
 
 
 
 
 
 
were first calculated, followed by an analysis of the 1000 average values (one per cohort). 
This resulted in means and standard deviations of the incremental costs, complication 
incidences, LE, and QALE for both IDM and OAD. Lastly, these means and standard 
deviations were calculated and compared for IDM versus OAD.  
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Results 
 
Base Case Scenario: Analysis 1 
 
IDM use resulted in a longer LE (+0.56 years) and QALE (+0.92 years) than OAD use 
(Table 1). IDM also reduced the rates of major hypoglycemia, ESRD, CVD / CAD, 
nephropathy, and neuropathy. 
 
Although IDM resulted in greater clinical effectiveness, IDM patients also incurred 
higher costs (by $11,166) than OAD patients, with pharmacy costs accounting for the 
majority ($8,768) of this difference. The incremental cost-effectiveness ratio for IDM 
versus OAD was $12,097 per QALY gained, using total healthcare costs. 
 
Adherence-adjusted Model: Analysis 2 
 
After adjustment for adherence, IDM still led to a longer LE and QALE than OADs by 
+0.33 and +0.68 years, respectively, although the differences observed between IDM and 
OADs were smaller than without adjustment for adherence. While gaps between IDM 
and OADs in the incidence rates of some complications shrank, the rate of major 
hypoglycemia increased. 
 
Total costs remained higher for IDM than for OAD (+$10,963) after incorporating 
adherence. The incremental cost-effectiveness ratio of IDM versus OAD increased to 
$16,241 per QALY gained, again using total costs. 
 
Impact of Adherence on Modeled Output  
 
Adjustment for adherence affected the differences between IDM and OAD treatment in a 
number of ways, including: (1) generating smaller differences in LE and QALE, (2) 
smaller differences in all complication rates except for major hypoglycemia,which 
increased by 3.1%, and (3) a 34.3% higher ICER for IDM versus OADs ($16,241/QALY 
versus $12,097/QALY).   
 
Comparing analysis 2 with analysis 1, LE and QALE for OADs improved 45% and 54% 
more than for IDM, and the relative difference in rates of ESRD, amputation, and 
neuropathy between IDM and OADs narrowed by 40%, 25%, 53%, respectively, and 
CVD / CAD, nephropathy, and stroke by 2/3 each. 
 
Sensitivity Analyses 
 
Probabilistic simulations did not meaningfully alter ICERs for IDM versus OADs in 
analysis 1 or 2, indicating a sufficient approach at limiting modeled uncertainty. Our base 
case model generated a range of ICERs from $7,155 to $18,300/QALY, and our revised 
model generated a range of $11,217 to $23,892/QALY. 
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Table 1. Summary of modeled results: IDM vs OADs* 
 
 
 
 
 
Discussion 
 
Utilizing a Markov model of fundamental T2D health states, we specifically aimed to (1) 
describe a new approach for modeling medication adherence, and (2) illustrate its impact 
on estimated cost-effectiveness. Our simulations demonstrated that adherence may be 
meaningfully incorporated into comparative economic analysis through its associations 
with level of glycemic control, which has an important impact on the risk of downstream 
diabetes complications (e.g., major hypoglycemia) and costs.  
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In the adherence-adjusted model (analysis 2), we observed an increased ICER, resulting 
from several sources. Most notably, LE and QALE increased by up to 54% more for 
OADs than for IDM (although both cohorts saw slightly higher values than in analysis 1). 
The main reason for this effect was the increased number of patients modeled to HbA1c 
< 7% after stratifying by MPR, and thus experiencing less T2D complications and 
associated QoL disutilities (ie, the range of applied MPR estimates caused up to 13% and 
6% more OAD and IDM patients to have greater likelihood of HbA1c < 7% in analysis 
2). Secondly, although the differences for most complication rates between IDM and 
OADs decreased after adjustment for adherence, the difference in major hypoglycemia 
rates increased by 37%. Thirdly, a greater proportion of IDM lifetime costs were driven 
by direct medical costs, as opposed to pharmacy costs, after adjustment for adherence. 
These changes in modeled results likely occurred because more OAD patients were 
categorized into MPR ≥ 80% than IDM patients, and they therefore experienced less risk 
of major hypoglycemia (and related QoL disutility) as well as a greater chance of HbA1c 
< 7%, resulting in fewer complications and increased QoL over time. Similarly, a higher 
frequency of MPR < 80% amongst IDM patients meant a higher risk of hypoglycemia, as 
well as a higher risk of other complications and higher costs. Furthermore, a balancing 
effect between greater treatment potency and overall poorer adherence likely occurred for 
IDM versus OADs. In this way, the greater HbA1c-lowering effect of insulin, which 
would reduce complication rates and thereby improve health outcomes, may have been 
partially offset by a higher frequency of MPR < 80% and HbA1c ≥ 7%, and thus a higher 
starting HbA1c level in the first year of treatment.  
 
It is important to note several limitations to our modeling approach. Although the 
simulated diabetes population in our analyses was intended to represent a typical U.S. 
T2D population, our assumptions regarding transition probabilities, actual pharmacy 
costs, and QoL values may not have fully achieved this. However, it is important to note 
that the primary goal of this study was to illustrate how adherence may be included in 
diabetes health economic models, and to then estimate the impact of adherence on 
ICERs. Our goal was not to evaluate the cost-effectiveness of a specific treatment, nor to 
focus on a specific population. In keeping the treatments and simulated populations 
constant between analyses 1 and 2, the isolated effect on cost-effectiveness of modeled 
adherence was revealed.  
 
Although outside the scope of our current analysis, it is important to recognize the 
increasing evidence that T2D disproportionally affects minority sub-populations in the 
U.S. It would therefore be interesting and worthwhile to model the impact of adherence 
in these subpopulations in a future study. The choice to compare IDM with OADs as 
hypothetical therapies occurred solely because they clearly differ in treatment modalities 
which may impact degree of adherence. Although our model could have allowed 
switches to occur between OADs and IDM throughout a patient’s life, we chose not to 
allow these switches, since it would have complicated the model and would not have 
contributed to illustrating the potential effect of incorporating adherence. That is, the 
incorporation of treatment changes would have generated a “mixed effect” of the impact 
of medication adherence and the relative effectiveness of different treatment strategies at 
various points in a patient’s disease progression. Thirdly, transition probabilities in the 
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adherence-adjusted model are based largely on observational studies, which provide 
statistical associations that do not necessarily reflect cause-effect relationships. This 
underscores the importance of future work aimed at (1) developing more robust evidence 
on correlations between adherence and T2D outcomes, (2) identifying novel data sources 
and analytic techniques for observational, real-world research, and (3) further validation 
of different modeling approaches.  
 
Modeling techniques worth exploring in future analyses include application of 
differential- and regression-based equations where adherence is a continuous parameter 
(variable) that influences glycemic control and complication rates over time, as opposed 
to a categorical approach, as was done in this study. Additionally, deterministic 
sensitivity analyses using point estimates could be performed to gain more direct insight 
into how much influence a specific input variable has, as opposed to allowing multiple 
parameters to vary simultaneously in a probabilistic sensitivity analysis. Lastly, it is 
important to note that although our adherence-adjusted approach produced an ICER that 
was approximately 34% higher than the ICER without adherence adjustment, IDM 
remained well within conventional thresholds of what is considered “good value for 
money,” especially when considering preferences and trade-offs in healthcare from a U.S. 
societal perspective (up to $297,000/QALY) [23].  
 
Conclusions 
 
Medication adherence is an important issue in chronic disease, and in particular, diabetes 
care. However, current economic models of diabetes pay too little attention to adherence, 
even though it may meaningfully influence the estimated cost-effectiveness of diabetes 
medicines. As new data and analytic techniques become available, and as new T2D 
compounds are commercialized, this will become increasingly important to inform 
healthcare decision-making for real-world settings.  
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Discussion 
 
The primary aim of this thesis has been to improve healthcare decision-making for 
diabetes patients through development of a novel, enhanced framework for economic 
evaluation. This new approach at determining the relative cost-effectiveness of diabetes 
treatments is particularly warranted in a rapidly-evolving clinical environment which 
increasingly focuses on patient-centered, tailored therapy, and a market environment 
which increasingly emphasizes product differentiation through non-biological features. 
Both of these dynamics may influence the successful implementation of prescribed 
therapy as well as ensuing health outcomes and costs by impacting a patient’s perception 
of care and level of adherence. 
 
Broadly speaking, the steps taken to accomplish our aim have been to (1) establish 
existing methodologies of diabetes-related economic evaluation upon which to innovate, 
(2) document and quantify economically important correlations of measures of patient 
self-management and perceptions of care (which may be impacted by non-biological 
product features), (3) identify where current modeling techniques inadequately consider 
these relationships, and (4) propose and test a new approach to economic evaluations 
which integrate our findings.  
 
Numerous study designs and data sources contributed to carrying out the plan of research 
for this thesis. In doing so, the evidence generated to support our new approach is well-
rounded and dynamic. The types of studies we conducted fall into 4 main categories: (1) 
economic modeling analyses, (2) prospective, randomized clinical trials, (3) retrospective, 
observational studies, and (4) systematic literature reviews. Data sources ranged from 
publically available research articles, to administrative healthcare claims and self-
reported responses using psychometric instruments.  
 
Modeling assessments were the first and last components to this thesis. They served the 
dual purpose of establishing the initial set of methodologies on which we would base our 
work, as well as determined the analytic environment in which to test our approach – 
CEA by way of M/MC simulation. Prospective controlled studies also served several 
purposes, with particular focus on patient-reported outcomes. First, they were used to 
differentiate patient perceptions of care (preference and satisfaction) between diabetes 
treatments with distinct non-biological profiles, namely mode of administration, 
ergonomics/handling (pen device vs. vial/syringe), and dosing. Secondly, prospectively 
gathered PROs from one of these trials became a valuable data source for retrospective 
analysis, correlating treatment satisfaction associated with non-biological product 
features to clinical parameters (HbA1c and hypoglycemia) used in driving CEA results.  
 
Several other retrospective, observational analyses were performed utilizing healthcare 
claims databases. These facilitated investigation of measures of self-management 
between diabetes treatments having different non-biological profiles, specifically in terms 
of resource use and costs. The goal was to detect and quantify improvements in 
medication adherence and/or persistence for treatments with modern non-biological 
innovations, and to correlate these with outcomes that could be meaningfully brought into 
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CEA. Systematic literature reviews also contributed to estimating the health economic 
impact of medication adherence, specifically among a broader set of diabetes treatments 
(oral medications). Furthermore, these reviews were a primary means by which we 
formally identified gaps in current CEA techniques and developed our conceptual 
framework for relationships between patient perceptions of care, non-biological product 
features, self-management, clinical parameters, and reimbursement policy. In all, each 
chapter became an integral part for creating the innovative framework for diabetes cost-
effectiveness analysis presented in this thesis. Figure 1 illustrates how the different 
concepts examined in this thesis are relevant for current decision-making as well as 
useful in guiding future work. By adapting CEAs to include the impact on outcomes and 
costs of self-management and patient perceptions (which are influenced by real world 
factors and non-biological product features), decision-makers may be better equipped 
when establishing access to new treatments. 
 
 
Figure 1. Adapted approach of economic evaluation for real-world decision-making in 
diabetes 
 
 
 
 
 
A general description and short summary of main conclusions by chapter is provided 
below to briefly describe each segment’s contribution to the overall flow of this thesis. 
 
Chapter 2. The opening chapter establishes a core set of techniques which are suitable 
for modeling the long-term health and economic outcomes of improvements in HbA1c. 
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Prior to the inclusion of treatment-specific effects, it was relevant to demonstrate the 
ability of a defined methodology to generate reasonably-expected ICERs which focus on 
the main clinical parameter underlying the natural disease progression of diabetes. Based 
on published examples, and its historically common use in health technology assessment 
(HTA), cost-effectiveness analysis (more accurately, cost-utility analysis) utilizing a 
Markov structure of the range of diabetic health states and Monte-Carlo simulation was 
our chosen methodology. 
 
Hypothetical, step-wise improvements in HbA1c were applied amongst a population of 
T2D patients exhibiting typical socio-demographic and clinical profiles. Over a long-term 
time horizon (35 years from diagnosis), three separate scenarios of incremental HbA1c 
reduction – 9.5 to 8.0%, 7.9 to 6.5%, and 6.4 to 6.0% (all vs. no reduction) – resulted in 
QALY gains of 0.58, 0.38, and 0.18 years, respectively.  
 
Cumulative incidence of T2D complications, time delay to onset of complications, and 
related costs were also improved, in parallel. As anticipated, benefit was most 
pronounced among those experiencing the greatest reduction (i.e., patients with the 
highest baseline HbA1c), yet notable gains remained present in those able to meet the 
most stringent goal (6.5%). Sensitivity analyses supported the main results, and we were 
able to conclude that our baseline approach at modeling diabetes treatments (CEA with 
HbA1c as the primary clinical parameter) was reliable and appropriate to use. 
 
Chapter 3. Applied within the same general model of diabetic health states as the 
previous chapter, with transition probabilities modified to fit an adult T1D population 
(insulin-dependent), our second analysis extended the first by incorporating the 
treatment-specific efficacy, safety, and costs of 3 separate types of insulin – detemir, 
glargine, and NPH. Two analyses were conducted – IDet vs. IGlar, and IDet vs. NPH – in 
order to demonstrate the influence of treatment-specific differences in HbA1c, 
hypoglycemia, and acquisition costs on ICERs. 
 
The cost-effectiveness of the two competing analog insulins (IDet vs. IGlar) was 
estimated using trial-reported differences in hypoglycemia (glycemic control was 
statistically similar). However, when compared to less potent human insulin (NPH), 
significant reductions in HbA1c favoring IDet were also able to be considered (i.e., along 
with less hypoglycemia). Pharmacy costs were similar between IDet and IGlar, yet were 
considerably higher for IDet versus NPH. These 2 scenarios allowed us to test our base 
modeling approach beyond focus on HbA1c alone by observing: (1) the influence of 
safety outcomes (major hypoglycemia) in isolation of HbA1c; and (2) the mixed effect of 
improving HbA1c while reducing hypoglycemia, but at a much higher acquisition cost.  
 
As anticipated, differences in QALYs gained between IDet vs. IGlar, as compared to IDet 
vs. NPH, were less pronounced due to the added benefit of glycemic control, along with 
more pronounced reduction in hypoglycemia, which IDet patients received versus NPH. 
For IDet vs. IGlar, patients gained 0.063 QALYs and incurred approximately $5,000 less 
in medical costs, attributable predominantly to reduced hypoglycemia, thus producing a 
dominant base case ICER. Comparing IDet to NPH yielded more considerable gains of 
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0.698 QALYs, however, at an additional cost of nearly $6,000. Still, an ICER of 
$14,974/QALY was generated and was shown to have 100% acceptability at a threshold 
of willingness-to-pay (WTP) equal to approximately $30,000/QALY. These results 
demonstrate that our modeling approach is sensitive to efficacy and safety outcomes alike, 
and that it may reasonably accommodate variation in treatment-specific pharmacy costs, 
whether in isolation or experienced simultaneously.  
 
Chapter 4. Having defined our base modeling approach (to be built upon in later work), 
focus was placed on investigating differences in patient-reported perceptions of care in 
the context of therapies which fundamentally differ in a non-biological manner. We 
began by evaluating patient preferences and treatment satisfaction for adult insulin-
dependent diabetes patients (adult T1D and T2D patients included) using two distinct 
insulin delivery systems – a handheld pen device vs. standard vial/syringe. Non-
biological features exhibited by the handheld device include easier dosing (large dose-
dial), higher gauge needle (less injection pain), improved ergonomics (handheld fit), and 
less burdensome administration (single pre-filled device vs. need to manually fill syringe). 
A randomized, cross-over design was employed using a total of 162 patients (mean age: 
59.8 years), and several validated psychometric instruments used to ascertain PRO 
differences between treatments. Included were the IDPQ (Insulin Device Preference 
Questionnaire) and the ITSQ (Insulin Treatment Satisfaction Questionnaire).  
 
Although there were no significant differences in efficacy or safety (bio-equivalent 
insulin was used for each arm, and there were no per-protocol treatment changes – only 
device changes), major improvements in preference for and satisfaction with the 
handheld pen device were seen, attributable to the non-biological features of the pen 
device. Overall, up to 75% of patients preferred the pen (p<0.0001) on various measures, 
including convenience, ease of use, comfort, less interference with daily activities, and 
improved social life. Of those who preferred the pen, 4 out of 5 reported a strong or very 
strong preference (n=92). Treatment satisfaction was similarly improved within each 
domain, as well as overall satisfaction. Measures of convenience (p<0.0001), lifestyle 
flexibility (p<0.0006), perceived glycemic control (p<0.0001) and hypoglycemic control 
(p<0.0001), delivery system satisfaction (p<0.0001), and overall satisfaction (p<0.0001) 
were significantly improved when the pen device was used. 
 
Chapter 5. After demonstrating improved patient perceptions of care with treatments 
exhibiting favorable non-biological profiles, it became necessary to further link these 
improved perceptions with clinical parameters that are a main driver of CEA. In doing so, 
we would have cause to incorporate the health economic effects associated with patient 
perceptions into our work on innovating CEAs. This was undertaken through 
retrospective analysis of PROs captured in a randomized controlled trial comparing two 
types of insulin (aspart 70/30 vs. IGlar) among T2D patients.  
 
Results from the ITSQ were again utilized. However, unlike in Chapter 4, significant 
improvements in HbA1c and hypoglycemia were found in one of the treatment arms 
(aspart 70/30). Additionally, patients on aspart 70/30 were administering their insulin 
with a handheld pen device, while patients on IGlar used vial/syringe. These 2 elements 
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allowed further insight into the mixed influence on patient perceptions of using a 
favorable non-biological treatment while concurrently experiencing improved efficacy 
and safety.  
 
Significantly higher scores in domain-specific as well as overall treatment satisfaction 
were observed for patients experiencing improved HbA1c and less hypoglycemia, the 
majority of which were on the pen device. Interestingly, it was also observed that patients 
using the pen device who had co-morbid retinopathy (low visual acuity), and/or 
neuropathy, reported improvements in satisfaction. This is very likely due to the non-
biological aspects of the pen device, in particular, the large dose-dialer (easier to see and 
accurately set) and smaller needle (less injection site pain). Combining results from 
Chapters 4 and 5, it is apparent that favorable non-biological features are associated with 
improved perceptions of care, and that these improvements are also related to the primary 
clinical drivers of CEAs. 
 
Chapter 6. Better perceptions of care play an important role in determining a patient’s 
ability to achieve HbA1c control in a safe manner. A logical explanation for this is that 
improved perceptions of care, associated with favorable non-biological features, may 
cause patients to adhere better and persist longer to prescribed therapy. Thus, optimal 
medication adherence is likely to be associated with improved HbA1c, and therefore any 
health economic impact related to adherence becomes important to consider for CEA. 
 
We performed a systematic literature review to (1) assess levels of adherence with a wide 
spectrum of injectable and oral treatments among T1D and T2D patients, and (2) 
document the economic impact of differences in adherence. Medication adherence, 
measured most frequently by MPRs, was found to have high variation among all 
treatment types – ranges of 36-87% and 54-81% for orals and injectables, respectively. 
Cost consequences were also substantial, with an approximate drop of 10-30% in 
healthcare costs for every 10% increase in adherence (depending on treatment type), 
stemming mostly from reduced hospitalizations. It became clear from this review that 
sub-optimal adherence is prevalent among diabetes patients, and that this in turn is 
associated with higher resource use and a significant economic impact. 
 
Chapter 7. Our next step was to investigate more refined differences in adherence and 
related cost consequences, focusing on use of a pen device versus vial/syringe, in line 
with previous chapters examining the same treatments (which have clear non-biological 
product differences). An intra-patient, pre-post design within a large healthcare claims 
database was used to assess medication adherence (MPR) before and after use of an 
insulin pen device among T2D patients.  
 
Patients converting from vial/syringe to a pre-filled pen device (with aspart 70/30 insulin) 
were identified and observed over a 2 year period (n=486). Measured outcomes included 
MPR, incidence rates of hypoglycemia, and total, diabetes-related, and hypo-related 
healthcare costs. Additionally, correlation analyses were employed to detect associations 
of MPR with hypoglycemia and individual cost groups.  
 
 
188 
Conversion to the pen device resulted in a 9% absolute gain in medication adherence 
(pre-MPR: 0.59; post-MPR: 0.68, p<0.01) and a 60% reduction in the likelihood of 
experiencing a hypoglycemic event (OR: 0.4, 95% CI 0.27-0.61, p<0.05). This is likely 
due to more accurate dosing and administration with the pen device (larger dial, better 
handling, no need to manually fill syringe) and improved convenience. For those with 
post-MPR ≥ 80%, a drop of two-thirds was observed in rate of hypoglycemia. These 
improvements were associated with 64% and 61% decreases in hypoglycemia-related 
emergency room and physician visits, respectively, as well as yearly reductions in total, 
hypoglycemia, and diabetes costs ($1748, $908, $643 per patient, respectively). 
Furthermore, patients with post-MPR ≥ 80% exhibited a reduction of 45% in total annual 
healthcare costs. These results clearly demonstrate that adherence is significantly 
associated with the use of a treatment with favorable non-biological features, and that 
numerous cost benefits may be expected as a result. 
 
Chapter 8. Several gaps remained before we could proceed to developing and testing an 
innovative approach at CEA. First, we had to assess whether adherence and patient 
perceptions could be quantified in terms of HbA1c improvements. That is, we had shown 
in previous chapters that HbA1c is influenced by patient perceptions, but not by how 
much, and that adherence was related to hypoglycemia, but not HbA1c. This was 
important because HbA1c is the main clinical driver of our base CEA approach, and we 
needed to tie our proposed innovations back to this. Also, because our base CEA model 
includes risk adjustment for non-diabetes factors (CVD), we needed to answer the 
question, ‘does adherence to diabetes treatments impact non-diabetes-specific outcomes?’ 
Secondly, it was necessary to explore the extent to which these relationships are already 
included in current economic evaluations. This would ensure our contributions to 
innovating CEA in diabetes would not be redundant.  
 
Medication adherence was found to be significantly associated with HbA1c on several 
levels: (1) a 15% increase in adherence improves ability to achieve a target HbA1c ≤ 7%, 
and (2) every 10-25% relative increase in MPR may result in a 0.1-0.2% absolute 
decrease in HbA1c. Additionally, patients with MPR ≥ 80% may exhibit up to 0.7% 
absolute lower HbA1c versus those < 80%. Sustained adherence with diabetes treatments 
may also improve blood pressure, lower LDL, and reduce mortality. Numerous studies 
confirmed our findings in Chapters 6 and 7, that improved adherence is associated with 
significant cost reductions (up to $3,400 per patient per year). Treatment satisfaction and 
patient preference were also shown to be associated with clinical parameters important 
for CEA – an absolute HbA1c reduction of 0.4-1.43% may be seen with improved 
satisfaction, as well as reduced hypoglycemia and better lipid profiles. Cost reductions 
may also be seen – reduced utilization of emergency room and other services may drop 
up to 63%, and a daily savings of $80 per patient (due to reduced nursing/caregiver need) 
may occur with improved perceptions related to use of a pen device. 
 
We were also able to confirm that current approaches at CEA do not adequately consider 
these economically important relationships. Of 16 economic models we reviewed (up to 
82% of which were CEA, depending on treatment type), zero included medication 
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adherence or patient perceptions (non-HRQoL PROs) as input variables or risk adjusters 
over time.  
 
Chapter 9. Our conceptual framework in Chapter 8, describing relationships leading to 
reimbursement decision-making, served as a foundation for developing a new approach at 
CEA in diabetes. This new approach began where the strongest and most direct link 
between non-biological product features, HbA1c, and a health economic impact found in 
previous chapters exist – medication adherence. An entirely new Markov structure of 
T2D health states and transition probabilities (adapted largely from the CEA model in 
Chapters 1 and 2, and utilizing the same M/MC methodological approach) was built, and 
two separate analyses were run – the first which ignored adherence, and the second which 
incorporated it.  
 
A categorical approach, rather than incremental approach, was taken to incorporate 
adherence in the second analysis, whereby a cut-off threshold of MPR ≥ 80% was used to 
adjust HbA1c and risk for complications. The categorical approach was chosen because 
we did not feel there was sufficient evidence to take the incremental approach. As 
discussed later in more detail, further work is needed in order fully describe how 
incremental improvements in adherence correlate to HbA1c and cost consequences. 
Although an incremental approach may facilitate a more realistic reflection of how 
patients truly act and how costs are incurred in the real-world, this relationship is likely 
not linear, and the requisite log transformation and regression estimates do not yet exist 
to adjust modeled outcomes. 
 
The impact of +/- MPR=80% within our second analysis was applied in two main areas – 
HbA1c level and rates of hypoglycemia, as this is where sufficient data exists (found in 
our literature reviews and database analysis). Hypothetical oral and injectable treatments 
were created for our model because non-biological profiles clearly differ, which would 
logically explain assumed differences in applied adherence rates. Over a long-term 
horizon, it was found that our adherence-adjusted model (analysis 2) generated an ICER 
for oral vs. injectable treatment that was 34% higher than when adherence was ignored 
($16,421 vs. $12,097/QALY). Although both ICERs may be considered acceptable and 
‘good value’ under most WTP thresholds, the adherence adjustment caused much smaller 
differences in LE, QALE, and complication rates between treatments. This is due to the 
fact that evidence from Chapters 5 and 7 suggests that adherence with oral medication is 
greater than for insulin, thus generating better HbA1c control for oral medication in our 
adherence-adjusted model, and causing insulin to become less cost-effective. 
 
Summary and Future Work 
 
The overarching conclusions of this thesis are that (1) important relationships exist 
between non-biological product features, patient perceptions of care, and self-
management, particularly in terms of health and economic outcomes, and (2) innovative 
ways of meaningfully incorporating these relationships into CEAs are possible. Herein, 
this has been demonstrated among adult patients with diabetes, predominantly T2D, and 
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may be useful in serving as an example of how economic evaluations for patients with 
other chronic diseases can be improved upon. 
 
Each chapter leading up to and including development of our conceptual framework and 
novel approach at CEA illustrates the current need to more robustly consider these 
relationships within economic evaluations that are frequently a part of informed decision-
making. Their inclusion has been shown to meaningfully influence modeled results in 
CEA, and should therefore be used to generate more accurate estimates of the relative 
cost-effectiveness of modern therapies.  
 
Further work expanding on our findings is warranted in several areas. The three most 
crucial, in particular over the short-term (5-10 years), are: (1) expanding the number and 
richness of data sources; (2) generating more accurate and precise figures on relationships 
between perceptions of care, self-management, clinical parameters, and cost outcomes; 
and (3) continuously advancing modeling techniques. It is important that progress be 
made on all of these fronts as concurrently as possible, as each is complimentary to one 
another. 
 
In many regions globally, the political and market environment continues to emphasize 
the importance of comparative effectiveness research, health information exchanges, and 
software technology. Developments in these areas will no doubt lead to opportunities to 
develop more rich data sources, specifically, in the area of converging real-world, 
patient-level electronic medical records (EMRs), healthcare claims, and PROs. The 
contribution of each is critical: EMRs are able to provide clinical parameters such as 
HbA1c, lipid profiles, blood pressure, daily glucose, and even radiologic imaging; claims 
data provide diagnostic prevalence, procedural and event rates, drug utilization, and 
detailed cost information; and PRO scores provide additional patient-centric insight to the 
role of preferences and satisfaction. Together, these will reveal a much wider spectrum of 
the healthcare system upon which to perform research. At the moment, each data source 
exists, however, independently, and at various stages of development. 
 
Expanded data sources will facilitate research producing much more accurate, quantified 
estimates of correlations between all of the outcomes focused on in this thesis. For 
example, in theory, we already know that preference and satisfaction are important in 
determining a patient’s success at achieving goals of therapy, likely through a greater 
willingness to properly self-manage. And we do have some detailed data to support this, 
as seen throughout several chapters in this thesis – but the surface is just now being 
scratched. Truly linking patient-level PRO scores with EMRs and claims data, into one 
data source suitable for research purposes, will create the ability to adequately quantify 
the interaction of adherence, preferences, and satisfaction, beyond just the conceptual 
level. The goal should be to generate treatment-specific, non-biological feature-specific, 
time-dependent, and population-specific regression coefficients and estimates, and 
calculations for log transformation (or simple linear, where appropriate), which could be 
used as adjustment factors on HbA1c and other clinical parameters within CEA. 
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Additionally, as these new data sources are developed and become available across 
different geographies, there will be greater opportunity to conduct country-specific CEAs 
to facilitate more localized decision-making. It is important to note that the modeling 
analyses conducted in this thesis were taken from the perspective of the U.S. healthcare 
system and payer environment. As such, the results are not necessarily generalizable or 
representative of what may be seen elsewhere – this is especially true where significant 
differences exist in (1) types of patient populations (e.g., ethnicities, risk levels, lifestyles) 
and (2) healthcare system processes and payment structures (e.g., co-payment levels, 
access to care, finance/reimbursement mechanisms). For example, it is very plausible that 
healthcare systems with low co-payments, or an infrastructure which improves the 
doctor-patient relationship over a long time period, will increase a patient’s satisfaction 
with care and result in improved medication adherence, better outcomes, and reduced 
costs. Such features in healthcare systems are found in several European countries, and 
therefore, research in these countries on the impact of adherence and other real-world 
factors is important. Any potential country-specific effects identified in these efforts 
could be captured for application in a novel framework described in Chapters 8 and 9. 
 
Furthermore, it remains essential to continuously incorporate modern clinical knowledge 
and practice into modeling. The CEAs found in this thesis utilize HbA1c targets as the 
primary intermediate clinical outcome driving modeled results. Although optimizing 
HbA1c has long been suggested as fundamental in determining diabetic outcomes, and 
remains important as a marker for tracking disease progression, recent evidence puts into 
question the benefit of strict glucose management on cardiovascular outcomes, and 
supports the need to counterbalance tight control with a focus on avoiding major 
hypoglycemia [1,2]. Accordingly, innovative work on modeling methods which properly 
illustrate the risk-benefit context of the various strategies to treat diabetes are warranted. 
Of note, as we found in Chapter 7, patients who achieve high levels of adherence 
experience a significant reduction in risk for major hypoglycemia, even with insulin 
therapy. It therefore could be possible that when patients use products they prefer and are 
more adherent with, their risk for serious hypoglycemia can be reduced to some extent. If 
this is achieved, clinicians may be able to pursue tight glucose control more aggressively 
than they otherwise would have. 
 
Lastly, modeling techniques must keep pace with product innovation to fit current market 
conditions and payer needs. This is true at the structural and mathematic level. As the 
data sources and correlation estimates for various populations and diabetes treatments 
continue to be developed, models should be modified accordingly. As seen in Chapter 9, 
additional health states and relationships between adherence, patient perceptions, and 
clinical parameters may become part of new Markov structures. Simulation techniques, 
ranges for sensitivity analysis, updated transition probabilities, and related equations 
which yield more precise findings on these relationships should be developed and applied 
over time. For example, new techniques may be developed for incremental modeling of 
adherence, rather than the categorical (+/- MPR 80%) approach that was taken in this 
thesis. This is important because in the real world, where decisions need to be made, it is 
very likely that patients moving from 50% to 60% adherence will receive more benefit 
than those moving from, say, 90% to 100%. Patients with an MPR=79% are likely not 
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very different from patients with MPR=81%, and this is why relative and absolute 
changes in adherence, for adjustment purposes in future models, should be taken in 
context from a patient or population’s baseline/starting level of adherence. 
 
As pressure continuously mounts on reimbursement authorities to develop strategies and 
tactics which curb costs through efficient care, we hope that our approach to improving 
the quality of CEAs will also improve the quality of decision-making. If this can be 
achieved, then we can expect to also achieve the ultimate goal of improving the health 
and well-being of diabetes patients. 
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Thesis Summary 
 
 
The incidence and costs of diabetes are rising dramatically across the globe. In response, 
healthcare decision-makers have attempted to control costs yet maintain appropriate 
access to care. For this to happen, it’s crucial that decision-makers have the most reliable 
and accurate evidence on which treatments provide the greatest value for the populations 
that they oversee. Economic evaluations, and in particular cost effective analyses, have 
become an important part of this evidence. 
 
Type 2 diabetes, which is a metabolic disorder and is commonly diagnosed in adulthood, 
is the most prevalent form of diabetes. However, there are also many people with Type 1 
diabetes, an autoimmune disorder usually diagnosed among children or adolescents. Both 
types require chronic treatment, and patients may live a full life with effective care. 
Therefore, adult patients with diabetes, mostly Type 2, represent the greatest health 
economic burden for this disease and are the focal group of patients in this thesis. 
 
Tailored therapy which emphasizes a patient-centered approach is now an important 
concept for both clinicians and pharmaceutical manufacturers alike. Treatment guidelines 
and modern clinical practice highlight the importance of individualized goals given a 
specific patient’s social, demographic, and clinical characteristics. Manufacturers of new 
diabetes treatments are increasingly enhancing the non-biological features of their 
products with the goal of making them easier to use and less inconvenient. This patient-
centered approach makes it more likely that patients will properly adhere to treatment due 
to greater preference and satisfaction for certain therapies. Patients who are more 
adherent with diabetes medication may have more tightly-controlled HbA1c, and thereby 
experience better outcomes, consume fewer resources, and overall be less costly. 
 
Current economic evaluations in diabetes largely ignore the impact on outcomes and 
costs that adherence may have. The consequence is that decision-makers who use these 
evaluations may have incomplete or insufficient evidence when allocating resources and 
establishing levels of access to care. As non-biological product features, which impact 
patient perceptions and behavior, become further refined and more prominent in modern 
treatments, it will be increasingly important to capture their full impact in economic 
evaluations. 
 
The primary aim of this thesis is to improve the health of diabetes patients by identifying 
areas in which improvements in economic evaluations are warranted, and proposing a 
novel framework wherein adaptations addressing these areas can be made. To this end, 
we have documented associations amongst non-biological product features, patient 
perceptions, medication adherence, resource use and costs, and have developed a new 
way of incorporating them into cost effectiveness analysis. This should support better 
decision-making, and ultimately, help ensure patients receive proper care at the proper 
time. 
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Thesis Samenvatting 
 
 
In de hele wereld zijn de incidentie en kosten van diabetes de laatste jaren dramatisch 
gestegen. Als reactie hierop hebben beleidsmakers in de gezondheidszorg geprobeerd de 
kosten te beheersen zonder de toegang naar de noodzakelijke zorg te belemmeren. Om te 
kunnen bepalen welke behandelingen de meest aantrekkelijke zijn is het van cruciaal 
belang dat beleidsmakers het meest betrouwbare en nauwkeurige bewijs hebben van de 
verschillende behandelopties. Economische evaluaties - oftewel 
kosteneffectiviteitsanalyses - vormen een belangrijk onderdeel van dit bewijs. 
 
Type 2 diabetes is een stofwisselingsziekte die doorgaans bij volwassenen 
gediagnosticeerd wordt. Alhoewel type 2 diabetes de meest voorkomende vorm van 
diabetes is, zijn er echter ook veel mensen met type 1 diabetes, een autoimmuunziekte die 
meestal gediagnosticeerd wordt bij kinderen of adolescenten. Beide typen vereisen 
chronische behandeling maar met effectieve zorg zijn diabetespatiënten in staat om een 
normaal leven te leiden. De grootste gezondheids- en economische lasten voor deze 
ziekte worden veroorzaakt door volwassen diabetespatiënten met vooral type 2 diabetes. 
Deze patiënten staan centraal in dit proefschrift. 
 
Therapie op maat, een patiëntgeoriënteerde benadering, is inmiddels een belangrijk 
begrip voor zowel clinici als de farmaceutische industrie. Zowel behandelrichtlijnen als 
de dagelijkse praktijk wijzen op het belang van het stellen van patiëntspecifieke doelen 
gebaseerd op sociale, demografische en klinische kenmerken. Fabrikanten van nieuwe 
diabetes behandelingen besteden steeds meer aandacht aan verbeteringen van de niet-
biologische kenmerken van hun producten om zo de patiëntacceptatie en het 
gebruiksgemak van deze behandeling te vergroten. Deze patiëntgeoriënteerde benadering 
verhoogt de kans dat patiënten de therapie nauw zullen blijven volgen. Patiënten die 
trouwer zijn met het gebruik van hun diabetes medicatie kunnen een betere controle 
hebben over hun HbA1c. Hierdoor ervaren zij een betere gezondheid en maken minder 
gebruik van de zorg, wat resulteert in minder kosten. 
 
Beleidsmakers maken gebruik van economische evaluaties bij vergoedingsbeslissingen 
over nieuwe therapieën. In economische evaluaties van diabetesbehandelingen wordt 
vrijwel geen rekening gehouden met de invloed van therapietrouw op de 
(kosten)effectiviteit van deze behandelingen. Het gevolg is dat beleidsmakers onvolledige 
of onvoldoende bewijs hebben van de (kosten)effectiviteit. Als de niet-biologische 
kenmerken van een therapie nog verder verfijnd worden, zal het steeds belangrijker zijn 
om de volledige impact goed vast te leggen in economische evaluaties. 
 
Het primaire doel van dit proefschrift is om het beleid van diabetes behandelingen te 
verbeteren door: a) gebieden te identificeren waarbij economische evaluaties aangepast 
moeten worden en b) een nieuw kader voor te stellen waarin deze aanpassingen gemaakt 
kunnen worden. Om dit doel te kunnen bereiken, hebben we de mate van samenhang 
gedocumenteerd tussen de niet-biologische aspecten van het product, de patiëntpercepties, 
therapietrouw, het zorggebruik en de zorgkosten. Verder hebben wij een nieuwe methode 
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ontwikkeld om deze aspecten te integreren in kosteneffectiviteitsanalyses. Dit zou 
moeten leiden tot het maken van betere vergoedingsbeslissingen waardoor de patiënt 
verzekerd is van de juiste zorg op het juiste moment. 
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Propositions 
 
 
1. A valid manner to assess future costs and health outcomes for diabetes patients is 
through economic evalutation performed by Markov/Monte-Carlo (M/MC) methods, 
utilizing HbA1c as the clinical marker driving modeled disease progression (this 
thesis) 
 
2. Non-biological product features for diabetes treatments are increasingly prevalent and 
diverse, and may impact patient perceptions of care as well as ability or willingness to 
properly self-manage (this thesis) 
 
3. Perceptions of care among diabetes patients, specifically preferences for and 
satisfaction with treatment, are related to willingness to properly self-manage, and 
therefore likelihood of attaining HbA1c treatment goals (this thesis) 
 
4. Self-management (medication adherence) is a relevant input parameter for economic 
evaluations in diabetes due to its relationship with overall, diabetes-related, and 
adverse-event-related healthcare costs (this thesis) 
 
5. Although methodologic innovations in M/MC modeling which incorporate measures 
of self-management are possible, many current economic evaluations inadequately 
capture this impact, and therefore may be providing incomplete information to 
decision-makers (this thesis) 
 
6. Baseball is 90% mental...the other half is physical (Yogi Berra; N.Y. Yankees) 
 
7. Every system is perfectly designed to achieve the results it yields (W. E. Deming) 
 
8. Many healthcare payers in the U.S. place a primary emphasis on costs in the decision-
making process, and often neglect other important factors such as quality of life 
 
9. Any intelligent fool can make things bigger, more complex, and more violent…it 
takes a touch of genius -- and a lot of courage -- to move in the opposite direction 
(and) make things as simple as possible, but not simpler (Albert Einstein) 
 
10. Science and religion need not be mortal enemies, for they are connected by human 
nature and the immortal desire to better understand what seems uncertain 
 
11. Earning a PhD reveals more about one’s determination and work ethic than it does 
raw intelligence 
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